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ABSTRACT
Interaction of two nutrients, carnitine and choline, has been reported. Choline
supplementation causes a significant conservation of carnitine in normal healthy humans
and guinea pigs. The choline supplementation promoted tissue carnitine accretion,
particularly in skeletal muscle of guinea pigs, and livers of rats. Also, choline
supplemented guinea pigs had lower percentage of carcass fat and higher percentage of
protein but the body weights or the respiratory quotient (RQ) were not affected.
Based on these observations, we hypothesized that a combination of choline and
camitine may further increase camitine accretion by tissues, and if energy needs were
increased by exercise and fat mobilization was stimulated by caffeine, there may be
reduction in body fat. In other words, simultaneous availability of carnitine, choline, and
caffeine may induce mobilization, transport and delivery of fat as the energy substrate of
choice, and therefore, enhance utilization of fat. In a 2 x 2 factorial design, male
Sprague-Dawley rats were assigned to nonsupplemented and supplemented groups and
one-half of each group was exercised. Body weight was significantly reduced by exercise
only, however, regional fat pad weights and serum leptin concentration were significantly
reduced by the combination of carnitine, choline and caffeine supplements as well as by
exercise. Regardless of exercise, supplements significantly lowered triglycerides in
serum but increased triglycerides in the skeletal muscle.
We postulated that fat loss in rats was due to enhanced fat mobilization and fatty
acid oxidation. To support this, we determined the RQ and several metabolic markers of
fat oxidation in the rat model. No significant differences were found in the mean RQ
V

values of the groups at rest in all groups and at exhaustion between the two exercised
groups. However, increased maximal oxygen uptake (V02max) and delayed exhaustion
time was found in the supplemented rats. Post-exercise concentrations of serum
triglycerides were decreased, but P-hydroxybutyrate, acylcarnitine and acetylcarnitine
were increased in the supplemented rats. The changes in serum metabolites were
complemented by the changes in the muscle and urinary metabolites. The magnitude of
increase in urinary acylcarnitine (34 to 45-fold) of the supplemented rats is a unique
effect of this combination of the supplements. Evidence indicates enhanced P-oxidation
of fatty acids without a change in the RQ because acetyl units were excreted in urine as
acetylcarnitine and not oxidized to carbon dioxide. For this phenomenon we proposed
the term, "fatty acid dumping".
Finally, we determined fat loss and metabolic effects of this unique nutrient
nutrient interaction in humans. We asked, if the shift in tissue carnitine partitioning will
result in enhanced fat oxidation in humans. Healthy adults aged 18-54 y were randomly
assigned to a placebo or supplement groups. Supplementary choline and camitine
increased serum concentration of P-hydroxybutyrate. Another biochemical marker of
fatty acid oxidation, acetylcarnitine, was elevated about 2-fold and 3-fold in serum and
urine, respectively. Short-chain acylcarnitines were moderately elevated in serum but
significantly increased in the urine by the supplementation. The observations in humans
are consistent with those in rats. This research in rats and humans firmly established that
the supplementation with camitine, choline and caffeine promoted fatty acid oxidation to
short-chain fatty acids and their disposal in urine as acylcarnitines.
VI
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CHAPTER I
INTRODUCTION

Camitine, choline and caffeine are common constituents in our diets. These
compounds are also popular ingredients of dietary supplements, because of their
involvement in certain metabolic processes, including those of energy metabolism for
weight loss and sport performance.
We have previously reported that choline supplementation results in a significant
conservation of camitine in normal healthy humans (Dodson and Sachan 1996) and
. guinea pigs (Daily and Sachan 1995). The choline supplementation promoted tissue
carnitine accretion, particularly in skeletal muscle of guinea pigs. In addition, choline
supplemented diet decreased percentage of carcass fat and increased percentage of
protein, without significantly changing body weight or the respiratory quotient (RQ) in
guinea pigs (Daily et al. 1998). Based on these observations we hypothesized that a
combination of choline and camitine may further increase camitine accretion by tissues,
and the energy substrate utilization may be altered, if fat was mobilized by caffeine, and
energy needs were increased by exercise. Simultaneous availability of caffeine, carnitine
and choline was proposed to induce mobilization, transport and delivery of fat as the
energy substrate of choice, and thus promote fat loss.
In the first study, rats were chosen for ease of exercise training and the choline
dosage was increased to compensate high choline oxidase activity in this species. Male
Sprague-Dowley rats were assigned to nonsupplement and supplemented groups and one1

half of each group was exercised. The diet was fortified with carnitine, choline and
caffeine (CCC). We determined the effects of CCC on body weight, fat pad mass,
metabolic indices of fat oxidation, and serum leptin concentration. This study is
presented in Chapter III.
We postulate that CCC supplementation will enhance fat mobilization and fatty
acid oxidation. To support this hypothesis, we determined the RQ and several metabolic
markers of fat oxidation in the rat tissue, especially skeletal muscle, where most fat is
oxidized. The functional consequence of CCC supplementation on fat oxidation was
assessed by V02max of the nonsupplemented and supplemented, exercised rats. The
method and findings of these experiments are presented in Chapter IV.
We were also interested in knowing how the combination of CCC affects various
tissue carnitine concentrations. The camitine concentrations of various tissues (liver,
heart, kidneys, brain and testes) are reported in Chapter V .
After the establishment of the animal models (guinea pigs and rats), we asked if
this unique nutrient-nutrient interaction could be seen in humans as well. Healthy,
untrained adults of 1 8-54 y of age were randomly assigned to a placebo or supplement
groups. All subjects were asked to exercise in the last part of the experiment ( 1 wk :QJ.ild
exercise intervention). Measurements were made of body weight, body fat, serum lipid
profiles, serum leptin, 24-hr urinary metabolites and metabolic markers of fat oxidation as
determined ·in the rat model. Also, nutrient intake analyses for every wk were determined
by using 3-day dietary diary. Effects of CCC supplementation on fat metabolism in
healthy humans are presented in Chapter VI.

2

The results of these studies provide evidence supporting our research hypothesis,
i.e. increased fatty acid oxidation by the combination of CCC supplements. We found
that the combination of supplements alters partitioning, metabolism and excretion of fatty
acid metabolites in rats and humans.
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CHAPTER II
LITERATURE REVIEW
CARNITINE
Carnitine, P-hydroxy-y-trimethylammonium butyrate, is a very hygroscopic
compound with a molecular weight of 1 6 1 .2 g/mol (inner salt) (Figure 2-1). Only the L
isomer is biologically active, and it is essential for the oxidation of long-chain fatty acids.
Camitine is present in serum, urine and tissues of mammalian as free camitine and as
acylcamitine, which are metabolic products catalysed by camitine acyltransferases.
Carnitine was first isolated from meat extracts in 1 905 (Gulewitsch and Krimberg
1 905) and demonstrated to be an essential growth factor for a meal worm, Tenebrio
molitor (Carter et al. 1 952). In 1 955 Friedman and Fraenkel demonstrated that camitine
can be acetylated to form acetylcamitine from acetyl-Coenzyme A (CoA) and camitine
(Friedman and Fraenkel 1 955), and Fritz showed that carnitine stimulates fatty acid
oxidation in liver homogenates (Fritz 1 955). The best characterized role of carnitine in P
oxidation of long chain fatty acids was discovered in the early 1 960s (Bremer 1 962, Fritz
and Yue 1 963 ). These findings stimulated a great amount of research for understanding
the physiological and metabolic functions of camitine. Since then, several other roles of
camitine in mammalian metabolism have been identified (Hoppel 1 992). In addition,
many studies were undertaken to investigate the mechanisms of metabolic effects of
camitine (Peluso et al. 2000) as well as effects of pharmacologic administration of
camitine on various disease conditions (Brass et al. 200 1 , Di Donato et al. 1 992).
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FIGURE 2-1 Structure s ofcarnitine, its metabolic precursor gamma-butyrobetaine,
and the acetyl andpalmitoyl esters ofcarnitine.
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Carnitine is not a dietary essential nutrient for humans because of ample
endogenous biosynthesis. However, there is nutritional and clinical evidence indicating
that carnitine is a "conditionally essential" nutrient; that is, a dietary requirement of
carnitine may become obligatory under certain pathophysiological conditions. An
excellent example is supplementation of soy-derived infant formulas (containing little or
no carnitine) with carnitine to obtain the carnitine concentration approximating that found
in human milk. Newborn infants rapidly increase their reliance on endogenous and
exogenous fat to meet energy needs (Wolf et al. 1 974 ). According to rat study findings,
immediately after birth an increase in the activity of carnitine palmitoyltransferase and in
the capacity to oxidize fatty acids takes places in the liver (Augenfeld & Fritz 1 969) and
heart (Warshaw 1 972). During this period, the availability of camitine may be critical
for optimal fatty acid oxidation in different tissues. Since 1 985, all commercial
soyprotein-based formulas manufactured in the United States are fortified with L
carnitine (Borum 1 99 1 ). A substantial amount of research has been done to define a
dietary requirement of carnitine for a special population that is physiologically and
metabolically stressed, for examples, cardiac and renal patients.
Dietary Sources of Camitine

In human, diets containing meat, poultry, fish and dairy products are the major
sources of carnitine (Broquist 1 994). Table 2-1 lists the carnitine content of selected
foods. Vegetables, fruits, grains and other plant-derived foods contain little or no
carnitine. Normal non-vegetarian and strict vegetarian diets have been estimated to

6

TABLE 2-1

Carnitine content in common foods 1•2
MEAT PRODUCTS

DAIRY PRODUCTS

VEGETABLES

Beef steak
Ground beef
Pork
Bacon
Fish (cod)
Chicken breast

20
Whole milk
Goat milk
15
Sheep milk
100
7
Human milk
American cheese 23
23
Ice cream
7
Cottage cheese

Asparagus (cooked) 1.21
0.02
Beets (cooked)
0.04
Carrots
Green beans (cooked) 0.02
Green peas (cooked) 0.04
0.08
Potato (baked)
0.00
Lettuce

BEVERAGES

FRUITS

592
582
172
146
35
24

BREAD AND CEREAL

Whole-wheat bread
White bread
Rice
Macaroni
Com flakes

3
0.9
0.1
0.8
0.1

Apples
Bananas
Peaches
Pineapple
Pears

INFANT FORMULAS

MISCELLANEOUS

Eggs
Peanut butter
Soy Milk

0.01
ND3
0.1
0.01
0.03

Coffee
Cola
Grape juice
Orange juice
Tomato juice

0.08
0.05
ND

Milk based formulas 7-23
Premature formulas 5-30
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Values are µmol/100 g (solid foods) or µmol/100 ml (liquids) of total carnitine.
1 µmol = 0.161 mg of carnitine.
2
Modified from Rebouche and Engel 1984, Penn et al. 1987.
3
ND, not detectable.
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0.01
0.00
0.01
0.01
0.01

provide approximately 2- 12 µmol and 0. 1-0.2 µmol of carnitine/kg body weight/d,
respectively (Rebouche 1992).
Carnitine Homeostasis
Dietary carnitine intake and nutritional status affect plasma and tissue carnitine
concentrations. After feeding a carnitine-free diet over 7 months, plasma and tissue
carnitine concentrations of rats were decreased 50% (Heinonen & Takala 1994), which is
comparable to those in secondary carnitine-deficient patients (Tein et al. 1993). The
carnitine free diet contained lysine, methionine, ascorbic acid and iron, which are
essential for endogenous carnitine biosynthesis. Therefore, the study indicates that
exogenous carnitine in a diet is necessary to maintain normal carnitine concentration.
Juvenile visceral steatosis (JVS) mice have been reported to have systemic
carnitine deficiency (Kuwaj ima, et al. 1991). These mice are autosomal recessive
mutants that exhibit severe fatty liver, hypoglycemia, and growth retardation (Koizumi et
al. 1988). Their hepatic carnitine stores are below 5% of those normally observed in
control mice. The JVS mice showed decreased tissue carnitine concentrations, decreased
hepatic fatty acids metabolism, and decreased functions of other organs such as skeletal
muscle and heart (Nakajima et al. 1997).
In neonatal rats, as in human newborns, carnitine concentrations were directly
related to dietary supply, i.e. milk carnitine (Flores et al. 1996). Newborn rats were fed a
rat milk substitute with or without 300 µmol/L carnitine, corresponding to the
concentration of carnitine in rat milk, from birth to either 2 or 4 d. Carnitine
supplementation resulted in significantly higher concentrations of carnitine in the heart,
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skeletal muscle, liver and small intestine. The most pronounced differences in organ
concentrations were found in the small intestine. Significant differences of carnitine
concentration in the small intestine between supplemented and nonsupplemented pups
were observed even after 2 d of milk feeding. The accumulation of camitine was the
greatest in the proximal intestine as has been previously reported in adult rats (Sachan &
Ruark 1985). This indicated that the small intestine contributes substantial quantities of
the body carnitine pool in rat pups. Other studies involving suckling animals
demonstrated that milk-carnitine increased the concentrations of carnitine in the liver,
heart and skeletal muscles in rabbits (Penn and Schmidt-Sommerfeld 1988) and piglets
(Coffey et al. 1991). The increased carnitine in these organs was due to increased intake
of exogenous carnitine, in addition to endogenous biosynthesis of camitine. In suckling
rats 45-59% of tissue carnitine is derived from endogenous sources (Davis 1989).
In healthy full-term infants fed carnitine-free soy formulas there was lower plasma
carnitine concentration, reduction of ketogenesis, and accumulation of fatty acid in
plasma, compared to the infants provided carnitine in either bovine milk-derived infant
formula or in human milk (Novak et al. 1983). Similar observations have been made in
preterm infants (Penn et al. 1980) and adult patients (Hahn et al. 1982, Bowyer et al.
1986) receiving total parenteral nutrition.
The carnitine status of individuals consuming self-selected diets low in carnitine
were studied in lacto-ovo and strict vegetarians (Lombard et al. 1989, Sachan et al. 1997,
Richter et al. 1999). Lombard et al. (1989) reported that in both adults and children,
plasma carnitine concentrations and urinary carnitine excretion of both lacto-ovo and
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strict vegetarians were significantly lower than those eating the mixed diet. The
differences in plasma carnitine concentrations were greater in children than adults,
indicating higher carnitine requirements for growth and tissue deposition in children. The
relationship between plasma and urinary excretion of total carnitine suggests that low
carnitine intake increased renal tubular carnitine transport (reabsorption) capacity to
minimize renal loss of camitine and thus maintain normal plasma carnitine concentration.
Less efficient reabsorption of filtered camitine by the kidney was observed when rats
were administered diets high in carnitine (Rebouche· and Mack 1 984 ). These observations
are in agreement with those of other investigators where lacto-ovo vegetarians were found
to have lower circulating camitine concentrations than omnivores (Richter et al. 1 999).
Very little data exist concerning the carnitine status of elderly humans. Sachan et
al. ( 1 997) assessed dietary intake of nutrients essential for carnitine biosynthesis and
urinary excretion of camitine in elderly (mean age of 70.5 y) lacto-ovo vegetarian and
non-vegetarian women. They found that dietary intake of protein and essential amino
acids, lysine and methionine, were significantly lower in vegetarian than non-vegetarian
women. Vegetarians showed 50% reduction in urinary excretion of carnitine that non
vegetarians. Mean (±SEM) urinary carnitine excretion for lacto-ovo vegetarians and non
vegetarians were 45 .8 ± 6.7 and 92.5 ± 9.5 µmol/d, respectively. The reason for the
significant reduction of urinary carnitine excretion in the lacto-ovo vegetarians was that
these women consumed soy-milk, and did not consume cow' s milk, which is a rich
source of carnitine. From the dietary analysis and urinary carnitine excretion, it was
concluded that elderly vegetarians do not meet a nutritional requirement for carnitine
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(Sachan et al. 1997).
Dietary factors other than camitine content in diets may influence camitine status
in humans. Cederblad (1987) determined the effect of dietary macronutrient content
(carbohydrate and fat) on plasma camitine concentration and urinary excretion of
camitine. Healthy male volunteers consumed a high-carbohydrate, low-fat diet (high
carbohydrate diet) and a low-carbohydrate, high-fat diet (high-fat diet). After baseline
blood samples were drawn, each diet regimen was maintained for 4 d, followed by a 3 d
break, and then other diet regimen for another 4 d. The two diet regimens contained same
amount of energy and camitine-rich foods. Total and free camitine concentrations in
plasma were higher in people on a high-fat diet than on a high-carbohydrate diet by d 3.
Both diets increased plasma acylcamitine level and acyl:free camitine ratio compared to
the initial levels. In urine of the high-fat diet, all camitine fractions (i.e. total, free and
acyl camitine) were increased by d 2. Urinary excretion of the acylcamitine increased
significantly from an initial value of 283 ± 94 to 431 ± 119 µmol/24-h on d 5 with a high
fat diet. Increased urinary camitine excretion observed in a high-fat diet may be due to an
increased renal camitine clearance. Renal camitine clearance (C) was calculated as C
(ml/min) = (U x V) IP where U and P are the camitine concentrations in urine and
plasma, respectively, and V is the urinary volume/unit of time. The study showed that
composition of a diet with constant camitine content affects plasma and urinary excretion
of camitine (Cederblad 1987).
Stadler et al. (1993) determined the mechanisms by which macronutrient
(carbohydrate, fat and protein) content affect camitine status by examining glomerular
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filtration rate (GFR), excretion, reabsorption, and filtered load of carnitine. Healthy
adults consumed five different diets: high-protein, low-protein, control, high-fat, high
carbohydrate. The diets were isoenergetic and contained equal amount of carnitine,
approximately 32 µmol/kJ/diet (equals to 133 µmol/kcaVdiet). On d·6, plasma carnitine
concentration was significantly lower after the high-carbohydrate diet than after either the
high-fat or control diets. Urinary excretion of total carnitine was 4-fold higher after the
high-fat diet compared to the high-carbohydrate diet, which confirmed the previous
findings by Cederblad (1987). The rate of carnitine excretion was lower after the low
protein diet than after the high-protein diet because of lower GFR after the low-protein
diet. An increased rate of carnitine excretion after a high-fat diet, compared with a high
carbohydrate diet, is due to a higher filtered load of carnitine. The results of this study
may in part explain the decreased urinary carnitine excretion among individuals
consuming vegetarian diets, which tend to be high in carbohydrate and low in fat and
protein (Abdulla et al. 1981 ).
It is clear that dietary intake of carnitine and macronutrient affect plasma carnitine
concentration and urinary carnitine excretion in humans. However, it is not known to
what extent humans rely on dietary carnitine and what are the functional consequences of
variations in dietary intake of carnitine. There are no known adverse effects attributed to
the diet poor in carnitine. It must be noted that carnitine concentration in human muscle
tissue is 4- 5-fold higher than in rat, whereas plasma carnitine concentration are of the
same order of magnitude (Cederblad and Lindstedt 1976). Total muscle carnitine in rats
is -1 µmol/g wet weight (Hongu & Sachan 2002), compared to -4.2 µmol/g wet weight
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(Lennon et al. 1 983) in human. Therefore, humans have a large camitine buffer in case of
limited dietary intake or biosynthesis of camitine. In summary, camitine changes in urine
and plasma involves dietary supply, biosynthesis, transport in and out of the tissue and
excretion of camitine, which together make up homeostasis of camitine in the body.
Supplement Forms of Carnitine

Chemically synthesized camitine (L-camitine free base) became available on the
market in the early 1 980's (Zurbriggen 2000). Today, 4 main commercial forms of
camitine are available as nutritional supplements: L-camitine free base, L-camitine L
tartrate, L-camitine magnesium citrate, and acetyl-L-carnitine hydrochloride.
Supplementation studies have used L-camitine with dosages ranging from 500 mg/d to
6 g/d. The typical dosage used in most studies were 1 -2 g/d for 50- 1 00 kg body weight,
respectively. The dosages being even higher and reaching as much as 1 00-350 mg/kg
body weight are mostly administered for medical treatment; e.g. removal of excessive
organic acids as in variety of acidemia (Roe et al. 1 984b, ltoh et al. 1996). It is important ·
to note that a bioavailability of the 2 g dose of camitine, if given orally, is reported -1 5%
(Harper et al. 1 988).
It appears that L-camitine supplementation is safe with typical dosages used in
most studies and no adverse effects has been reported. Camitine consumed in the large
doses, about 5g/d by an adults, may cause diarrhea or fish odor syndrome in some people
(Rebouche 1 999). Importantly, myasthenia-like symptoms have been found in
hemodialysis patients administered D,L-camitine for 45 d (Bazzato et al. 1 979). In rat
study, intraperitoneal injection of D-camitine (750mg/d) for 4 d produced an L-camitine
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deficiency in cardiac and skeletal muscle (Paulson and Shug 1981 ). Thus, the D,L
racemic mixtures, which are present in some commercial products, can result in harmful
effects, therefore it should not be used in camitine therapy. It should be also noted that
camitine supplement products may vary considerably in their purity (Borum 2000). Non
pharmaceutical grade camitine products have been found to contain undetectable
concentration of camitine to 100 % pure camitine. Bioavailability data were not available
for these non-pharmaceutical grade products (Millington & Dubay 1993).
Carnitine Biosynthesis
In 1961, several investigators demonstrated that methionine provides the methyl
groups of camitine (Wolf and Berger 1961, Bremer 1961 ), and the immediate precursor
of camitine is y-butyrobetaine, which is hydroxylated to form camitine (Lindstedt and
Lindstedt 1961, Bremer 1961). However, the source of the carbon chain of camitine
remained unknown. Later, Broquist and co-workers working with Neurospora crassa
discovered that lysine provides the carbon-nitrogen backbone of camitine (Home et al.
1971 , Tanphaichitr and Broquist 1 973). It was clear then that camitine is synthesized
from two essential amino acids lysine and methionine (Figure 2-2).
The biosynthesis of camitine begins with the enzymatic trimethylation of a
peptide-bound lysine residue to form 6-N-trimethyllysine. Camitine is formed from this
6-N-trimethyllysine after its release due to protein breakdown in the lysosomes (Dunn &
Englard 198 1). In the next step, the 6-N-trimethyllysine is hydroxylated to form 3hydroxy-6-N-trimethyllysine. The reaction is catalyzed by 6-N-trimethyl-lysine
hydroxylase (E. C. 1.14 .11. 8), which is found in mitochondria of kidney (Sachan and
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FIGURE 2-2 Biosynthesis ofL-carnitine.
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Hoppel 1 980), liver, heart, skeletal muscle, and other tissues (Stein & Englard 1 982).
The enzyme requires cx-ketoglutarate and oxygen as cosubstrates, and ferrous iron (Fe2+)
and ascorbic acid for optimal activity (Hulse et al. 1 978). The 3-hydroxy-6-N
trimethyllysine undergoes aldol cleavage to glycine and y-butyrobetaine aldehyde. Serine
hydroxymethyltransferase (E.C. 2. 1 .2. 1 ), a pyridoxal phosphate-requiring enzyme,
catalyzes this reaction. The y-butyrobetaine aldehyde is then oxidized to a precursor of
L-carnitine, y-butyrobetaine, by nicotine adenine dinucleotide (NAD+) requiring
aldehyde dehydrogenases (Hulse et al. 1 978). The final step is a hydroxylation of y
butyrobetaine to form L-camitine. The enzyme catalyzing this reaction is y-butyrobetaine
hydroxylase (E.C. 1 . 14. 1 1 . 1 ), which also requires an cx-ketoglutarate and oxygen as
cosubstrates, Fe2+ and Vitamin C as the reducing agent for its activity (Bremer 1 983).
Most tissues can convert N-trimethyllysine to y-butyrobetaine, but the last step of
biosynthesis, the hydroxylation of butyrobetaine to carnitine, is limited to liver and testis
in rats; liver, kidney and brain in humans (Bremer 1 997). The rate of camitine
biosynthesis in humans is estimated to be about 1 .2 µmoll kg body weight/d (Lombard et
al. 1 989). Studies in rats have shown that the availability of 6-N-trimethllysine
determines the normal rate of carnitine biosynthesis (Rebouche et al. 1 986). However,
regulation of carnitine biosynthesis in humans is not well understood. It is important to
note that lysine and methionine are often the most limited amino acids in vegetable
proteins consumed by vegetarians (Sachan et al. 1 997, Siddiqui & Bamji 1 980, Young
and Pellet 1 994). As was shown in Table 2- 1, plant foods are also very low in camitine
content. Therefore, diets in certain populations may not adequately support the rate of
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carnitine biosynthesis, when the demand for carnitine is increased under physiological
and pathological conditions.
Absorption

Dietary carnitine is rapidly absorbed from the intestinal lumen by an active
transport mechanism as well as by a passive diffusion process (Gross and Henderson
1 984, Hamilton et al. 1 986). Absorbed carnitine is taken up by the liver from the portal
vein and then released into the systemic circulation (Gudjonsson et al. 1 985). Live
animal studies, using male Sprague-Dawley rats, demonstrated 80% of L-carnitine was
taken up by the intestinal tissue in 30 min after intraluminal injection of carnitine. After
5 h, 30% and 7% of L-carnitine were found in the skeletal muscle and urine, respectively
(Gross and Henderson 1 984).
It is estimated that about 70 to 80% of carnitine is absorbed under normal
conditions in omnivores (Rebouche and Chenard 1 991 ). The efficiency of absorption was
reduced to 20% after 2 g daily supplementation of carnitine (Rebouche 1 999). In
mammals, carnitine is not catabolized except by microorganisms in the large intestine.
Carnitine is mainly excreted in the urine as free and acylcarnitines (Brass and Hoppel
1 978). Carnitine supplemented mice and rats have also shown increased urinary
excretion of trimethylamine, trimethylamineoxide, y-butyrobetaine, crotonobetaine
(Bremer 1 983). The previous study on the metabolism of L-[methyl- 1 4C]carnitine in rats
showed conversion of carnitine to y-butyrobetaine in feces and trimethylamineoxide in
urine (Rebouche et al. 1 984). It is also reported that nearly 1 00% radioactivity was
recovered in rats receiving the isotope intravenously and in germ-free rats receiving the
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isotope orally or intravenously. Results of this study concluded that L-carnitine is
degraded in the intestine, and that intestinal microorganisms are responsible for these
conversions. (Rebouche et al. 1984).
Transport and Tissue Uptake

Camitine is present in most tissues and transported from the blood plasma. The
concentration of total carnitine in blood in humans is 0.03 to 0.05 mM, and that is far
lower than in tissues (Bieber 1988). Most of the carnitine is found in the skeletal
muscles, which contains 95% of the total camitine in the body (Rebouche and Engel
1984). Since carnitine concentration of tissue is 10- 100-fold higher than that in blood
plasma, a concentration gradient must exist to maintain carnitine homeostasis.
Mechanisms of sodium-dependent, active transport systems have been suggested in the
intestine (Shaw et al. 1983), liver (Christiansen and Bremer 1976), skeletal muscle
(Rebouche 1977), and kidney (Rebouche and Mack 1984).
The carnitine transport system in the liver is important for the whole body
carnitine homeostasis, because the liver is the major site of carnitine biosynthesis and the
first site exposed to camitine before the systemic camitine distribution. The liver
transport system has a high Km and the hepatic carnitine content is readily altered by
exogenous carnitine (Brass and Hoppel 1980, Ruff et al. 199 1 ), fasting (Brass and Hoppel
1978) and diabetes (McGarry et al. 1975). In the perfused rat liver Km for carnitine
uptake was "lower in fasted rats (2.59 mM) than fed rats (4.2 mM) with the unchanged
maximal rate of transport (Kispal et al. 1987). Glucogan increased camitine uptake in
both fed and fasted rat liver, while insulin decreased carnitine transport in fasted rat liver.
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The uptake and release of carnitine in liver are partially regulated by hormones (Bremer
1983) and by different membrane carriers (Hokland 1988).
The properties of transport systems in cardiac and skeletal muscles differ from
those of the liver. The rate of maximal uptake in muscle is only 1/ 1000 of the rate of the
maximal uptake in liver (Bremer 1983). This agrees with the turnover time of muscle
carnitine, which is 100- 150 times longer than liver carnitine in vivo (Brooks & McIntosh,
1975). Carnitine is slowly released from muscle cells, and exogenous camitine stimulate
this process. Normal serum carnitine concentration (26-69 µM) is positively correlated
with skeletal muscles and heart carnitine concentration (Rebouche 1989).
A cardiac carnitine binding protein has been isolated from rat hearts which may
serve as the carrier for the transport of carnitine across the heart cell membrane (Cantrell
and Borum 1982). Maximum binding of carnitine was obtained after incubation for 1 h at
25 °C. This relatively slow uptake of carnitine in the heart may be related to this slow
binding. Another feature of this protein is that butyrobetaine is a relatively weak inhibitor
of carnitine biding to this heart protein. In liver cells, butyrobetaine is taken up with a
lower Km than is carnitine. This suggests that the cardiac carnitine binding protein is
different from that of hepatocyte cell membrane (Cantrell and Borum 1982).
The kidney plays roles not only in carnitine biosynthesis, but also in carnitine
reabsorption, acylation/deacylation, and excretion of carnitine. Carnitine, a small water
soluble molecule, is readily filtered by the renal glomerulus. Filtered carnitine is
reabsorbed by the proximal tubule to prevent excess urinary loss (Rebouche and Engel
1984). A sodium-dependent transport system has been suggested in rat kidney cortical
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slices (Huth and Shug 1 980) and proximal tubular brush border membranes (Rebouche
and Marek 1 984). Guder and Wagner (1 990) observed that the total carnitine content in
isolated proximal tubule of rat kidney was 2.85 ± 0. 1 5 µmol/g protein and about 50% of
it was acetylated. When it was incubated at 37 ° C in vitro for 60 min·, the
acylcarnitine/carnitine ratio decreased without changing total carnitine, indicating
deacylation of acylcarnitine. Subsequently, when 1 mmol/L of carnitine was added to the
incubation medium, it showed 7-fold increase in acylcarnitine formation by the tubules.
This observation suggested that proximal tubule cells actively take up carnitine and
convert it to acyl derivatives (Guder and Wagner 1 990).
Tissue uptake of carnitine occurs at widely varying rates (Bremer 1 983). The
turnover times for carnitine in rat tissues have been estimated to be 0.4 h in the kidney,
0.33 h in liver, 2 1 h in skeletal muscle, and 220 h in brain (Brooks and McIntosh 1 975).
In humans the turnover times of carnitine in skeletal muscle was estimated to be 1 9 1 h
(Rebouche and Engel 1 984). This suggests reutilization of carnitine among the various
tissues of the body.
Excretion

When plasma carnitine concentration exceeds the renal reabsorption maximum,
carnitine is eliminated in the urine. In rats 1 -2 µmol of carnitine/1 OOg body weight are
excreted each day (Cederblad and Lindstedt 1 976, Tsai et al. 1 975). In fasting rats both
the plasma concentration and the renal excretion of carnitine decreased at first, but
increased above the initial values after fasting for 3-4 d (Brass and Hoppel 1 978). Similar
observations have been reported in humans. In man a filtered carnitine load is 4
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µmol/min in contrast to the 1 25 µmol of daily urinary excretion (Brass 1 992). Tubular
reabsorption in the kidneys was estimated to be 96-99% (Frolich et al. 1 978). When the
plasma carnitine concentration is increased by supplementation or dietary intake of
carnitine in vegetarians, the renal tubular reabsorption of carriitine declines, suggesting
that plasma camitine levels are regulated by renal clearance of carnitine (Engel et al.
1 98 1 , Lombard et al. 1 989).
Other factors affecting urinary carnitine excretion have been reported. Adult men
excreted more urinary camitine than adult women (Cederblad and Lindstedt 1 97 1 ,
Maebashi et al. 1 976 ) , but adult male rats excrete less carnitine than adult female rats
(Carter and Stratman 1 982). Camitine excretion varied widely in women during the
menstrual cycle but reached maximum at the time of ovulation (Maebashi et al. 1 976).
Functions
A. Mitochondrial fatty acid oxidation

Carnitine has a critical role in energy metabolism. Camitine serves two
important, well established functions in cellular metabolism; 1 ) mitochondrial fatty acid
oxidation and 2) modulation of acyl-CoA/CoA ratio. Carnitine facilitates the entry of
long-chain fatty acids into the mitochondrial matrix for oxidation (Figure 2-3) . The
mitochondrial inner membrane is impermeable to long-chain fatty acids and fatty acyl
CoA, which is formed on the outer surface of the mitochondrial outer membrane via a
fatty acyl CoA synthetase (Lehninger et al. 1 993). The long-chain fatty acyl-CoA
between the outer and inner membranes is transesterified to carnitine to form long-chain
fatty acylcarnitine by camitine palmitoyltransferase I (CPT I), also designated as CPT- 1 ,
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FIGURE 2-3 Fatty acid entry into mitochondria via the acylcarnitine transport. Long-chain fatty acid acyl-CoA in
the cytoplasm is bound to carnitine in a reaction mediated by carnitine palmitoyltransferase I (CPT I). The acylcarnitine
is transported across the mitochondrial inner-membrane via a carnitine-acylcarnitine translocase, where carnitine
palmitoyltransferase II (CPT II) catalyzes the reaction between acylcarnitine and CoA. In this reaction, carnitine is
regenerated and transported back to the inter-membrance space for further reactions and acyl-CoA is released and goes
on to P-oxidation.

CPTo, CPT-A. The acylcamitine is transported across the mitochondrial inner membrane
via a camitine acylcamitine translocase. The second transesterification with CoA in the
mitochondrial matrix is catalyzed by camitine palmitoyltransferase II (CPT II), also
designated as CPT-2, CPTi, CPT-B. This intramitochondrially regenerated fatty acyl
CoA enters the P-oxidation pathway to provide cellular energy. Free camitine released in
the matrix is translocated back to inter mitochondrial space by camitine acylcamitine
translocase, where it can repeat the fatty acid transport process. In summary this transport
process, the "carnitine transport shuttle", involves two transesterifications and three
mitochondrial enzymes: CPT I, CPT II and camitine translocase. The result of the
c_oncerted actions of these enzymes is that long-chain fatty acids are transported into the
mitochondria by being esterified to carnitine (acylcamitine).
Short-chain fatty acids, such as propionic acid and acetic acid, in all tissues can
enter mitochondria without the carnitine translocator and be activated inside of the
mitochondria to form the short-chain fatty acyl-CoA. Medium-chain fatty acids may be
activated by the liver peroxisomal medium-chain acyl-CoA synthetase and trnsesterified
to carnitine for entering into mitochondria (Bahl and Bressler 1987).
B. Modulation of acyl-CoA/CoA ratio

Under some metabolic conditions acetyl-CoA and other short CoA esters may
accumulate in the mitochondria. For example, P-oxidation of fatty acid generates acetyl
CoA. If acetyl-CoA is not consumed by the tricarboxylic acid (TCA) cycle for energy
production, the availability of free CoA is reduced. CoA is a required cofactors for many
cellular oxidative and biosynthetic reactions. Therefore, if free CoA is not available, the
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enzymes that required this cofactor (i.e. pyruvate dehydrogenase, fatty acyl CoA
synthetase, etc.) will not function (Brass 1 994). Carnitine facilitates the removal of
excess acetyl residues generated by enhanced P-oxidation in mitochondria (Pearson and
Tubbs 1 967). In starved rat liver, the acetyl-CoA/CoA and the acetylcarnitine/carnitine
ratios increase (B0hrner 1 967). In muscles these ratios increased with exercise. During 4
min intense exercise, 90% of the predicted V02max, there was an increase in skeletal
muscle acetylcarnitine with almost equivalent decrease in free carnitine without changing
total carnitine (Harris et al. 1 987). When exercised for 30 min at a work load between the
lactate threshold and maximal work capacity, the muscle short-chain acylcarnitne content
increased 5 .5-fold, while free and total carnitine content decreased, 66% and 1 9%,
respectively. However, these changes in skeletal muscle carnitine were poorly reflected
in the plasma and urinary carnitine concentrations (Hiatt et al. 1 989). Similar results
were observed in other studies in humans and rats (Sahlin 1 990, Carter et al. 1 98 1 ).
These observations are consistent with the hypothesis that camitine function in the
regulation of the acetyl-CoA/CoA ratio by buffering excess accumulation of acetyl units.
This function of carnitine has important implication in normal and abnormal
cellular metabolism associated with defects in organic and fatty acid metabolism. For
example, the excretion of propionylcarnitine is elevated in propionyl-CoA carboxylase
deficiency individuals (Roe and Bohan 1 982). In this disorder there is a block in the
oxidation of the propionyl-CoA, resulting in acyl-CoA accumulation and inhibition of
oxidative phosphorylation. Propionic acidemia showed a significant clinical response to
carnitine treatment (Roe et al. 1 984a). The acyl moiety, propionate, becomes a carnitine
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ester and is excreted in urine. Thus, it does not disturb the function of mitochondrial
CoA dependent metabolic pathways. The excretion of specific acylcarnitine conjugates
of two drugs that are metabolized to acyl-CoA in humans has been reported.
Valprolylcarnitine and pivaloylcarnitine are excreted as a result of valproic acid (Vickers
et al. 1 985) and pivalic acid-therapy (Millington et al. 1 985). These organic acidemias (a
fall in blood pH caused by high levels of specific organic acids) are metabolic diseases
that can be successfully treated by the pharmacological use of carnitine (Chapoy et al.
1 980). Treatment generally consists of administration of 1 00 mg/kg/d of carnitine in 3 to
4 doses (Stumpf et al. 1 985).
Numerous studies investigated the functions of carnitine and its derivatives
beyond the well-defined roles of carnitine described above. These include the roles of
carnitine in branched-chain amino acids metabolism (Solberg and Bremer 1 970, Bieber
and Choi 1 977), ketone body utilization (McGarry and Foster 1 980), peroxisomal P
oxidation (Bieber et al. 1 98 1 ) and membrane trapnsport/permiability (Fix et al. 1 986).
Nutrient-Nutrient Interactions

Carnitine status and metabolism are affected by several nutrients. Guinea pigs fed
a vitamin C deficient diet decreased plasma carnitine levels and increased the rate of
urinary carnitine excretion (Rebouche 1 991 ), which corresponded to a 1 5% decrease in
the rate of carnitine reabsorption in the vitamin C deficient guinea pigs (Rebouche 1 995).
Livers of iron deficient rat pups contained significantly less carnitine than livers of the
control pups. Impaired ketogenesis and hyperlipidemia were observed in iron deficient
pups (Bartholmey & Sherman 1 985). The study of 70 children in Turkey suffering from
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iron deficiency anemia aged 6 months to 2 years (mean age 14.5 ± 10.9 months) showed
significantly lower serum free camitine than the healthy controls (18.9 ± 0.43 nmol/ml
and 45 .9 ± 1.47 nmol/ml, respectively), where serum triglyceride, total cholesterol and
very low density lipoprotein (VLDL) levels were significantly increased. The authors
speculated that iron deficiency anemia may be linked to the endogenous camitine
synthesis which may be underlying causes of hyperlipidemia in pediatric age group
(Tanzer et al. 2001).
Previous investigators reported that choline deficiency alters camitine
metabolism. Choline deficiency decreased camitine concentration in liver, heart and
skeletal muscle (Carter and Frenkel 1978, Corredor et al. 1967) . Despite the decreased
tissue camitine concentrations, a significant increase in the serum camitine in choline
deficient rats was reported by Carter and Frenkel (1978) and Sheard and Krasin (1994)
However, no explanation of this phenomena was given by these investigators.
The changes in camitine concentration were observed in both choline deficient
and choline supplement�d rats after a 48 hr fast (Carter and Frenkel 1978). In the choline
deficient rats, camitine increased in the liver about 3-fold, but decreased slightly in the
heart and muscles. In choline supplemented rats 48 hr fasting increased the camitine
concentration in the heart, skeletal muscles and the liver. There were no differences
between choline deficient and supplemented rats in the concentration of plasma ketone
bodies after a 48 hr fast. Subsequently, these choline deficient rats were injected with
choline intraperitoneally to examine the changes in liver camitine. Choline injection was
able to raise the concentration of liver camitine to normal values within 1.5 hr. In
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addition to the choline injection, the other methyl-group donors, methionine, betaine and
sarcosine were injected to determine their ability to increase the concentration of liver
carnitine. None of these compounds were ineffective in increasing liver carnitine
concentration within the time period of this experiment (Carter and Frenkel 1 978). It
seems that increased liver carnitine concentration, after choline injection and a 48 hr fast,
were due to increased transport and uptake of carnitine into the liver.
In another study the decreased rate of palmitate oxidation was demonstrated in the
heart and liver homogenates from choline deficient rats (Corredor et al. 1 967). Addition
of carnitine, but not of choline, to heart homogenates from both the choline deficient and
control rats resulted in increased palmitate oxidation. When the rats were given
intraperitoneal injection of choline or carnitine before being killed, the rate of palmitate
oxidation was increased by liver and heart homogenate in both groups. Choline
administration to choline deficient rats increased their tissue carnitine concentrations.
The authors concluded that the decreased tissue carnitine in choline deficient rats are
responsible for the decreased rates of long-chain fatty acid oxidation (Corredor et al.
1 967).
Providing choline to ch(?line-deficient rats resulted in significant increases in the
carnitine concentrations of liver and muscle, and significantly lower urinary carnitine
excretion (Carter and Frenkel 1 978). Choline supplement also increased the total body
pool of carnitine and increased carnitine turn over rate in rats (Tsai et al 1 975). However,
serum and urinary carnitine concentration were significantly lower in choline
supplemented than choline deficient rats (Carter and Frenkel 1 978, Sheard and Krasin
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1994, Tsai et al. 1974). These studies suggested that the effects of choline on camitine
may extend the relationship beyond camitine biosynthesis; that is choline, as a methyl
group donor for the methylation of lysine residues, choline may participate in modifying
the transport of camitine into all tissues where camitine is needed.
Choline supplementation in choline sufficient humans and animals demonstrated
the alteration of camitine homeostasis. In 1996, Dodson and Sachan demonstrated for the
first time, that choline supplementation resulted in conservation of camitine altered renal
clearance and urinary excretion of most fractions ofcamitine in 23 to 52 y healthy
humans of diverse ethnic background. Their urinary camitine concentrations became
similar to the ones reported in vegetarians (Lombard et al. 1989, Sachan et al. 1997).
Serum total camitine (TC), frequently used as the evaluation of camitine status of
humans, was not affected by the choline supplement. However, one case was reported to
exhibit 50% reduction of serum camitine concentration after 7 d of supplement of
choline; and it would have been assessed as camitine deficient (Dodson and Sachan
1996).
These observations in humans lead to a search for an animal model for studying
choline-camitine interaction, and rats were used first for this purpose (Daily and Sachan
1995). Male Sprague-Dawley rats were fed control and choline supplemented diets.
There were no significant differences in the serum and urinary camitine in the two
groups. Other investigators were also unable to show the effects of choline on camitine
concentrations in rats (Sheard et al. 1992). It was postulated (Daily and Sachan 1995)
that the lack of effects in rats might be due to their 60-fold higher hepatic choline oxidase
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activity compared to humans showed by Sidransky and Farber (1 960). The specie that is
the closest to human in choline oxidase activity is guinea pig. Guinea pigs have hepatic
choline oxidase activity about 3 times higher than that of humans (Table 2-2). Therefore,
guinea pigs were used to determine the effects of choline on carnitine homeostasis (Daily
and Sachan 1 995).
Guinea pigs had free access to a nonpurified guinea pig diet (Purina Mills,
Richmond, IN). The choline-supplemented diet was prepared by adding 3 g choline as
choline chloride/kg diet to the control chow diet for 1 0 d. Plasma TC concentration was
significantly higher in the choline supplemented than in nonsupplemented guinea
pigs, which was different from results seen in humans study (Dodson and Sachan 1 996).

TABLE 2-2

Hepatic choline oxidase in selected species 1-2
Species

Rat
Chicken
Mouse
Hamster
Monkey
Guinea Pig
Human
1

Choline oxidase activity

2408 ±
131 1 ±
895 ±
361 ±
1 44 ±
1 36 ±
40 ±

Comparison to humans

121

60.2

72
63
21
43
7

22.4
9.0
3.6
3.4
1 .0

8

Values are µL of 02 uptake / hr / g wet liver ± SEM.
Modified from Sidransky and Farber (1 960)

2
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32.8

Urinary excretion of carnitine was significantly lower in the choline supplemented
guinea pigs. This conservation of carnitine led to the determination of carnitine
distribution among various tissues in the guinea pigs. The concentration of carnitine were
increased in all tissues, especially in skeletal muscle (Daily and Sachan 1995).
Subsequently, metabolic consequences of choline-induced carnitine accretion in
guinea pigs were determined under normal, starvation and treadmill running exercise
conditions (Daily et al. 1998). The respiratory quotient (RQ) of both groups decreased
over the 8 hr starvation period. The increased hepatic CPT-I due to starvation was
significantly increased in nonsupplemented, but not in the choline supplemented guinea
pigs. There were no significant differences in RQ during exercise, but there was 30%
increase in the running time of the choline supplemented guinea pigs. There was
significant loss of body fat and gain of protein by the choline supplementation (Daily et
al. 1998).
In summary, the human study clearly showed that choline supplementation results
in carnitine conservation as indicated by the reduced urinary carnitine excretion. Plasma
carnitine values were not altered except in few individuals (Dodson and Sachan 1996).
These finding were confirmed in the guinea pig model (Daily and Sachan 1995). It
demonstrated that reduced excretion of carnitine is not an indicator of choline-induced
carnitine deficiency. Instead, there is an increased camitine accretion in skeletal muscle.
A consequence of this shift of carnitine is related to lower carcass fat in choline
supplemented guinea pigs. However, there is no evidence of enhanced fat oxidation as
determined by the change in RQ values in choline supplemented guinea pigs under
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normal and exercised conditions (Daily et al. 1998).
Carnitine supplementation
A. Physical performance
It is clear that camitine has important functions in cellular metabolism in muscles
during exercise. Muscle camitine homeostasis is perturbed during exercise. There is
theoretical basis for camitine supplementation to improve exercise performance in
healthy humans. Brass (2000) summarized the potential mechanisms for a beneficial
effect of camitine supplementation on exercise performance in healthy humans. These
include: 1) enhance muscle fatty acid oxidation, 2) preserve muscle glycogen during
exercise, 3) enhance acylcamitine production, 4) activate pyruvate dehydrogenase via
lowering of acetyl-CoA content, 5) improve muscle fatigue resistance and 6) replace
camitine losses during training.
The obligatory role of camitine is the transfer of long-chain fatty acids across the
mitochondrial membrane. It has been hypothesized that camitine supplementation might
increase the availability and capacity to transport fatty acids into mitochondria as well as
subsequent fatty acid oxidation, thus making more adnosine triphosphate (ATP) available
for work. If camitine supplementation increases muscle fatty acid oxidation, this would
delay the depletion of muscle glycogen and thus delay fatigue development (Marconi et
al. 1985). Camitine supplementation showed increased concentration of camitine in rat
muscle (Simi et al. 1990), but the effects of camitine supplementation on humans'
skeletal muscle accretion are not unequivocal. Arenas and coworkers (1991) reported
that camitine supplementation, 2 g/d for 6 mo, increased muscle camitine content by 6 %
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in endurance athletes and sprinters. However, other studies with shorter periods of

supplementation, 5 g/d for 5 d (Sumida et al. 1 989), 6 g/d for 7- 14 d (Vukovich et al.
1 994), or 4 g/d for 14 d (Barnett et al. 1 994) showed no effect on muscle camitine

concentration, despite increases in plasma camitine concentrations (Vukovich et al. 1 994,

Barnett et al. 1 994) . The reasons for this discrepancies may well fit the pharmacokinetic
considerations of camitine. Camitine is taken up by muscle against a concentration
gradient, i.e. approximately 0.05 mM in plasma and 1 mM in skeletal muscle. This

gradient is so large that even a substantial oral intake would not result in a measurable

change (Hawley et al. 1 998). Furthermore, after acute administration of large doses of

camitine, most of the camitine is rapidly eliminated in the urine (Brass et al. 1 994).

Considering its gradient, renal loss, low bioavailability of oral camitine supplement

(-1 5%) and slow trunover rate in skeletal muscle ( 1 9 1 h), it seems that very large dosing
for a long period of time would be necessary to significantly affect muscle camitine in

healthy people.

In agreement with the hypothesis of enhancing fatty acid oxidation by carnitine

supplementation, Broderick and coworkers (1 992) demonstrated increased oxidative

metabolism of glucose, and improved function of isolated rat hearts perfused with

exogenous camitine. Shifting substrate used in muscle from fatty acid to glucose allows
more ATP generation per 02 consumption (Wasserman and Whipp 1 975). This

mechanism (camitine induced enhanced glucose oxidation) may be associated with the

activation of pyruvate dehydrogenase that is related to reductions of acetyl-CoA by
acetylcamitine formation (Uziel et al. 1 988).
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Carnitine concentration in skeletal muscle has been reported to decrease during
high intensity exercise (Hiatt et al. 1989) and in the non-professional athletes during 4 mo
period of training (Arenas et al. 199 1). It is one of the hypothesized benefit of carnitine
supplementation; replacement of carnitine loss during training would enhance exercise
performance. However, it has not yet established that carnitine availability might become
a rate-limiting factor of fatty acid oxidation. No experimental studies are available to
assess the functional significance of changes in carnitine concentration in skeletal muscle
in humans.
The idea of improving muscle fatigue resistance by carnitine supplementation was
supported by the in vitro animal studies (Brass et al. 1993, Dubelaar et al. 199 1). High
carnitine concentrations were shown to increase force generation and decrease muscle
fatigue. This mechanism is applicable to human exercise, and needs to be further
investigated.
Previous studies of carnitine supplement effects on exercise performance in
healthy humans are summarized in Table 2-3 . It should be noted that the experimental
designs in these studies varied a great deal. Carnitine was supplemented in various doses,
routes and durations of treatment. Some of these may or may not give pharmacological
benefits of carnitine to individuals. In addition, these studies involved populations of
groups diverse in age, gender and different physical-training experience. Endpoints of
these studies were either performance (i.e. V02max, athletic performance, running time,
etc.) or metabolic indexes of fatty acid oxidation (i.e. RQ, lactate accumulation, etc.).
Short-term administration (up to 2 wk) of carnitine failed to show an increase in
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TABLE 2-3
SummarJ::._ ofresults [!om studies o[. carnitine on exercise 2.er[2rmance 1
Daily
Finding
Treatment
Carnitine
Study
Duration
Dose
Subject
2 wk
l V02max
6 competitive
4g
Marconi et al.
walkers
(1985)
Greig et al.
(1987)

9 untrained

2g

2 wk

No effect

Oyono-Enguelle
et al. (1988)

10 untrained

2g

2 wk

No effect

Soop et al.
(1988)

7 trained

5g

5d

No effect

Gorostiaga et al.
(1989)

10 trained

2g

28 d

i RQ

110 trained

3g

3 wk

l V02max, i FFA
i triglycerides

Siliprandi et al.
(1990)

10 trained

2g

i postexercise lactate
1 dose
1 hr prior to test & pyruvate

Vecchiet et al.
(1 990)

10 trained

2g

l V02 max, i lactate
1 dose
I hr prior to test

Wyss et al.
(1990)

7 untrained

3g

Natali et al.
(1993)

12 untrained

Dragan et al.
(1989)

Trappe et al.
(1994)

· 20 trained

7d

No effect

l fatty acid
3g
1 dose
Intravenously 40 min prior oxidation during
to test
recovery
No effect
7d
4g

Brass et al.
14 untrained
--1 g
1 dose
No effect
Intravenously at start of test
(1 994)
1
Abbreviation used: FFA, serum free fatty acids; RQ, respiratory quotient; V02max,
maximal oxygen consumption.
34

TABLE 2-3 (continued)

Study

Summary ofresults from studies of carnitine on exercise per[ormance 1
Daily
Camitine
Treatment
Finding
Subject
Dose
Duration

Vukovich et al.
(1994)

8 untrained

6g

7- 14d

No effect

Colombani et al.
(1996)

7 untrained

4g

Day of
event

No effect

Zajijc et al.
et al. (200 1)

12 trained

2g

8 wk

T V 02max, T speed
T power, l body fat

Volek et al.
(2002)

10 trained

l purine degradation,
l free radical
l tissue damage, and
l muscle soreness
during recovery
1
Abbreviation used: FFA, serum free fatty acids; RQ, respiratory quotient; V02 max,
maximal oxygen consumption.
2g

3 wk

exercise capacity (Colombani et al. 1996, Greig et al. 1987, Trappe et al. 1994, Soop et al.
1988), with few exceptions. As shown in rats (Berardi et al. 2000) and humans (Brass et
al. 1994), administration of a single dose of camitine may not be able to increase the
camitine skeletal muscle. On the other hand, if it were possible to increase the skeletal
muscle camitine content, an increase in physical performance could be expected.
Few studies have reported beneficial effects ofshort-term camitine administration
(up to 2 wk) on exercise performance (Marconi et al. 1985, Siliprandi et al. 1990,
Vecchiet et al. 1990). Exercise-induced lactate accumulation was reduced by camitine
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supplementation (Siliprandi et al. 1 991, Vecchiet et al. 1 990). Siliprandi et al. ( 1 990)
found that plasma lactate and pyruvate concentrations were decreased after exercise in the
carnitine-supplemented subjects. This decrease was accompanied by an increase in
plasma acetylcarnitine (AC). The authors speculated that carnitine administration (2 g) 1
hr before high intensity exercise would stimulate pyruvate dehydrogenase, reducing
lactate concentration and forming acetyl-CoA, as indicated increasing AC concentration.
Vecchiet and coworkers (1 990), using a similar experimental protocol, reported that
supplementation (2 g/dose) significantly increased V0 2max and reduced lactate
concentration. In another study, 3 g of intravenously injected carnitine lead to a
significantly higher lipid oxidation rate during an exercise task, comprised of 40 min of
aerobic exercise followed by 2 min of anaerobic exercise (Natali et al. 1 993).
Long-term administration (4 wk or longer) of carnitine showed an increase in
exercise capacity (Dragan et al. 1 989, Gorostiaga et al. 1 989, Marconi et al. 1 985,
Volek et al. 200 1 , Wyss et al. 1 990, Zajc1c et al. 200 1). Gorostiaga and coworkers (1 989)
found that 28 d of carnitine supplementation, 2 g/d, resulted in a lower RQ during
exercise at 66% V02 max compared to a placebo group. Carnitine supplementation
increased V02 max following 2 to 3 wk of carnitine supplementation, 3 to 4 g/day in
trained athletes (Dragan et al. 1 987, Marconi et al. 1985). Work by Zajclc and coworkers
(2001 ) provided evidence for positive effects of carnitine supplementation, 2 g/d for 8 wk
in trained athletes. Speed and power were assessed by the 20 m sprint, using electronic
photocells, and the vertical jump using the vertex device, respectively. Body fat content
was significantly reduced in the supplemented athletes and showed improvement in speed
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and power. In another study, camitine supplementation (2 g/d for 3 wk) showed a
favorable effect on assisting recovery from high-repetition squat exercise (Volek et al.
2002). There was significantly less accumulation of markers of purine degradation, free
radical formation and tissue damage, and muscle soreness compared to placebo.
Studies that have used longer supplementation periods have reported no effects of
camitine supplementation (Greig et al. 1 987, Oyono-Enguelle et al. 1 988). Greig et al.
(1 987) reported no benefit from 2 g/d of camitine for 4 wk. They found no changes in
V0 2max, RQ, or plasma lactate and P-hydroxybutarate concentration. In another study,
Oyono-Enguelle gave 2 g/d of camitine for 4 wk, showed that plasma total and free
camitine concentration reached a plateau about 9-20 d after the supplementation. There
was no change in V02max, and RQ in the untrained subjects. The elevated serum
camitine concentration returned to the baseline values at 6-8 wk after termination
(Oyono-Enguelle et al. 1 988).
Given these diverse findings, it is difficult to draw definitive conclusions about
the ability of camitine supplementation in improving exercise performance in healthy
humans. Although, there are insufficient data to support camitine as an ergogenic aid,
there are also insufficient data to ignore the effects of camitine on exercise performance.
It appears that additional comprehensive human studies are needed to evaluate the effects
of camitine supplementation on lipid metabolism during exercise, before general use of
camitine can be recommended for the stated promises.
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B. Weight loss and management

The relationship of the carnitine homeostasis to the critical metabolic processes of
fatty acid oxidation has led to speculation about the potential benefits in obese persons
undergoing weight reduction. The most frequently used strategy of weight loss is low
calorie diets together with physical exercise. Both of these measures, diet and exercise,
may induce reduction of carnitine in a body. Carnitine supplementation is known to
provide a lipotropic effects. Carnitine increases the hepatocellular uptake of carnitine and
fatty acids under the circumstance of starvation (Kispal et al. 1987) and alcohol induced
fatty liver (Sachan et al. 1984). Low levels of carnitine may cause triglycerides to rise,
weight to gain, and may lead to heart disease due to possible impairment of P-oxidation.
These speculations may be justified on theoretical grounds, but they are not validated
through in animal or human studies. In addition, comprehensive clinical trials in humans
are lacking. At this time there is no experimental evidence of potential promotion of fat
oxidation by camitine in obese individuals.

CHOLINE

Choline, trimethyl-P-hydroxyethylammonium, is similar to carnitine in structure
with a molecular weight of 121 .2 g/mol (Figure 2-4). Choline is widely distributed in
our foods and is essential for normal function of all cells (Zeisel 1981 ). Choline and its
metabolites are important for providing structure of cell membranes, facilitating
transmembrane signaling, manufacturing the neurotransmitter responsible for memory
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FIGURE 2-4 Structures of choline and related metabolites. R1 and R2 represent fatty
acyl groups.
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and muscle contractions, and metabolizing fat and cholesterol. Choline is also known for
a lipotropic compound, preventing deposition of fat in the liver (Best and Huntsman
1 932).
Most choline is stored in the animal tissues such as brain, kidney and liver
primarily as phosphatidylcholine (lecithin) and spingomyelin (Houtsmuller 1 979). Other
important metabolites of choline are listed in Table 2-4.
Choline was first discovered by Strecker in 1 862, when it was isolated from the
bile of a pig (Strecker 1 862). The structure of choline was determined and synthesized in
1 866 (Baeyer 1 866). Choline was recognized as a component of phospholipids, but the
pathway for its incorporation into phosphatidylcholine (lecithin) was not elucidated until
1 956 (Kennedy and Weiss 1 956). Early studies with insulin led to study of choline as an
important nutrient. Metabolism of depancreatized dogs was demonstrated to prevent
hepatic damage after the administration of raw pancreas, where the active component was
pancreatic phosphatidylcholine (Allan et al. 1 924, Best and Hershey 1 932, Hershey
1 93 0). The development of fatty livers in rats fed a low-choline, high-fat diet was
prevented by choline supplementation (Best and Huntsman 1 932). Subsequently, Best
and co-workers showed that choline supplementation prevented the formation of fatty
liver in chronic ethanol-fed rats (Best et al. 1 949).
Dietary supplementation with soybean polyenylphosphatidylcholine, a purified
extract comprising 94-96% of polyunsaturated phosphatidylcholines, prevented the
development of alcohol-induced fibrosis and cirrhosis in nonhuman primates (Lieber et
al. 1 994). In another study the same authors showed attenuation of fatty liver and
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TABLE 2-4
Choline-containing compounds and their physiologic importance 1
Compound

Physiological function

Choline

Methyl group metabolism, constituent of various
compounds (see below)

Betaine

Methyl group donor, renal osmolyte

Acetylcholine

Neurotansmitter used by cholinergic nerves

Phosphatidylcholine (Lecithin)

Necessary building block of biomembranes
Component necessary for hepatic VLDL secretion
Choline reserve; provides 1,2-sn-diacylglycerol
(DAG), fatty acids, phosphorylcholine for cell
signaling

Sphingomyelin

Necessary building block of biomembranes,
Participate in cell signaling

Platelet-Activating Factor

Activation of platelets, inflammatory and immune
response, egg implantation, induction of labor

Lysophosphatidylcholine

Putative second messenger modulating protein
kinase C (PKC) activity

Lysosphingomyelin

Putative second messenger mediating growth-factor
actions, mitogen

Glycerophosphocholine

Renal osmolyte

Phosphocholine

Intracellular storage pool of choline

Plasmalogen

Found in sarcolemma, the membrane of cardiac
muscle; breakdown may contribute to sequelae of
myocardial infarction

1

Modified from Canty and Zeisel (1994), Zeisel and Blusztajn (1994).
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hyperlipemia by the administration of polyenylphosphatidylcholine for 3 wk in rats
(Navder et al. 1997). This finding suggested that the preventive effect of
polyenylphosphatidylcholine was, at least in part, mediated by the correction of hepatic
mitochondrial fatty acid oxidation.
There are exciting observations that greatly enhance our understanding of the
metabolism, functions, physiologic effects and pharmacology of choline. In 1946,
Copeland and Salmon first reported that prolonged choline deficiency developed liver
cancer in rats (Copeland and Salmon 1946). Subsequently, numerous studies showed that
a choline-deficient diet promotes liver carcinogenesis in animal models (Ghoshal and
Farber 1984, Locker et al. 1986, Newbeme and Rogers 1986). A number of possible
mechanisms have been proposed for the development of cancer by choline deficiency.
Some of these include increased cell proliferation with an associated rate of DNA
synthesis (Rushmore et al. 1986), induced apoptosis in hepatocytes (Albright et al. 1996),
decreased DNA methylation and repair (Locker et al. 1986), increased lipid peroxidation
and free radical damage (Rushmore et al. 1984, Ghoshal and Farber 1993 ), and the
formation of an excessive amount of DAG, which overstimulates PKC (da Costa et al.
1993 , da Costa et al. 1995).
Since mid- 1 970, several researchers have reported that administration of choline
accelerates the synthesis and release of acetylcholine by neurons (Cohen and Wurtman
1975, Haubrich et al. 1974, Rada et al . 1994, Wecker 1 986 and 1 990b). This relationship
of choline and acetylcholine synthesis promoted an interest in dietary choline
supplementation and brain function. Recent research has shown a beneficial effect of
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prenatal choline supplementation in brain development in rats. Dietary choline
supplementation during embryonic days 1 1 to 1 7, which is a period of high cell division
and programmed cell death in fetal rat brain, leads to a life-long improvement of visuo
spatial memory performance in the offspring (Meck et al. 1 989, Meck and Williams
1 999). Possible mechanism of this memory facilitation induced by prenatal choline
supplementation are; 1 ) alterations of acetylcholine synthesis and release (Blusztajn and
Wurtman 1 989, Cermak et al. 1 998), 2) enhancement of hippocampal function (Jones et
al. 1 999, Montoya and Swartzwelder 2000, Pyapali et al. 1 998) and 3) changes in choline
containing phospholipids cell signaling event in the brain (Zeisel and Blusztajn 1 994).
In 1 998, choline was classified as an essential nutrient for humans by the Food
and Nutrition Board of the Institute of Medicine of the National Academy of Science
(Food and Nutrition Board 1 998). This official recognition of the importance of choline
was the result of many studies, that identified choline deficiency in humans under certain
clinical conditions and disorders (Buchman et al. 1 992, Sheard et al. 1 986, Shronts 1 997).
When healthy humans consumed an experimental diet deficient in choline for 3 wk, they
depleted stores of choline in tissues and developed signs of liver dysfunction (Zeisel et al.
1 99 1 ). Thus, choline is an essential nutrient for humans.
Dietary Sources of Choline

Choline is widely distributed in many foods (Table 2-5), primarily in the form of
lecithin (Engel 1 943, Wurtman 1 979). Lecithin is approximately 13% choline by weight.
The richest food sources of choline are egg yolk and organ meats. Other good sources of
choline include beef, nuts, leafy greens, soy beans, seed oils, and dairy products.
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TABLE 2-5

Food
Meat Products

Choline and choline ester content in commonfoods 1-2
Lecithin
Sphingomyelin
Choline
(mg/serving)

Beef liver (3 .5 oz)
Beef steak (3.5 oz)
Lamb chop (3.5 oz)
Ham (3.5 oz)
Trout (3.5 oz)

600
80
NR3
1 20
84

3363
466
753
800
580

135
69
NR
NR
NR

Whole milk ( 1 cup)
Cheese ( 1 oz)
Margarine ( 1 oz)

3.0
NR
0.08

28
1 4-28
' 1 .4-2.8

15
NR
0.04

Apple ( 1 medium)
Banana (1 medium)
Carrot ( 1 oz)
Cabbage ( 1 oz)
Cauliflower (1 oz)
Cucumber ( 1 oz)
Iceberg lettuce (1 oz)
Kale (1 oz)
Orange ( 1 medium)
Potato (1 medium)
Spinach ( 1 oz)
Tomato (1 oz)

0.4
4.4
2-3
13
22
0.63
8.5
25
3.0
6.0
1 . 1 -4.9
1 .3

4
0.7
1 .5-2.3
NR
0.6
0.22
3 .0
0.6
53
26.0
1 .7-4.0
0.2

0.2
0.4
NR
NR
NR
0.08
9.0
NR
2.5
2. 1
·NR
0. 1

Oat meal ( 1 oz)
Polished rice ( 1 oz)
Whole wheat bread (1 slice)

37
NR
3.0

1 86
1 67
1 .0

NR
NR
0.03

Coffee (6 oz)
Grape juice (6 oz)

19
9.0

2.0
2. 1

3 .0
0.7

Dairy Products

Fruits and Vegetables

Bread and Rice

Beverages

Miscellaneous

0.2-0.3
256-350
82
Egg (1 large)
1 3.0
97.4
0.2
Peanut butter (2 Tbsp)
Peanuts (1 oz)
1 3 .2
1 07
1 .6
Soybeans (1 oz)
68
423
NR
1
Values are mg/serving. Serving size is indicated in the parentheses.
2
Modified from Canty and Zeisel (1 994), Wurtman ( 1 979).
3
NR; Data were not reported in the above referenced papers.
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Choline, in the form of lecithin, is also added to many processed foods as an additive or
emulsifier. Lecithin helps disperse water in oil, and it increases the wetting
power of cocoa powder in chocolate bars (Wurtman 1979).
Human milk, bovine milk, and bovine milk-derived infant formulas contain
approximately 1-2 mmol/L (121-242 mg/L) choline and choline containing compounds
(Holmes-McNary et al. 1996, Zeisel et al. 1986). Human milk contains choline in the
form of choline, phosphocholine, glycerophosphocholine, sphingomyelin, and
phosphatidylcholine. Human milk has significantly higher phosphocholine than either
bovine milk or infant formulas. Phosphatidylcholine and sphingomyelin concentrations
are similar in both human and bovine milk. Soy-derived infant formulas have lower
sphingomyelin concentration and higher phosphatidylcholine concentration than human
milk or bovine milk-derived infant formula (Holmes-McNary et al. 1996).
It is estimated that average choline intake (free choline and choline esters) by
human adults is in a range of 6- 10 mmol (700-1200 mg) per day (Wurtman 1979, Zeisel
1999). Daily consumption of choline can be affected by many factors such as individual
food habits, religion, ethnic background, economic stat�s, geographic location, diet and
health considerations, and personal food preferences (Wurtman 1979). Diets high in
choline can be consumed by many normal healthy persons, if they include foods such as
beef liver, egg and other processed foods in their diets (Shronts 1997).
Human infants consume a choline-rich diet. Assuming that an infant drinks 800
mL/d, the daily choline intake would be approximately 1.2 mmol (145 mg). This intake
per kg body weight is 2-3 times more choline than average adults daily choline intake
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(Zeisel 1999). Because human milk and colostrum are rich sources of choline, the Infant
Formula Act of 1980 sets choline chloride at 7 mg/100 kcal as a requirement for all infant
formulas in the United States (American Academy of Pediatrics 1985). Importantly, the
Food and Nutrition board recognized that the growing fetus and neonate need increased
amount of choline and issued separate choline intake guidelines for nonpregnant,
pregnant and lactating women, which are 425, 450 and 550 mg/d, respectively (Food and
Nutrition Board 1998).
Choline Homeostasis

Serum and tissue choline concentration depends on the dietary intake of choline.
In human adults who are consuming common foods plasma choline concentrations
fluctuate over approximately 2-3 - fold range, 7-20 µmol/L (Zeisel 1992, Zeisel et al.
1980b ). Plasma choline concentration was elevated 300-400% after a single dose of
choline chloride in healthy humans (Hirsche et al, 1978, Hollister et al, 1978). Large oral
doses of lecithin (0.3 g/kg body weight) increased serum choline concentration 400% and
its significant elevation was sustained for 1 2 hours (Zeisel et al. 1 980b ). The prolong
effects of lecithin may be due to it's resistance to degradation to trimethylamine within
the gut (Zeisel 1981 ).
Lactating women consuming a low choline diet produced milk with lower choline
than in those consuming more adequate diet high in choline (Zeise! et al 1982). When
lactating rat dams were provided with either a control, choline-deficient, or choline
supplemented diet, their milk composition reflected the choline content of their diets.
Milk phosphocholine concentrations were increased by 4-fold with the choline ·
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supplemented diet in the lactating rats (Holmes-McNary et al. 1996). Thus, dietary intake
of milk choline contributes to the maintenance of high serum choline concentration in the
neonates, which have 4-7 times higher serum choline concentration than adult humans or
rats (Zeisel et al. 1980a).
Choline Biosynthesis
Diet is not the only source of choline. De novo synthesis of choline molecules
occurs by two pathways (Figure 2-5). In the first, phosphatidylethanolamine is
sequentially methylated to form phosphatidylcholine, using S-adenosyl methionine
(SAM) as methyl donor (Vance and Ridgway 1988). This is the only pathway for de
novo synthesis of new choline moiety in adult mammals (Bremer and Greenberg 1961 ).
It is catalyzed by the membrane bound enzyme phosphatidylethanolamine-N
methyltransferase (EC 2. 1.1.17), which is active in liver, but it is also found in many
other tissues, including brain (Blusztajn et al. 1979), and the mammary gland (Yang et al.
1988). In rats 15% of the daily requirement of choline, about 13 µmol/g of liver, is met
by this methylation pathway (Bremer and Greenberg 1961 , Schneider and Vance 1979).
The activities of the methylation pathway are increased by choline deficiency and ethanol
ingestion in rats (Fallon et al. 1961, Uthus et al. 1976).
Another pathway for phosphatidylcholine biosynthesis is the cytidine
diphosphocholine (CDP) pathway. In this pathway choline is first phosphorylated, then
converted to cytidine diphosphocholine (CDP-choline). This intermediate in combination
with diacylglycerol, forms phosphatidylcholine. Within the liver most of the
phosphatidylcholin is synthesized by the CDP pathway (Sundler and Akesson 1975).
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The biosynthesis of phosphatidylcholine is regulated by the enzyme, phosphocholine

cytidylyltransferase (EC 2 . 7. 7 . 1 5). The content of phosphatidylcholine in the membrane
also regulates the amount of enzyme bound to membranes. Binding of

cytidylyltransferases to membranes increases when their phosphatidylcholine content
decreases, whereas the reverse occurs when membrane phosphatidylcholine content

increases (Watkins and Kent 1 992, Jamil et al. 1 993). These findings may explain why

cytidylyltransferase activity increases in choline deficient hepatocytes (Yao et al. 1 990).
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Absorption

Choline is absorbed as free choline from the small intestine, mainly in the jejunum
(Sanford and Smith 1 971 ), and it enters the portal circulation. Unabsorbed choline is
metabolized to betaine and trimethylamine by bacteria in the lower gut (De La Huerga
and Popper 1 95 1 , Flower et al. 1 972). As noted before, most dietary choline is in the
form of phosphatidylcholine. Both pancreatic secretions and intestinal mucosa! cells
contain enzymes (namely phospholipase A 1 , A2 , and B) that can hydrolyze
phosphatidylcholine (Houtsmuller 1 979, Parthasarathy et al. 1 974). The other choline
containing phospholipid, sphingomyelin, is not degraded by intestinal microflora, but is
taken up by the enterocyte, then extensively hydrolyzed in the mucosa! cell. The enzyme
sphyingomyelinase is found in the liver, which hydrolyzes sphyingomyeline and forms
phosphorylcholine and ceramide (Heller and Shapiro 1 966). In the brain, kidney, liver
and spleen phospholipase C acts on syphingomyelin, forming phosphorylcholine. Then,
they can be cleaved by phosphatase, producing free choline (Fujino 1 952, Illingsworth
and Portman 1 973).
The ingestion of large amount of choline chloride causes the unpleasant smell,
fish-odor syndrome, but this is not observed when lecithin is administered (Zhang et al.
1 999). The explanation for this beneficial effect of lecithin is that lecithin is hydrolyzed
by phospholipase A, found in pancreatic juice, to produce lysolecithin in the intestinal
lumen. Further degradation does not occur in the upper gut and there is no release of
choline available for the intestinal microflora (Houtsmuller, 1 979).
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Transport and Tissue Uptake

Most tissues take up choline by a combination of diffusion and carrier mediated
transport systems (Haubrich et al. 1 975). Choline is transported via an active uptake
system in the liver where it is converted to betaine, phosphocholine and
phosphatidylcholine (Zeisel 1 990). Kidneys also oxidize choline to form betaine, which
may serve as an important osmoprotectant within the kidney (Grossman and Hebert
1 989). Mammary cells accumulate choline by both energy-dependent and passive
transport mechanisms. Choline is delivered to the fetus across placenta, where it is stored
in large amounts as acetylcholine. All of the acetylcholine synthesized within the
placenta must be made by using exogenous choline, since the placenta lacks the ability to
synthesize choline de novo. Acetylcholine within the placenta is not associated with
neurons, and its function is not known (Welsch 1 976).
Choline is used by brain cells for the synthesis of phophatidylcholine and other
choline-containing lipids. The brain lacks the metabolic machinery to synthesize choline
de novo. Therefore, the brain is dependent on circulating free choline and choline
phospholipid in plasma and the liver for its supply (Freeman and Jenden 1 976). The
choline-phospholipids in cholinergic neurons provide a precursor pool of free choline that
can be used for the synthesis of the neurotransmitter, acetylcholine (Wecker 1 990a). Free
choline is transported across the blood brain barrier by a specific carrier (Cornford et al.
1 978). Subsequently the choline is transported into brain cells via either a low-affinity or
a high-affinity choline transport system (Yamamura and Snyder 1 973 ).
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Within cholinergic terminals, choline is coupled with glucose-derived acetyl-CoA to form
the neurotransmitter acetylcholine.
Metabolism

Choline can be acetylated, oxidized and phosphorylated. A small fraction of
dietary choline is acetylated to form acetylcholine by a reversible reaction (Figure 2-6) .

choline acetyltransferase
•
Choline + Acetyl CoA ,..
Acetylcholine + CoA
FIGURE 2-6 Acetylcholine formation.

The reaction is catalyzed by choline acetyltransferase (EC 2.3 . 1 .6), a cytoplasmic enzyme
that is highly concentrated in the terminals of cholinergic neurons (Haubrich et al. 1 975).
There is considerable interest in the role of choline as a precursor of acetylcholine.
Exogenous choline administered by an acute injection or through dietary supplementation
raises: 1 ) serum choline concentration, 2) brain choline and acetylcholine and 3) the
acetylcholine at cholinergic neurons (Cohen and Wurtman 1 975). Further studies are
needed to elucidate the mechanisms that would account for increased synthesis of
acetylcholine by choline supplementation. This information will allow the development
of therapeutic strategies for the treatment of neuropsychiatric disorder, such as
Alzheimer's disease (Wecker 1 990a).
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Oxidation of choline to betaine is a major pathway for choline catabolism and it is
active in liver and kidney, but it does not seem to be present in brain and muscle.
(Bernheim and Bernheim 1933). This process involves the following steps: 1) transport
of choline from the cytosol to mitochondria, 2) oxidation of choline to betaine aldehyde
by choline dehydrogenase (EC 1.1. 9. 91 ), 3) oxidation of betaine aldehyde to betaine by
betaine aldehyde dehydrogenase (EC 1.2.1.8) and 4) release of betaine from the matrix
into the cytosol.
Betaine, the end product of choline oxidation, cannot be reduced to form choline.
However, it can donate a methyl group to homocysteine, forming dimethylglycine and
methionine. The availability of choline as a methyl donor is the major factor that
determines how quickly a choline-deficient diet leads to a pathologic condition (Zeisel
2001 ). Therefore, the metabolisms of methionine and folate is closely interrelated with
choline in methyl group metabolism (Figure 2-7). Rats fed a diet deficient in choline
develop diminished tissue concentration of methionine and SAM (Barak et al. 1982,
Zeisel et al. 1 989) and total hepatic folate (Selhub et al. 199 1 ).
The phosphorylation of choline is catalyzed by choline kinase (EC 2.7.1.3 2) using
adenosine triphosphate as the phosphate donor. It is a soluble, cytosolic enzyme, widely
distributed in tissues including liver, brain, kidney and lung (Brophy et al. 1977).
Phosphorylation of choline is the first step in the CDP-pathway for the synthesis of
phosphatidylcholine (lecithin). In this pathway cytidine triphosphate and phosphocholine
are combined and forms CDP-choline and inorganic phosphate. This is a rate limiting
step for the pathway. The CDP-choline is subsequently combined with diacylglycerol
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and forms lecithin (Figure 2-5). The rate of phosphorylation of choline in forming
phosphocholine is slower (1 µmol/hr/g) than the rate of oxidation of choline in forming
betaine (9 µmol/hr/g) in rat liver (Weinhold and Sanders 1 973).
Functions

Choline serves several biological functions in the body. Choline is a component
of a number of important metabolites (Table 2-4 ). The formation of betaine from choline
provides an important source of methyl groups for generating methionine (Figure 2-7).
Betaine concentrations in livers of choline deficient rats are significantly reduced (Barak
and Tuma 1 983), as are total folate concentrations (Home et al. 1 989). A disturbance in
choline metabolism results in changes in methionine and folate metabolism. Recently,
oral administration of bataine for 1 y showed significant biochemical and histological
improvement in patients with nonalcoholic steatohepatitis. There were significant
improvements in the degree of steatosis, necroinflammatory grade, and stage of fibrosis .
. Authors suggested that increased SAM levels by betaine may play a role in marked
improvement in these patients (Abdelmalek et al. 200 1 ).
Another biochemical function of choline is the formation of phosphatidylcholine
(lecithin). Due to the function of choline metabolites in membrane structures, a choline, .
deficient diet results in a variety of phospholipid-related dysfunctions, such as fatty liver
and impairment of lipoprotein metabolism. Choline acts as a lipotropic agent, and
therefore, it decreases the rate of deposition and accelerates the rate of removal of fat
from the liver (Best et al., 1 950). During choline deficiency, large amounts of lipid,
mainly the form of triglycerides can accumulate in the liver (Yao and Vance 1 988). The
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triglycerides produced by the liver are delivered to other tissues, mainly in the form of
VLDL. Phosphatidylcholine is a required component of VLDL, and other phospholipid
compounds similar to phospatidylcholine can not substitute for phosphatidylcholine (Yao
and Vance 1 989). Chronic ingestion of a diet deficient in choline diminishes synthesis of
phosphatidylcholine, and t�at can result in intracellular accumulation of triglycerides, due
to continuing triglycerides synthesis, regardless of choline status of rats. A soy
phosphatidylcholine diet has been reported to be a potent hypocholesterolemic agent
because it reduces the absorption of cholesterol and increase the excretion of sterols in
rats (Omullane and Hawthorne 1 982). Consistent hypocholesterolemic of
phosphatidylcholine effects have been shown in hypercholesterolemic rabbits (Mastellone
et al. 2000, Polichette et al. 2000) and in patients with hyperlipidemia after the dietary
lecithin supplementation (Kesaniemi and Grundy 1 986, Polichetti et al. 1 998).
Recent studies show that choline phospholipids (i.e. phosphatidylcholine,
sphingomyelin and their metabolites) play important roles in signal transduction (Zeisel
1 993 ). Signal transduction begins with the binding of extracellular stimulus, such as a
hormone, antigen and neurotransmitter, to a receptor on the cell membrane surface. This
activates a guanosine triphosphate (GTP)-binding protein (G-protein), which then,
activates phopholipase C (PLC), phospholipase D (PLD), or phospholipase A (PLA)
within the plasma membrane. Phosphatidylcholine is broken dawn by lecithin-specific
PLC, PLD, or PLA. PLC generates DAG and phosphocholine; PLD generates
phosphatidic acid and choline; and PLA generates free acids (e.g. arachidonate) and
lysophosphatidylcholine. All the hydrolysis products, except choline, may act as second
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messengers (Besterman et al. 1 986, Exton 1 990). DAG, fatty acids, and
lysophosphatidylcholine stimulates PKC. By catalyzing phosphorylation reactions, PKC
can activate or inactivate a broad range of proteins including, membrane proteins,
receptor proteins, contractile and cytoskeletal proteins, and microtubule-associated
proteins (Nishizuka 1 986).
In cell membranes, phosphatidylcholine exists in a variety forms due to fatty acyl
chains. Therefore, hydrolysis of phosphatidylcholine can generate multiple forms of
diradylglycerides (DRG) in addition to DAG. These subclasses of DRG may differ in
their ability to activate PKC and may provide another mechanism for signal specificity
(Cabot and Jaken 1 984, Daniel et al. 1 988).
It has been recognized only recently that choline sphingolipids are necessary for
the survival and growth of cells (Hanada et al. 1 992). Metabolites of sphingolipids also
function as second messengers that inhibit the activity of PKC and terminate the signaling
cascade (Merrill and Jones 1 990). Sphingomyelin is hydrolyzed by sphingomyelinase,
producing ceramide and phosphocholine. Ceramide is a potent inhibitor of cell growth as
well as a mediator of apoptosis in response to extracellular agents and insults (Obeid et al.
1 993). Sphingosine, metabolite of ceramide, is a potent inhibitor of PKC, cell growth,
and it also exhibits antitumor properties (Hannun et al. 1 99 1 ). Lysosphingomyelin,
another product of sphingomyelinase hydrolysis, also inhibits PKC (Hannun and Bell
1 989).
In summary, choline phospholipids have the unique functions in cellular
regulation in addition to their essential roles as structural components of membranes and
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lipoproteins. The new finding of the role of choline phospholipids in signal transduction
may provide a molecular basis for the influence of choline in normal physiological and
disease processes, such as cancer and Alzheimer's diseases. Additional research is
required to determine how dietary and pharmacological intake of choline,
phospatidylcholine or other phospholipids may favorably alter the phospholipid
metabolism in humans.
Choline Supplementation
A. Nervous system and maintenance of normal lipid profile

Choline has been used to treat human diseases, primarily those of the nervous
system and the liver. It has been shown that choline supplementation increases not only
serum choline levels, but also brain choline and acetylcholine contents in rats (Cohen and
Wurtman 1975, Haubrich and Pflueger 1979). Furthermore, the administration of choline
as well as lecithin, has been demonstrated to be effective in increasing serum choline
levels in humans (Hirsch et al. 1 978, Zeisel 1 980b). These findings and the fact that
acetylcholine is a neurotransmitter in the central nervous system were used as rational for
the choline loading of the patients who exhibited a deficiency of cholinergic
neurotransmission. The therapeutic strategy has been to increase brain choline above
normal level by large pharmacological doses of choline in order to stimulate acetylcholine
synthesis within nerve terminals (Chan 199 1 ).
Choline was first tried as therapy for a patient with tardive dyskinesia that is a
movement disorder generally associated with the long-term use of neuroleptics (Davis et
al. 1 97 5). The pathophysiology of this syndrome was involved in inadequate
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neurotransmission at striatal cholinergic intemeurons (Davis and Berger 1 978). All
neuroleptics used in the United States have a potential for producing tardive dyskinesia
and the estimate of prevalence was reported from 0.5% to 50% (Jus et al. 1 976). Oral
administration of choline or lecithin have shown considerable success in the treatment of
tardive dyskinesia (Growdon et al. 1 977). Choline and lecithin has been used in the
treatment of other disorders or symptoms associated with inadequate cholinergic
transmission including: Huntington' s chorea, Alzheimer's disease, mania, Gilles de la
Tourette, and ataxia. The efficacy of choline/lecithin supplementation in these
disorder/symptoms has not been as convincing as it has been in tardive dyskinesia.
As discussed in a previous section, choline plays an important role in the
maintenance of normal lipid transport. The beneficial effects of choline supplementation
on serum lipids have been inconsistent. There are reports of a hypocholesterolemic effect
of choline. It is hypothesized that choline lowers blood cholesterol by stimulating biliary
cholesterol and lecithin excretion (Herrmann 1 947, Robins and Armstrong 1 976).
Contrary to this effect of choline, there are reports that oral administration of choline
increases plasma cholesterol, phospholipid, high density lipoprotein (HDL) and low
density lipoprotein (LDL) in rats (Olson et al. 1 95 8). If choline does increase blood
cholesterol concentration, it may be due to mobilization of lipids from hepatic stores.
Lecithin has been marketed as a dietary supplement, with claims that it lowers
blood cholesterol. Lecithin supplementation has been shown to lower serum cholesterol
and the incidence of atherosclerosis in rabbits fed a high cholesterol diet (Kesten &
Silbowitz 1 942). In healthy humans the effects of lecithin on serum cholesterol have
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been inconsistent (Grundy 1980, Hirsche et al. 1978, Steiner and Domanski, 1944). In
patients with type IIA hyperlipidemia, lecithin administration did not lower serum
cholesterol (Greten et al, 1980). In another study involving patients with type IIA
hyperlipidemia there was a significant increase in plasma level of apo AI-HDL (the major
contributor of the transport and exchange of cholesterol between tissues and plasma) after
a daily dietary supplement of purified soybean lecithin for 6 wk (Polichetti, et al. 1998).
There was no hypocholesterolemic effect; however, plasma concentration of unesterified
cholesterol was increased, which resulted in a decrease the ratio of esterifed:total
cholesterol. Authors suggested that soybean lecithin led increased unesterified
cholesterol, which in turn stimulated the reverse cholesterol transport by enhanced AI
HDL system (Polichetti, et al. 1998).
B. Physical performance
Choline has been used as a dietary supplement or ergogenic aid as a means of
enhancing acetylcholine synthesis and release at the neuromuscular junction (Kanter and
Williams 1995). Choline supplementation has been demonstrated to increase plasma
choline levels (Haubrich et al. 1974, von Allworden et al. 1993) and increase
acetylcholine release at the neuromuscular junction (Bierkamper and Goldberg 1980,
Blusztajn and Wurtman 1983). When an electrically stimulated skeletal muscle was
placed in a low choline medium, acetylcholine release decreased. However, when the
nerve was not stimulated, changing the choline concentration in the medium did not
change acetylcholine release (Bierkamper and Goldberg 1980). Thus, in theory, increased
acetylcholine availability should result in increased muscular contraction and a delay in
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muscular fatigue.
Physical exercise has been shown to reduce plasma choline concentrations in
human subjects (Conlay et al. 1 992, von Allworden et al. 1 993). There was about 40 %
decline in mean plasma choline in subjects running the Boston Marathon (Conlay et al.
1 992). Authors suggested that neuromuscular transmission may have been impaired by
the end of the race in these runners. In another study (von Allworden et al. 1 993),
triathletes performed a bicycle exercise at an average speed of 3 5km/hr for 2 hr showed
about 1 7% decline (range: 3 .6-54.7%) in plasma choline concentration. When 0.2 g
lecithin/kg body weight was administered 60 min prior to exercise, mean plasma choline
concentrations remained at the same level as the initial values. It is speculated that the
decline of choline may be due to the enhanced use of choline in the synthesis of
acetylcholine or as an intramuscular methyl donor during a long duration with a high
intensity of exercise. However, there are no direct experimental data to support these
mechanisms in exercising humans.
A few studies investigated the potential use of choline supplement as an
independent factor for improving physical performance (Sandage et al. 1 992, Spector et
al. 1 995, Warber et al. 2000). The preliminary report by Sandage et al. (1 992)
demonstrated that the mean run time of a 20-mile run was significantly shortened by
ingestion of 2.8 g choline citrate 1 hr prior to, and again after, completing 1 0 miles of a
20-mile ran. The supplementation prevented the decline of plasma choline which was
observed in placebo treated runners. Spector et al. ( 1 995) reported that trained cyclist did
not benefit from choline supplementation to delay fatigue nor improve work performance
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under the conditions of 1 50% and 70% of V02max at cadence of 80-90 rpm. Warber et
al. (2000) determined the plasma choline metabolites and physical performance measures
through a 4 hr load carriage treadmill exercise (3% grade at 5 .6 km/hr) carrying a total
load of 34. 1 kg in 1 4 male soldiers with or without 8.425 g of choline citrate. Following
the treadmill test, a run to exhaustion test and leg strength test using a barbell squat were
performed. Their mean (± SD) V02max was 60.3 ± 2.3 ml/kg/min, which is higher than
that previously reported for a similarly aged Amy population (Sharp et al. 200 1 , Vogel et
al. 1 986). Results showed that plasma choline, glycerophosphocholine, and
phosphatidylcholine concentrations did not change from baseline to post-exercise for
either treatment. There was no significant effects of choline supplementation on any
performance tests in this study. Researchers concluded that no merit at this time to
support a requirement of choline supplementation to reduce muscle fatigue and increase
physical performance in physically active humans (Warber et al. 2000).

CAFFEINE

Caffeine, 1 ,3,7-trimethylxanthine, is a white odorless powder with a molecular
weight of 1 94.2 g/mol (Figure 2-8). It is one of a family of purine derivative methylated
xanthines, which are often referred to as methylxanthines or merely xanthines. While the
class of methylxanthines is large, caffeine is the most common methylxanthine in nature
(James 1 99 1 ). Figure 2-8 shows the structure of .caffeine, and its dimethylxanthine
isomers: paraxanthine (1 ,7-dimethylxanthine), theobromine (3,7-dimethylxanthine) and
theophylline (1,3-dimethylxanthine).
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Caffeine was first isolated from green coffee beans in Germany by Runge (1 820)
and confirmed by von Giese the same year. Theobromine, an immediate precursor in
caffeine biosynthesis, was discovered in cocoa beans by Woskresensky in 1 842
(Woskresensky 1 842). In 1 861, Strecker converted theobromine to caffeine, leading to
the conclusion that theobromine was a dimethylxanthine, and caffeine was a
trimethylxanthine (Strecker 1 86 1 ). In 1 888 Kossel isolated theophylline from tea leaves
and identified it as a dimethylxanthine (Kossel 1 888). The third dimethylxanthine,
paraxanthine, was recently isolated from plants by Chou and Waller ( 1 980). However,
Salomon who isolated purine alkaloids from human urine, discovered paraxanthine for
the first time in 1 883 (Salomon 1 883).
Caffeine is the most widely consumed psychophysiologically active substance in
the world (Gilbert 1 984). Today, more than five million tons of green coffee beans are
produced annually in approximately 50 coffee-growing countries. The U. S. is the largest
importing country and 1 . 1 million tons were imported in 1 991 (National Coffee
Association, 1 99 1 ). That equals 3 billion dollars worth of green coffee beans (Lundsberg
1 998). It is estimated that four out of five Americans consume caffeine knowingly or
unknowingly every day (Harland 2000).
Although humans have consumed caffeine-containing plant products over the
centuries, interest in caffeine among the general public and the scientific community was
low before the late 1 970s. Intensive investigations of caffeine started after the re
evaluaiton of the risk of caffeine for human health by a special committee on generally
recognized as safe (GRAS) substances by the Food and Drug Administration (FDA) of
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the U.S. Public Health Service in 1978 (Dews 1984). Since then, significant numbers of
studies have been done to determine, if caffeine is potentially harmful to health. There
have been many contradictory results, thus, no conclusive recommendation yet exists for
the general population concerning how much caffeine can be consumed safely on a
regular basis (James 199 1).
The therapeutic use of caffeine has a long list due to its complex effects on
different organ systems, i.e. cardiovascular, respiratory, gastrointestinal, neuroendocrine,
and reproductive systems. General therapeutic applications, including effects and
rationales for the use of caffeine, are listed in Table 2-6. Most of the applications listed
in Table 2-6, except a few exceptions, have not been researched in sufficient detail to
permit firm conclusions about the effects of caffeine. In addition to the clinical
applications of caffeine listed in Table 2-6, it has been used as an ergogenic aid by
athletes of all ages to get an edge on their competitors (Lamarine 1998). Caffeine is a
common substance in the diets of most athletes, and it is also consumed in many new
products, including energy drinks, energy bars, caffeinated waters, alcoholic beverages,
diet aids and supplement pills (Graham 200 1). In the last decade the popularity of
caffeine in athletes has increased, probably because of the more convincing research on
the ergogenic nature of caffeine (Graham et al. 1994, Jacobson & Kulling 1989).
Recently, several investigators looked at the additive effects of caffeine and another drug
(ephedrine) and nutrients (carnitine, choline, creatine) on enhancement of physical
performance (Bell et al. 1998, Bell et al. 2002, Sachan and Hongu 2000, Vanakoski, et al.
1998). These studies are still in their early stage of the final conclusion. There have been
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TABLE 2-6

Therapeutic use of caffeine 1
Application

Effects of caffeine (references)

Neonatal apnoea

Successful treatment (Martin et al. 1986), used in
preference to theophylline (Bairam et al.1987, Nahata et al.
1989)

Sperm motility

Increased by direct exposure to caffeine (Bunge 1973)

Cancer

Potentiating effect on the action of certain antineoplastic
agent (Tomita & Tsuchiya 1989, Yunis et al. 1987)

Pain

Analgesic adjuvant (Beaver 1984), vasoconstrictor action
on cerebral blood vessels (Mathew & Wilson 1985

Nutrition

Dietary sources of minerals: manganese, potassium, copper
(Gillies & Birkbeck 1983)

Obesity

Thermogeinic drug (Acheson et al. 1980, Dulloo et al.
1989, Grollman 1930, Haldi, et al. 1941, Jung et al., 1981,
Means et al., 1917), used in combination with other
substances, i.e. ephedrine (Astrup et al. 1992), chromium
(Pasman et al. 1997, Hoeger et al. 2000), camitine
(Decombaz et al. 1987), choline and camitine (Hongu et al.
2000), inhibit adipocite proliferation (Bukowiecke et al.
1983)

Respiratory dysfunction

Relaxant effects on bronchial smooth muscle (Lima et al.
1989)

Postprandial hypotension

Pressor effects (Onrot et al. 1985)

Allergic reaction

Successful in the treatment of atopic dermatitis (Kaplan et
al. 1978) and allergic ·rhinitis (Shapiro 1982)

1

Modified from James 1991.
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only a few studies to confirm the findings on these additive effects of caffeine and other
drugs and nutrients. Thus, there has not been a final conclusions on the efficacy of the
combination of these substances as an aid to athletic performance. The interest in
caffeine's potential as an ergogenic aid will continue, and its use will not decline because
it is an inexpensive, relatively safe and readily available legal drug.
Dietary Sources and Consumption of Caffeine

The primary dietary sources of caffeine are coffee and tea, with varying amounts
in soft drinks, chocolate products, and medicine (Lundsberg 1 998). The caffeine content
of beverages, foods and medicines are listed in Table 2-7. As shown in the Table 2-7,
caffeine content of coffee, tea and other products can vary substantially. Caffeine content
in 5 oz of coffee is as high as 1 56 mg (Starbucks coffee) and 74 mg for percolated coffee.
Instant coffee contains significantly less caffeine at 66 mg, and negligible caffeine is
found in decaffeinated coffee. Thus, caffeine concentrations in coffee depends on the
product (e.g. ground roasted vs instant), the method of brewing, the amount of coffee
used, and the brewing time. In addition to these conditions, the caffeine content of the
natural product (e.g. coffee beans, tea leaves) can significantly differ due to the plant
variety and growing conditions of the plants (Kaplan et al. 1 974). Recognizing that there
are significant variability in caffeine content from a given sources, the FDA has selected
the following standard range of caffeine per 5 oz cup of coffee and bagged tea: 75-1 55
mg and 28-44 mg, respectively (FDA 1 980).
Americans consume 7 5% of caffeine from coffee, and the remaining 25% of
caffeine from both tea and cocoa products (Barone and Roberts 1 996). Caffeine content
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TABLE 2-7

Caffeine content of beverages, foods and medicine 1
Product
Coffee

0\

-.....J

size

Caffeine (mg)

Product
Tea

size

Caffeine (mg)

5 oz
27
Average blend
74
5 oz
Roasted and ground,
19
5 oz
Green Tea
percolated
Leaf Tea
30-48
5 oz
Roasted and ground, drip 5 oz
1 12
28-44
Bagged Tea
Roasted and ground,
2
5 oz
5 oz
Tea, decaffeinated
5 oz
0
decaffeinated
Instant Tea
9
66
5 oz
5 oz
Instant
Lipton Iced Tea,
3
16 oz
5 oz
35
Instant, decaffeinated
assorted
General foods
55
Lipton Natural Brew
8 oz
25
International swiss mocha 8 oz
Iced Tea, unsweetened
8 oz
26
International Viennese
8 oz
Lipton Natural Brew
15
chocolate
Iced Tea, sweetened
69
Maxwell house
5 oz
Lipton Natural Brew
8 oz
10
regular, drip
Iced
Tea,
diet
25
Cappuccino, amaretto
8 oz
Lipton Natural Brew
<5
45
8 oz
Cappuccino, French
8 oz
vanilla, or Irish cream
Iced Tea, decaffeinated
3
Nestea pure sweetened
17
8 oz
8 oz
Cappuccino,
Iced Tea
decaffeinated
Nestea pure lemon,
250
8 oz
8 oz
11
Starbucks coffee, short
12 oz
Sweetened Iced Tea
375
Starbucks coffee, tall
16 oz
Arizona Iced Tea,
15
550
Starbucks coffee, grande
16 oz
assorted varieties
Starbucks caffe, Am.ericana 8 oz
35
1
Values are mg/serving size. Modified from Barone and Roberts 1996, FDA 1980, Gilbert 1981, Nutrition action health letter
1996, Physicians' Desk Reference (PDR) 2000.

TABLE 2-7

Caffeine content ofbeverages, foods and medicine (Continued)
Product
Coffee
Starbucks caffe, mocha,
short
Starbucks caffe, latte, short
Starbucks espresso
Starbucks espresso,
decaffeinated
Soft drinks
Canada Dry cola
Canada Dry cola, diet
Coca Cola
Coca Cola, diet
Dr. Pepper
Mellow Yellow
Mountain Dew
Pepsi
7-Eleven Big Gulp Cola
Ice cream, Yogurt
Haagen-Dazs, coffee ice
cream
Ben & Jerry's coffee fudge
1

size

Caffeine (mg)

8 oz

250

8 oz
1 oz
1 oz

35
35
5

1 2 oz
1 2 oz
1 2 oz
1 2 oz
1 2 oz
1 2 oz
1 2 oz
1 2 oz
64 oz

30
1
46
46
10
53
54
38
1 90

8 oz

58

8 oz

85

Product

size

Tea
Snapple Iced Tea, all

1 6 oz

Chocolate beverages,
8 oz
1 envelope hot-cocoa mix
Chocolate cake, cookies, candy
2.5 oz
Chocolate cake
Chocolate frosting
2.5 oz
0.7 oz
Chocolate chip cookies
1 .5 oz
Chocolate brownies
Fudge
0.8 oz
Chocolate bar, .Hersheys 1 .5 oz
Caffeinated water
12 oz
Aqua Blast, 0.5L
Java Water, 0.5L
12 oz
Medicines
1 tablet
Anacin
Excederin
1 tablet
Dexatrim (weight loss)
1 dose
1 tablet
Dristan (decongestant)
No Doz, (stimulant)
1 tablet

Caffeine (mg)

48
5
6
7
4
10
11
10
64
90
33
65
200
16
10

Values are mg/serving size. Modified from Barone and Roberts 1 996, FDA 1 980, Gilbert 1 98 1 , Nutrition action
health letter 1 996, Physicians' Desk Reference (PDR) 2000.

in coffee is 50-70% higher than it i s in tea. Alternative source s of caffeine include soft
. drinks , which are increasing i n popularity in all industrialized nations of the world
(Gilbert 1984). Other dietary source s of caffei ne are foods that contain cocoa or
chocolate, such as candie s and sweets . Sub stantial quantitie s of caffeine are pre sent in
pre scripti on and non-pre scription drugs . It was esti mate d in 1980 that there was more
than 1000 prescription and 2000 non-pre scription drug s containing caffeine i n the U.S.
(Barone & Roberts 1996). The primary indications for the se caffeine-containing drug s
are pain relief, cough or col d, diet or weight lo ss , the need for alertne ss and diure si s (PDR
2000, Roberts & Barone 1983).
From various caffe ine-consumption survey and product usage data bases , the
mean daily intake of caffeine was e stimated to be 3-4 mg/kg bo dy weight for all adults
(Barone and Roberts (1984). For the heavie st caffeine consumers (901h - 1 oo•h percentile s)
the mean intake was 7 mg/kg/d . For chil dren under 18 y, the mean intake was 1 mg/kg,
and for the 901h - 1 oo•h percentile s it was 3-5 mg/kg (Barone and Roberts 1984). Many
chil dren consume caffeine from soft drink, iced tea, chocolate-containing foods and
candy, re sulting in significant cumulati ve caffeine intake (Lundsberg 1998). The daily
caffeine intake by pregnant women was 2 mg/kg/d and the 901h - 95 th percentile s were 5.0
- 6.5 mg/kg/d, respectively (Barone and Roberts 1984). It i s important to recognize that 1
can of cola (about 50 mg of caffeine) may not pro duce the same biological and
physiological effect s of caffeine in chil dren as it doe s in grown adults (Skinner et al.
2000).
The trends in consumption of caffeinate d beverage s in the U.S.A. over the 197069

1992 is shown in Table 2-8. There was a reduction in coffee consumption, a slight
increase in tea consumption, and a dramatic increases in soft drink consumption
(Lundsberg 1998, USDA 1995). The declines in coffee consumption may be explained
by increasing consumption of other caffeinated beverages, particularly soft drinks and
iced teas, that attract children and adolescents. The general public may have been cutting
back coffee consumption, due to the information of the epidemiological studies and
scientific finding on caffeine's negative influence on health. However, the overall
exposure to caffeine has increased approximately 20% over these last 20 years.

TABLE 2-8

Per capita consumption ofvarious beverages in the USA

1

Year

1970

1980

1985

1990

1992

Coffee

35.7

27.2

26.8

26.4

26. 1

Tea

5.2

7.8

7.3

7.0

6.8

Soft drinks

22.7

34.2

40.8

47.7

48.0

1

Values are gallons. Data from USDA 1995.

70

Absorption

Caffeine is absorbed through the gastrointestinal tract into bloodstream
(Blanchard & Sawers 1983a). Peak plasma concentration of caffeine is typically reached
within 30 to 120 min after ingestion. This variability in peak time appears to be due to
several factors. The absorption rate for caffeine contained in soft drinks has been found
to be slower than that for coffee and tea (Marks & Kelly 1973 ). Coffee and soft drinks
have a pH which varies from 5.0-6.0 and 2.0-4.0, respectively (Bettelheim & March
199 1). Several investigators have reported that increased doses of caffeine consumption
may raise the absorption rate (Bonati et al. 1982, Garattini et al. 1980, Passmore et al.
1987). The findings suggest that the characteristics of the medium in which caffeine is
dissolved (volume, pH, chemical components) influence its absorption rate. Caffeine
absorption after intraperitoneal administration was similar to the one after oral ingestion
(Wang & Lau 1998). However, the absorption rate was lower after intramusculer than
oral ingestion (Sant' Ambrogio et al. 1964). This indicates that solubility of caffeine at
the site of administration affects the absorption rates.
Transport and Tissue Uptake

Following absorption, caffeine is readily distributed into all tissues and total body
fluids by a simple diffusion (Rall 1985). Concentration and half-life (approximately 3-5
hr) of caffeine in saliva significantly correlated with serum concentration (Cook et al.
1976, Zylber-Katz et al. 1984). Caffeine is also present in semen in concentrations that
are equivalent to serum levels (Beach et al. 1984). Caffeine crosses the placenta and
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enters into fetus and amniotic fluid. It also enters into breast milk in lactating mothers
(Bonati & Garattini 1 984).
Excretion
Caffeine is biotransformed to several metabolites in the liver. Less than 3 % of the
administered caffeine is unmetabolized and eliminated in urine (Arnaud 1 987). The
excretion rates of caffeine may vary among individuals, and are influenced by a variety of
factors (Table 2-9). Gender differences were observed by Callahan et al. (1 983) when
catabolism of caffeine was determined in males, females, and females on oral
contraceptives during 24 hr. Females showed a 55 .9% higher rate of catabolism ( 1 7.3 vs.
1 1 . 1 µg/min/kg) than men in the first hour after ingesting 5 mg/kg caffeine. The half-life
of caffeine in females was 20-30 % shorter than in males. However, more caffeine was
left in the body of females on contraceptives than those not on contraceptive. The
difference was especially noticeable in the first 1 2-24 hr after ingestion of caffeine. Also,
25% of total ingested caffeine was still in the bodies of oral contraceptive users,
compared to the complete elimination of caffeine in men during the same span of time
(Callahan et al. 1 983).
Metabolism
Caffeine is metabolized by the liver through a series of sequential reactions
(Figure 2-9). The dimethylxanthines (paraxanthine, theophylline and theobromine) are
first metabolized to dimethyluric acid or monomethylxanthines, and then they are
converted to monomethyluric acids (Yesair et al. 1 984). The major pathway of caffeine
metabolism begins with the demethylation of caffeine catalyzed by cytochrome P450
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TABLE 2-9
Factors influence half-life ofcaffeine

Factors

Effects

References

Gender

Female
on oral contraceptives
Older men l
with vitamin C ++
l (2-fold/trimester)

Callahan et al. (1983)

Age
Pregnancy
Newborns
Cigarette smoking
Hepatic disease
Exercise

T

l (2-fold)
l

Blanchard & Sawers (1983)
Trang et al. (1982)
Aldridge et al. (198 1)
Aranda et al. (1976), Parsons et al.
(1976)
Parsons & Neimes (1978)
Desmond et al. (1980)
Collomp et al. ( 1996)

Arrows indicate: l , increases half-life (caffeine remains in a body for a longer time);
l , decrease half-life (caffeine remains in a body for a shorter time); - , no effects on
half-life of caffeine.

1A2. The predominant (84%) metabolite of caffeine is paraxanthine. Theophylline and
theobromine are produced in much less quantities (Kalow and Tang 1993).
Various factors affect the metabolism of caffeine. Chronic use of caffeine leads to
its increased metabolism due to up-regulated cytochrome P450 1A2 with a higher affinity
for caffeine (Goasduff et al. 1996). Furthermore, it has been reported that exercise
increases the expression of cytochrome P450 1 A2, decreases peak plasma levels of
caffeine, and decreases half-life of caffeine (Collomp et al. 1996).
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Caffeine

l

Paraxanthine

7-dimethyluric acid
/

Theobromine

Theophylline

l

r

3, 7-dimethyldihydrouric acid

1 ,7-dimethyldihyd::;::cid �
I , 7-dimethyluric acid

�

7-methylxanthine

l

1 -methylxanthine
-....J
�

7-methyluric acid
3-methylxanthine

1 ,3-dimethyluric acid
1 -methyluric acid

FIGURE 2-9 Metabolic pathways ofcaffeine 1 •
1
Modified from Tarka (1 982 ) .

Mechanism of Action

Extensive research has been conducted to determine the mechanisms by which
caffeine produces its pharmacological effects on major organ systems. Three hypotheses
to explain the diverse actions of caffeine in humans have received the most attention.
These are A) translocation of intracellular calcium, B) inhibition of phosphodiesterases,
and C) the competitive antagonism of adenosine receptors.
A. Translocation of intracellular calcium

Studies of calcium translocation have been concerned mainly with the effects of
caffeine on skeletal muscles (Battig 1985). It is speculated that caffeine increases the
release of calcium from the stores in the sarcoplasmic reticulum (Rall 1985).
Experiments in vitro have demonstrated that caffeine lowers the excitability threshold and
extends the length of muscular contractions via calcium release (Blinks et al. 1972).
Alternatively, caffeine may inhibit calcium reuptake by the sarcoplasmic reticulum for
continuous availability of calcium for muscle work (Endo 1977, Fabiato & Fabiato 1977).
Furthermore, caffeine may increase levels of calcium indirectly by increasing the levels of
fatty acyl-CoA (Spriet et al. 1992), epinephrine and cortisol (Lovallo et al. 1996). As a
result of these actions, caffeine elevates intracellular calcium in skeletal muscles.
However, the mechanism appears to be of limited importance in explaining the effects of
caffeine in humans. The concentration of caffeine required to increase the levels of
intracellular calcium would be a toxic, even lethal, dose in humans (Nehling et al. 1992).
B. Phosphodiesterase inhibition

Caffeine was found to indirectly facilitate the accumulation of cyclic adenosine
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3 ',5'-monophosphate (cAMP), which is known to mediate the actions of many
neurotransmitters and hormones in the nervous system (Sutherland et al. 1 968). Butcher
and Sutherland (1 962) suggested that caffeine stimulates brain norepinephrine by
inhibiting the enzyme, cAMP phosphodiesterase, hence blocking the breakdown of
cAMP. As a result, the concentration of cAMP rises, which leads to an increase in fatty
acid metabolism and subsequent ATP production (Sutherland & Butcher 1 962).
It has been estimated that plasma concentrations required for calcium
translocation and phosphodiesterase inhibition are 300 µg/ml and 1 00 µg/ml, respectively
(Fredholm 1 985). The concentration of caffeine in plasma after ingestion of 200-300 mg
of caffeine is approximately 1 0 µg/ml or less in humans.
C. Adenosine receptor antagonism
Cumulative evidence indicates that many of the actions of caffeine are mediated
by antagonism to cell surface adenosine receptors (von Borstel & Wurtman 1 984).
Unlike other mechanism describe above, the majority of the pharmacological effects of
adenosine on the central nervous system can be inhibited by dosages well within
physiological norms. For an example, when adenosine binds to its adenosine receptors, it
inhibits lipolysis by suppressing adenylate cyclase activity. In the opposite case, chronic
caffeine ingestion has been shown to stimulate adenylase cyclase activity in platelet
membranes, which has been suggested to increase lipolysis (Zhang and Wells 1 990).
There are 4 · adenosine receptors subtypes that have been identified and characterized: A 1 ,
A2a, A2b, and A3 receptors (Olah and Stiles 1 995). The activation of these receptors by
endogenous adenosine regulates biological processes throughout the body including, the
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cardiovascular and nervous systems. Caffeine and adenosine purportedly have
antagonistic effects on blood pressure, central nervous system activity, lipolysis,
catecholamine release, respiration, renin release, urine output and intestinal peristalsis
(James 1 99 1 ). In general, caffeine has a stimulatory effect and adnosine decreases the
activity of each of the functions listed above.
Functions
A. Central nervous system

Caffeine is classified as a drug with pharmacological effects, especially as a
central nervous system (CNS) stimulant (Rall 1 985). The widespread use of caffeine is
certainly related to its ability to stimulate the nervous system and increase alertness
(Sinclair and Geiger 2000). The mechanism of caffeine increasing neuronal excitability
is not completely understood, however, it may involve neurotransmitter-mediated
mechanisms. The best known effect of caffeine on a neurotransmitter/neuromodulatory
system is its ability to block the inhibitory action of adenosine in the CNS (described in
this previous section). Caffeine can increase neuronal excitability via increasing the
release of excitatory neurotransmitters through blockage of adenosine receptors (Meeusen
and Meirleir 1 995).
Caffeine is also closely linked to the other neurotransmitter, including
epinephrine, norepinephrin, dopamine, serotonin, gamma-aminobutyric acid (GABA) and
acetylcholine (Spindel and Wurtman 1 984). Several studies have found that caffeine
ingestion increases concentrations of epinephrine and norepinephrine in blood and urine
(Bellet et al. 1 969, Robertson et al. 1 978). Caffeine has been reported to increase brain
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levels of serotonin in rats (Schlosberg et al. 1 981 ). However, there are some studies that
report no effect of caffeine on urinary and serum catecholamine in humans (Jung et al.
1 981, Spindel 1984). The mechanisms responsible for these effects are unknown, but it is
speculated that the effect is mediated via putative adenosine receptors (Fernstrom and
Fernstrom 1 984).
B. Renal Function

Another well-known function of caffeine is its diuretic effect. This effect seems
to be due in part to an increase in renal blood flow and increased glomerular filtration rate
(Fredholm 1 984). Adenosine regulates renal function and caffeine is an antagonist of
endogenous adenosine (Spielman and Thompson 1 982).
C. Cardiovascular system

Caffeine may have direct effects on the contractility of the heart and blood
vessels, as well as indirect peripheral actions mediated by catecholamines and renin
angiotensin system (Fredholm 1 984). Other possible effects include reduced cerebral
blood flow (Mathew et al. 1 983 ). There is evidence that caffeine withdrawal after
habitual caffeine intake produces severe headache, which is relieved by consuming
caffeine (Roller 1 981 ). It seems that cerebral blood vessels dilate during caffeine
withdrawal, but the process is reversed by caffeine ingestion. These effects are related to
caffeine's antagonism of endogenous adenosine which is a potent dilator of cerebral
blood vessels (Fredholm 1 984).
D. Respiratory system

In general, caffeine has little effect on respiration. An exception is the patients
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with a suppressed respiratory system (Bellville 1964 ). It appears that caffeine increases
blood flow throw the lungs by relaxing arterial smooth muscle, which increases the
supply of air to the lungs by relaxing bronchiolar and alveolar smooth muscle (Dorfman
& Jarvik 1970, Gilbert 1976).
E. Gastrointestinal system

The most frequently reported gastrointestinal symptom after the ingestion of
coffee is heartburn (Cohen 1980). Boekema et al. (1999) suggested that coffee promotes
a gastro-oesophageal reflex and is associated with this common disorder. Coffee induces
cholecystokinin release and gallbladder contraction (Douglas et al 1990). There is
evidence that coffee increases rectosigmoid motor activity (Brown 1990). Its effects on
the colon were found to be comparable to those of a 1000 kcal meal (Rao et al. 1998).
The mechanisms responsible for those effects have not yet been elucidated, and caffeine
alone can not account for these gastrointestinal effects.
Caffeine Supplementation
A. Physical performance

Because of caffeine' s availability and social acceptance, it has become the most
widely used ergogenic aid by athletes at all levels of competition, including the elite,
Olympic level athletes and recreational athletes (Applegate 1999). Young athletes start
using caffeine to enhance performance. The Center for Drug-Free Sport found that 35%
of 16,000 Canadian youths, aged from 11 to 18 y believe caffeine could enhance
performance and 27% reported having used caffeine to enhance performance (Graham et
al. 1994).
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The ergogenic potential of caffeine has been recognized, and currently the
International Olympic Committee (IOC) and National Collegiate_ Athletic Association
regard caffeine as a restricted substance with and allowance limited to 1 2 µg caffeine/ml
of urine (Sinclair & Geiger 2000). It was estimated that about 6-8 cups of coffee (95- 1 50
mg caffeine/250 ml) must be ingested in a 1 -2 hr period to reach 1 2 µg/ml in urine
(Birkett & Miners 1 99 1 ). Thus, it seems that the legal limit allows athletes to consume
caffeine and manipulate their metabolism without fear of disqualification from a
competition.
Studies on ergogenic effects of caffeine have produced confusing and inconsistent
results. The lack of standardized experimental protocols and small number of subjects
may contribute to some of the contradictory findings. Methodological problems include :
differences in work performance (types, intensity, and duration), caffeine dosages, time of
ingestion of caffeine, test environments, and physiological and somatic differences in
subjects.
a. Endurance performance

From 1 978 to 1 980 Costill and co-workers demonstrated that caffeine ingestion
increased time to exhaustion during submaximal (80% V02max) cycle ergometry (Costill
et al. 1 979) and increased total work output during prolonged (2 hr) cycle ergometry (Ivy
et al. 1 979). It was proposed that caffeine ingestion was associated with metabolic
substrate shifts, implying that caffeine enhanced fat oxidation and reduced carbohydrate
oxidation. This may effectively spare glycogen and help delay fatigue during prolonged
exercise (Essig et al. 1 980). Subsequently, many other studies produced positive results
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about caffeine's ergogenicity (Table 2-10).
McNaughton et al. (1987) examined effects of caffeine on high intensity, short
dura_tion exercise (approximately 7 min) using caffeine naive subjects who received a
high dose ( 10-15 mg/kg body weight) of caffeine 1 hr before testing. This study showed
significant enhancement of work performance and increased free fatty acid (FFA)
production (McNaughton et al. 1987).
Flinn et al. ( 1990) conducted a study to determine the effects of high doses of
caffeine ( 10 mg/kg body weight) on endurance performance in recreational athletes who
were caffeine native. The subjects ingested caffeine 3 hr prior to exercise allowing FF A
to reach at peak. These investigators suggested that their positive findings are due to: 1)
the use of caffeine naive subjects, 2) use of recreational athletes, 3) high doses of caffeine
and 4) timing of the caffeine ingestion (Flinn et al. 1990).
In another well-designed study, Graham and Spriet (1991) examined the effect of
caffeine on the endurance of 7 trained athletes (mean V02max, -::::.73 ml/kg/min). The
subjects ingested caffeine (9 mg/kg body weight) 1 hr prior to be tested with 2 types of
exercise (running and cycling) at high intensity, -::::. 85% V02max. The study confirmed
previous findings, demonstrating longer performing time in both running and cycling
(Graham and Spriet 1991).
In 1992 Spriet and his associates examined the glycogen sparing effects of
caffeine using muscle biopsy techniques. They took muscle biopsies from the subjects at
rest, 15 min after exercise and at exhaustion. The glycogen conservation by caffeine was
observed only in the initial phase of exercise, indicating only transient sparing of
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TABLE 2-10
Summary ofkey results from studies ofcaffeine and endurance exercise 1

# of
subjects

Caffeine
dose

Finding

80%V02max to
exhaustion

9

330 mg

l time to exhaustion

Ivy et al.
1979

69%V02max

9

250 mg

l [FFA] ,
l fat oxidation
l endurance

Essig et al.
1980

65-75%V02max
30 min

7

· 5 mg/kg bw

l [FFA], l m. TO use
l endurance

Power et al.
1983

80%V02 max

7

5 mg/kg bw

l [FFA],
No improvement

28

5mg/kg bw

No improvement

6

5 mg/kg bw

No improvement

Study

Test
condition

Costill et al.
1978

Butts & Crowell 75%V02max to
1985
exhaustion
Bond et al.
1987

75%V02max to
exhaustion

McNaughton
1987

Incremental exercise 10
;:: 7 min

10 or 15 mg/ l [FFA], l lactate
l time to exhaustion
kg bw

Tamopolsky
et al. 1989

80%V02 max
90 min

6

6 mg/kg bw

Flinn et al.
1990

Incremental exercise

9

10 mg/kg bw l time to exhaustion
l [FFA]

Dodd et al.
1991

80%V02max to
exhaustion

17

3 or 5 mg/ kg No improvement
bw

Graham & Spriet 85%V02max to
1991
exhaustion

7

1

9 mg/kg bw

No improvement

l time to exhaustion

Abbreviation used: bw, body wight; CHO, carbohydrate; FFA, serum free fatty acids;
m., muscle; TO, triglycerides
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TABLE 2-10
Summary ofkey resultsfrom studies of caffeine and endurance exercise 1 (Continued)
Caffeine
dose

Finding

8

9 mg/kg bw

T time to exhaustion,
l m. glycogen
T m. acetyl CoA/CoA

80% V02max to
exhausiton

9

0, 5, 9, 1 3 mg T time to exhaustion,
T [FFA]
/kg bw

Graham & Spriet 80% V02max to
exhaustion
1 995

8

0, 3, 6, 9 mg T time at 3 & 6 mg,
but not at 9 mg/kg bw
/kg bw

15

2, 2.3, 3 .2 mg T endurance, additive
kg/ bw + CHO effect

Study

Test
condition

Spriet et al.
1 992

80% V02max to
exhaustion

Pasman et al.
1 995

# of
subjects

Kovacs et al.
1 998

1 hr time trial
cycling

Anderson et al.
2000

2000 m rowing
< 8 min

8 (all � )

6 or 9 mg/ kg T endurance
bw

Bell et al.
2002

1 0 km run
:::: 46 min

12

4 mg/kg bw
+ ephedrine
0.8 mg /kg

1

ephedrine l run time

Abbreviation used: bw, body wight; CHO, carbohydrate; CoA, Coenzyme A;
FFA, serum free fatty acids; m., muscle; TG, triglycerides. �: Female subjects
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glycogen. However, following ingestion of caffeine (9 mg/kg body weight) the subjects
were found to increase their endurance. The investigators also determined the
intramuscular concentrations of several other metabolites that could explain the metabolic
shifts between fat and carbohydrate oxidation. At rest, 1 hr following caffeine ingestion,
muscle citrate and the acetyl-CoA/CoA ratios were elevated; however, throughout the
exercise, there were no differences between placebo and caffeine groups in these muscle
metabolites (Spriet et al. 1992).
The following year van Soeren et al. ( 1993) examined the metabolic and
catecholamine responses to caffeine in coffee users and nonusers after acute ingestion of
caffeine (5 mg/kg body weight) during 1 hr of steady state exercise (50 %V02max). The
nonusers responded to caffeine with a large rise in plasma epinephrine during 1 hr of
moderate exercise. However, there was no shift in RQ or plasma FFA concentration. In
contrast to the nonusers, the users did not exhibit any increased epinephrine after caffeine
ingestion, but the epinephrine response to exercise was 2-fold greater than that of the
nonusers. The RQ and plasma FFA were not significant differences between the groups.
Thus, these findings suggest that the epinephrine response to caffeine is influenced by the
subject's caffeine habits and it is not directly related to metabolic shifts after caffeine
ingestion or exercise (van Soeren et al. 1993).
Several studies examined dose-response of caffeine. Pasman and associates
examined the effect of different dosages of caffeine (0, 5, 9, 13 mg/kg body weight) on
endurance performance. Trained athletes ingested caffeine capsules and cycled until
exhaustion. All subjects were caffeine users in varying degrees (100-250 mg/d).
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Significant increases in both endurance and plasma FFA production were found for all
caffeine groups compared to placebo group. They also found that there was no dose
response effects on endurance performances. The stimulating effect of caffeine was
observed even at the lowest dose (5 mg/kg body weight) of caffeine given (Pasman et al.
1995).
In another study, similar results were obtained when various dosages (0, 3, 6, 9
mg/ kg body weight) of caffeine were used. Trained athletes were asked to run to
exhaustion and they showed significant improvement after 3 and 9 mg doses, but not after
the 9 mg dose. The investigators speculated that the failure to find the significance at 9
mg/kg body weight was due to the large numbers of caffeine naive subjects who may
have experienced adverse effects at this high dose (Graham and Spriet 1995)
Most of the previous studies on ergogenic effects of caffeine determined
performance (the time taken to reach exhaustion). Kovacs and coworkers (1998)
examined the effects of caffeine on 1 hr time trial cycling performance using a caffeinated
CHO-electrolyte solution mixture. Subjects ingested the mixture with different doses of
caffeine during a warm-up and at one-third and two-thirds of a I -hr time trial . Mean
caffeine contents of the mixtures were 2, 3 .2, and 4.5 mg/ kg body weight. The study
demonstrated that the subjects completed the time trial significantly faster after ingestion
of the mixtures. An ergogenic effect of caffeine was observed at the lowest dosage
(2 mg/kg body weight), and the highest dose did not result in further improvements
(Kovacs et al. 1998).
There have been many studies that have evaluated an ergogenic effect of caffeine
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on performance and metabolism in trained and untrained male subjects. Anderson and
associates examined the effect of caffeine ingestion on short-term (< 10 min), 2000-m
rowing performance, in trained (mean V02max , 48 ml/kg/min) female athletes. The
subjects ingested 6 or 9 mg/kg body weight caffeine 1 hr before the 2000-m time trials on
a rowing ergometer. The study demonstrated caffeine induced a dose-dependent
performance time improvement: 0.7 % with 6 mg/kg caffeine and 1 .3 % with 9 mg/kg
caffeine. To date, this is the first study showing that caffeine produced an enhancement
of performance by improving the first 500-m of a 2000-m row in female athletes
(Anderson et al. 2000).
Bell and associates published a series of papers on the additive effects of caffeine
and ephedrine on both aerobic and anaerobic exercise performance (Bell et al. 2001, Bell
et al. 2002). In an anaerobic exercise study they demonstrated a significant improvement
by caffeine (5 mg/kg body weight) and ephedrine (1 mg/kg body weight) in untrained
healthy men. These results were contradictory to their previously published work (Bell et
al. 1998), where the additive effects of caffeine and ephedrine were not observed. The
authors speculated that differences were due to the type of exercise, and the improvement
on anaerobic exercise performance was produced by caffeine and ephedrine
independently, which means that ephedrine may be influencing CNS drive and caffeine
may be enhancing muscle metabolism (Bell et al. 2000). Subsequently, Bell and
associates examined the effects of the combination of caffeine (4 mg/kg body weight) and
ephedrine (0.8 mg/kg body weight) on 10-km run performance in recreational runners,
where the half of the subjects were coffee users (1 cupid � 150 mg/d). The study showed
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run times for the ephedrine and the combination of ephedrine and caffeine significantly
reduced run times compared with placebo and caffeine alone. Caffeine increased
exercise-associated ephedrine response. The additive effects of caffeine and ephedrine,
as seen in the previous anaerobic study (Bell et al. 2000) was not evident in this study
(Bell et al. 2002).
Despite the impressive numbers of caffeine studies suggesting an ergogenic effect
of caffeine, there are equally as many studies that have failed to show enhancement in
endurance exercise by caffeine. Bond et al. (1987) and Powers et al. (1982), both using 5
mg/kg body weight caffeine, failed to demonstrate that caffeine increases exercise time to
exhaustion. Butt and Crowell (1985) recruited untrained subjects to test on a cycle
ergometry at submaximal exercise (75%V02max) after ingesting 300 mg caffeine. No
significant effect was detected in the time to exhaustion.
Tarnopolsy and colleagues (1989) studied the effect of caffeine using a 90-min
treadmill run with trained runners. All subjects were coffee users (mean intake 200 mg/d)
and they took 6 mg/kg caffeine 1 hr prior to testing. No significant difference in
metabolic effects were found, except that plasma FFA were significantly elevated
following administration of caffeine.
In another study, Dodd et al. ( 1991) determined the V02max and a time-to
exhaustion on a bicycle ergometer in trained men after administration of 3 or 5 mg/kg
body weight caffeine. There was no significant caffeine effect on exercise performance in
both caffeine naive (<25 mg/d) and tolerant (> 310 mg/d) subjects.
In summary, there have been convincing replicated findings that could permit the
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conclusion concerning the effects of caffeine as an ergogenic aid for endurance
performance. Since there are also a large number of studies indicating no effects, there
may be some variables that have not been clearly elucidate�. Different exercise protocols
(intensity, duration and mode of exercise) and doses of caffeine have been tested to
resolve the confounding results. Individual differences including nutritional differences,
muscle fiber differences, nutrient-nutrient interactions, genetic differences, mood and
motivation of athletes may be good candidates to be consider as modulating variables in
human performances.
There has been no well-designed study that could test the psychostimulant effect
of caffeine during exercise. Caffeine increases alertness and enhances mood. When the
improvements in performance were indirectly due to the caffeine' s effects on mood, we
are not able to distinguish, if that is simply the placebo effect or caffeine induced placebo
like effect.
b. Muscle strength

In vitro studies have indicated that caffeine may enhance the production of
muscular force by altering rate of substrate utilization, neuromuscular transmission
(Butcher and Sutherland 1962), and calcium manipulation (Kavaler et al. 1978). Human
studies have consistently failed to demonstrate the significant effects of caffeine on
muscular strength (Jacobson and Edwards 1991, Lopes et al. 1983, Powers and Dodd
1985, Williams et al. 1988) with a very few exceptions (Kruk et al. 1999).
Lopes and co-workers (1983) investigated the effects of 500 mg caffeine on
voluntary isometric and electrically stimulated contractions. The subjects performed 3
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maximal voluntary contractions followed by electrical stimulation of the ulnar nerve at
1 0, 20, 30, 50 and 1 00 Hz. The results of a curve force showed that caffeine produced an
increase in tension for all stimulation frequencies, except at 1 00 Hz. However, there was
no difference between placebo and experimental groups in the maximal voluntary
contraction (Lopes et al. 1 983).
In another study, the effect of caffeine (5 mg/kg body weight) on voluntary
dynamic contraction was investigated by Bond et al. (1 986). The subjects were tested for
isokinetic knee flexion and extension at selected velocities at 30, 1 50 and 300 ° /s. The
authors concluded that caffeine has no effect on skeletal muscle contraction at different
velocities (Bond et al. 1 986). For the P.resent, research findings do not offer much
support for caffeine's ergogenic effects on muscle strength.
B. Weight loss and management

Caffeine is one of the most popular ingredients of weight loss supplements (Egger
et al. 1 999). The rational behind this popularity is that caffeine has the lipolytic potential
(Essig et al. 1 980, McNaughton 1 986) and thermogenic property (Dulloo & Miller 1 986,
Hollands et al. 1 98 1 ). Caffeine stimulates catecholamine secretion by acting as an
adenosine receptor antagonism and by other unknown mechanisms. This in turn
stimulates adipose tissue lipolysis and elevates serum FFA concentration. Active skeletal
muscles take up FFA, and this causes a greater fat oxidation. Some studies demonstrated
the lipolytic effects of caffeine, for example, increasing FFA concentration and altering
metabolic rate after ingestion of caffeine in humans (Astrup et al. 1 990, Bracco et a.
1 995, Horton and Geissler 1 996).
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Furthermore, the effects of caffeine was investigated to determine whether it
continues to elevate oxygen consumption after exercise (55% V02max). Donelly and
McNaughton (1 992) have determined the effects of caffeine ingestion (5 and 1 0 mg/kg
body weight) on post-exercise oxygen consumption in 6 untrained women. During
exercise and 1 -hr-post-exercise, oxygen consumption was found to be significantly higher
in the caffeine groups compared to the placebo group. During the entire period of
experiments, FFA concentration was significantly higher, and RQ values were
significantly lower in the caffeine groups than in the·placebo group. The study
demonstrated that caffeine increased metabolic rate above normal levels in untrained
women during as well as after exercising at 55% V02 max (Donelly and McNaughton
1 992).
Well-designed studies have examined the effects of caffeine in combination with
ephedrine on weight loss in humans. Astrup and associates ( 1 992) determined whether
the combination of ephedrine and caffeine produces an additive effect on weight loss
compared with ephedrine and caffeine alone. In their randomized, placebo controlled,
double blind study, 1 80 obese patients were treated with low calorie diet ( 1 000 kcal/d)
and either an ephedrine/caffeine combination (20 mg/200 mg), ephedrine (20 mg),
caffeine (200 mg) or placebo for 24 wk. They found that when administered as an
adjuvant to a low calorie diet, the combination of caffeine and ephedrine significantly
reduced body weight, 1 .5 kg after 12 wk, 3 .4 kg after 24 wk, more than placebo; however,
neither ephedrine nor caffeine alone induced a significantly greater weight reduction than
placebo (Astrup et al. 1 992).
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Several other studies examined the effectiveness of weight loss using caffeine in
combination with fiber or chromium in humans. However, the findings of these studies
are confusing and farther studies are needed. In general, there is a theoretical basis for
using caffeine in weight control, and good evidence for its lipolysic effects. However,
there is no controlled study on fat loss in over weight individuals using caffeine without
an energy-restricted diet. No studies have reported on the effects of caffeine in individual
with high or low habitual caffeine uses.

OVERWEIGHT AND OBESITY

In adults, overweight is defined as a Body Mass Index (BMI) of 25 kg/m2 or more.
And obesity is defined as a BMI of 30 kg/m2 or more. Currently, the National Institutes
of Health ( 1998), Healthy People 20 10 (2000), the 2000 Dietary Guidelines for
Americans (2000) and the WHO (1998) all use similar cut-off points of BMI for defining
overweight and obesity. BMI is calculated as an individual's weight in kilograms divided
by the square of his or her height in meters (Bray 1994). BMI units are used in
classification of overweight and obesity (Table 2-1 1 ). Allowing for the ease of
measuring height and weight in a field setting, the BMI is an accepted indicator of the
risk of overweight in adults. However, the BMI has limitations; it does not incorporate
any measure of body composition. There is evidence that the relationship between BMI
and.percentage body fat (%BF) may be different in different ethnic groups (Dudeja et al.
200 1, Norgan 1994).
The assessment of body fat may help achieve a more accurate definition of
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overweight and obesity. The assessment of body fat is also important due to the
established association between high body fat and chronic disease conditions, such as
type 2 diabetes mellitus, hypertension and hyperlipidaemia. The upper limits of body fat
for defining obesity have been set as 25% and 30% for males and females, respectively
(Hortobagyi et al. 1 994).

TABLE 2-1 1

Classification of underweight, normal range, overweight and obesity in adults according
to BM/1

1

Classification

BMI (kg/m2 )

Underweight

<18.5

Normal range

1 8.5-24.9

Overweight

25.0-29.9

Obese

� 30.0
30.0-34.9
35.0-39.9
� 40.0

Class I
Class II
Class III

BMI = Body Mass Index
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There are various methods available for measuring body fat (Table 2-12).
Hydrodensitometry, or hydrostatic weighing (underwater weighing), is considered to be
the gold standard of the densitometric methods. Hydrostatic weighing uses the
Archimedes principle to determine body volume by measuring the difference between a
subject's weight in water and that in air and thus determining whole-body density (Bubb
1 992). This technique requires the subject to be completely submerged underwater while
exhaling maximally for yielding residual lung volume and minimize the effect of
buoyancy from lung air (Behnke et al. 1 942); The procedure provides a two-compartment
model of fat free mass and body fat. The limitations associated with this method include
the requirement of specialized technicians and equipment, time consumption, subject
discomfort and inaccessibility for many special populations such as elderly, infants, or
disabled.
Skinfold thickness is often used in clinical studies. However, it has been reported
to have large inter-observer and inter-individual variances (Pollock and Jackson 1 984).
In some obese individuals the skinfold caliper, the instrument used for the skinfold
thickness measurement, will not allow a satisfactory measurement of skinfold in some
areas. Furthermore, the equations for converting skinfold thickness into body fat of an
individual are often population specific and have been reported an overestimate or
underestimate of body fat in some population (Pollock and Jackson 1 984).
Dual-energy X-ray absorptiometry (DEXA) is becoming increasingly popular for
body composition assessment. DEXA provides a three-compartment model, which
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TABLE 2-12

Methods of measuring bodyfat
Advantage

Disadvantage

Accuracy

Time consuming,
Subject discomfort,
Impractical in certain
populations, Operator
training, Specialized
equipment, Can not
measure regional fat

Quick, Simple operation,
Accessible in special
population,

Expensive equipment,
Can not measure
regional fat

Skinfold thickness

Easy, Low cost, Measure
regional fat

High inter-individual
variances

Dual energy X-ray absorptiometry
(DEXA)

Easy, Accuracy

Expensive equipment

Bioelectric impedance (BIA)

Easy, Accuracy

Cari not measure
regional fat

Computed tomography {CT)

Accuracy, Measure
regional fat

Expensive equipment,
Radiation exposure

Magnetic resonance imaging (MRI) Accuracy, Measure
regional fat

Expensive equipment,
Radiation exposure

Circumferences
Waist circumference
Waist-hip ratio (WHR)

Population specific

Method
Density
Hydrostatic weighing

Air displacement
Plethysmograph

Easy, Accuracy
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separates the fat-free mass into bone mineral mass and lean tissue mass (Mazess et al.
1990). It appears to offer a precise and simple way of measuring total and regional body
fat and lean masses with a very low radiation exposure (Kohrt 1998). Svendsen et al.
(1993) found that abdominal fat measured by computed tomography (CT) in
postmenopausal women was better correlated to central abdominal fat estimated by
DEXA than either waist circumference or waist-hip ratio (WHR).
Bioelectric impedance analysis (BIA) has been used to measure body fat, which
estimates body resistance (impedance) from a voltage drop in a small current passed
between electrodes. The level of impedance is used to estimate lean tissue content and
body-water volume, then assuming a hydration fraction of lean tissue, farther estimate is
made of body lean and fat mass (Kuczmarski 1996). The method provides an easy and
fast means of estimating body fats, with very little inter-observer variation (Heitmann
1990a).
An alternative method for measuring body fat is air displacement
plethysmorgraphy, which determines body volume by measuring the reduction in
chamber volume caused by introduction of a subject into a chamber with a fixed air
volume. Similar to hydrostatic weighing, whole body density is determined and body
composition is estimated by using previously validated equations (Dempster and Aitkens
1995, McCrory et al. 1995). The device, BOD POD® (Life Measurement Instruments,
Concord, CA), has been developed based on the plethysmorgraphic measurement of body
volume for the purpose of estimating human body composition (Dempster and Aitkens
1995). The entire test process requires about 5 min, the device has an easy testing
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protocol and it is suitable for a wide variety of subjects, including the obese and elderly.
It has been recognized that measurements of body fat distribution are of great

value in assessing the degree of overweight (Kissebah et al. 1 983, Vague 1 956) .

Increased abdominal, particularly visceral adipose tissue, substantially increases the risk

of diabetes, high blood pressure and heart disease compared with lower body fat

distribution (Kissebah and Krakower 1 994). The recognition of visceral fat accumulation
as a potential risk factor led to the development of techniques to measure the amount of
intra-abdominal fat directly by computed tomography (CT) and magnetic resonance

imaging (MRI). They made a substantial contribution to the advancement of knowledge
in body composition research. However, because of the expense and radiation exposure
of these techniques, there are clear limitations to their use. Instead, simple

anthropometric measures, waist circumference and the ratio of the waist circumference

divided by the hip circumference (WHR), have been the most widely used to measure fat
distribution. There are several cut-off points for abdominal obesity based on waist

circumference and WHR. Some of the recommendations fre quently cited in various
studies are listed in Table 2-13.

In this section, the definitions and how we measure overweight and obesity were

examined. In the United States 63% of men and 55% of women aged 25 years or older
are overweight or obese defined by a BMI of higher than 25 (Must et al. 1 999). There

have been some concerns that the conventional cut-off points of the BMI underestimates
of overweight and obesity, when %BF is used as the standard to define overweight

(Dudeja et al. 200 1 ) . Based on the health-related risk factors and comorbidities, the
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TABLE 2-13

Cut-offpointsfor abdominal obesity

Waist circumference

WHR

Cut-off points

References

1 02 cm for men
88 cm for women

Lean et al. (1 995), American
Heart Association (2000)

1 00 cm for � 40 y
90 cm for � 40 y
(Not gender specific)

Lemieux et al. ( 1996)

1 02 cm for men
88 cm for women
(For BMI � 30 kg/m2)

Bray (1998)

1 .00 for men
0.80 for women

Bjomtorp ( 1 985)

1 .00 for men
0.85 for women
(For BMI � 30 kg/m2)

Bray (1 998)

0.95 for men
0.80 for women

Dietary guidelines for
Americans (1 990)

0.94 for men
0.88 for women

Lemieux et al. ( 1996)

BMI = body mass index; WHR = waist-hip ratio.
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WHO Western Pacific Region (2000) recommended different ranges for classifying
overweight and obesity for populations within the Asian-Pacific region. The lower cut
off points for Asians, BMI � 23 .0 for overweight and BMI � 25.0 for obesity, and the higher
cut-off points for Pacific Islanders, BMfa26.0 for overweight and BMfa 32.0 for obesity.
There is a variety of methods for estimating body fat and its distribution with
various advantages and disadvantages (Table 2- 1 2). There is a consensus about the cut
off points for abdominal obesity (central fat) based on WHR and waist circumference
(Table 2- 1 3 ). However; it is important to note that these cut-off points lack a systemic
evaluation, taking into account possible difference between the genders, age categories,
ethnic groups, and their rates of different diseases and mortality. More comprehensive
assessment in large population studies are required for the broader evaluation of possible
cut-off points for abdominal obesity.

RESEARCH OBJECTIVES

The overall objective of this study was to understand the interactive effects of
carnitine, choline and caffeine (CCC) on fat metabolism under the conditions of mild
exercise regimen in humans and animals. The specific objectives were:
1 ) To determine if CCC will alter the serum, urinary and tissue (liver, skeletal
muscles, heart, kidneys, brain and testes) carnitine profiles before and after
exercise.
2) To determine if CCC will reduce body weight and fat pad mass (% BF).
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3) To determine if CCC will promote fatty acid oxidation with and without
exercise.
4) To determine if CCC will affect a biochemical marker of body fat mass
(leptin), and physiological markers of exercise performance (RQ, V0 2 max
and running time to exhaustion).
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CHAPTER III
CAFFEINE, CARNITINE AND CHOLINE SUPPLEMENTATION OF RATS
DECREASES BODY FAT AND SERUM LEPTIN CONCENTRATION AS DOES
EXERCISE

This chapter is a slightly revised version of a manuscript published with co-author
Dileep S. Sachan in the Journal of Nutrition in 2000.
Nobuko Hongu and Dileep S. Sachan (2000) Caffeine, camitine and choline
supplementation of rats decreases body fat and serum leptin concentration as does
exercise. J. Nutr. 1 30: 1 52- 1 57.

ABSTRACT

The effect of a combination of caffeine, camitine and choline with or without
exercise on changes in body weight, fat pad mass, serum leptin concentration and
metabolic indices was determined in 20 male, 7-wk-old Sprague-Dawley rats. They were
given free access to a nonpurified diet without or with caffeine, camitine, and choline at
concentrations of 0. 1, 5, and 1 1 .5 g/kg diet, respectively. In a 2x2 factorial design, one
half of each dietary group was exercised, and the other half was sedentary. Body weight
and food intake of all rats were measured every day for 28 d. Rats were killed and blood
and tissue samples were collected and analyzed for biochemical markers. Food intake of
the groups was not different, but the body weight was significantly reduced by exercise in
both dietary groups. Fat pad weights and total lipids of epididymal, inguinal and
perirenal regions were significantly reduced by the supplements as well as by exercise.
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Regardless of exercise, supplements significantly lowered triglycerides in serum but
increased levels in the skeletal muscle. Serum leptin concentrations were equally lowered
by supplements and exercise. Serum leptin was correlated with body weight (r = 0.55, P
< 0.01), fat pad weight (r = 0.82, P < 0.00 1 ) and glucose (r = 0.5 1, P < 0.05). We

conclude that the indices of body fat loss due to dietary supplements were similar to those
· due to mild exercise, and there were no interactive effects of the two variables.

INTRODUCTION

Camitine is a facilitator of fatty acid oxidation by virtue of its role in inter
organelle translocation of fatty acids (Bremer 1997). Clinical studies have shown that
camitine supplementation improves muscle function in patients with camitine deficiency
(Brass and Hiatt 1 994 ). Several studies suggest an increased camitine utilization during
endurance exercise in humans (Decombaz et al. 1 992, Lennon et al. 1 983). However,
there is no clear agreement on the benefits of camitine supplementation in normal healthy
individuals (Neumann 1 996). Choline is a lipotropic agent (Best and Huntsman 1 935,
Leiber et al. 1 994), and its supplementation has been shown to enhance synthesis and
release of acetylcholine at the neuromuscular junction (Buyukuysal et al. 1 995, Zeisel and
Blusztajn 1 994). It has been observed that there is a decline in plasma choline
concentration in athletes after running a marathon (Conlay et al. 1992). Therefore,
choline supplementation may improve acetylcholine balance and prevent decrement in
physical performance. However, there are no definitive studies on the effects of choline
supplementation in normal healthy people. Caffeine is used widely as a general stimulant
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and a fatty acids mobilizer from adipose tissues (Bellet, et al. 1 968, Costill, et al. 1 978,
Denadai 1 994). It has been hypothesized that fat-mobilizing effects of caffeine and other
methylxanthines elevate blood free fatty acid concentration and spare carbohydrate stores,
prolonging endurance exercise. However, this hypothesis remains controversial, because
of a lack of standardized experimental procedures: the type, intensity and duration of
training, the dose of caffeine used and habitual use of caffeine by participants (Nehlig and
Debry 1 994).
Recently, we reported interactive effects of choline and carnitine in normal
healthy humans and animals. Choline supplementation resulted in significant
conservation of camitine in humans and guinea pigs (Daily and Sachan 1 995, Dodson and
Sachan 1 996); however, this effect of choline was not seen in the adult rats given choline
dosage similar to that given to humans and guinea pigs (Daily and Sachan 1 995, Rein et
al. 1 997). The choline supplementation promoted tissue carnitine accretion, particularly
in skeletal muscle of guinea pigs (Daily and Sachan 1 995) and livers of rats (Rein et al.
1 997). In addition, a choline supplemented diet decreased percentage of body fat and
increased percentage of protein without significantly changing body weight or the
respiratory quotient (RQ) in guinea pigs (Daily et al. 1 998). Guinea pigs would have
been a preferred animal model for their likeness to humans with regard to choline
carnitine interactions, but guinea pigs are not easily made to exercise on a treadmill. So,
we settled on a rat as a model with modification of dietary treatment in two ways. First,
we increased the supplementary level of choline to about 5-fold used in guinea pigs or
humans. Second, we included caffeine as one of the supplements for its fat-mobilizing
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property. We rationalized that besides increasing energy demand by exercising muscle,
simultaneous availability of caffeine, camitine and choline may induce mobilization,
transport and delivery of fat as the energy substrate of choice. This theoretically sound
rationale required experimental evidence which is presented in this chapter.
Leptin, a 1 6-kDa protein released from adipose tissue as a product of the obese
(ob) gene (Zhang et al. 1 994), is thought to play a role in the regulation of body weight,

energy expenditure and food intake (Campfield et al. 1 995, Halaas et al. 1 995,
Pelleymounter et al. 1 995). Studies have shown that leptin circulates in proportion to
body fat mass in humans (Considine et al. 1996) and rodents (Ahren et al. 1 997) and
reflects body lipid content in mice (Frederich et al. 1 995). The data on effects of
nutritional perturbations on serum leptin are beginning to accumulate. For example,
serum leptin concentration falls after fasting (Boden et al. 1 996) and energy restriction
(Wadden et al. 1998) with relatively small decreases in body weight and fat mass. In
addition, serum leptin concentrations fell following ultramarathon running in men (Landt
et al. 1 997) and 1 2 wk of aerobic exercise in women without changes in adiposity
(Hickey et al. 1 997). The list of nutritional factors that influence circulating leptin
concentrations is small, and there are no studies on the effect of dietary supplements plus
exercise on circulating serum leptin concentrations. Thus the objective of this study was
to determine changes in body weight, fat pad weights, serum leptin concentrations and
metabolic indices in rats fed a diet supplemented with caffeine, camitine and choline with
and without exercise.
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MATERIALS AND METHODS
Animals and treatment

The protocol of this study was approved by the University of Tennessee
Institutional Review Board. Twenty, 7-wk-old male Sprague-Dawley rats (Harlan
Sprague Dawley, Indianapolis, IN) were housed in a room controlled for temperature (2022 0 C), relative humidity (50%), and light ( 1 2-h light:dark cycle). Their initial mean body
weight was 2 1 8 g. Rats had free access to a ground nonpurified diet, Harlan Teklad 22/5 :
protein 22%, fat 5% and fiber 3 .83%, (Harlan Teklad, Madison, WI) and water. The diet
was fortified with caffeine, camitine, and choline at concentrations of 0. 1 , 5, and 1 1 .5
g/kg nonpurified diet, respectively, as the supplemented diet.
The endogenous concentrations of choline and camitine in this commercial diet
were 2. 1 g and 30 mg/kg diet, respectively. All rats were weighed daily and their food
intake was determined daily by the difference in the weight of food containers. Daily
food intakes throughout the 4-wk experimental period were used to calculate average
food intake. After arrival (1 wk), the rats were randomly divided into two groups (n = 1 0)
and assigned to the nonsupplemented or supplemented diet. Each dietary group was
subdivided into exercise and non-exercise groups (n = 5).
One-half of each dietary group was exercised on a rodent treadmill (Columbus
Instruments International, Inc., Columbus, OH). All rats in exercise groups were made to
run on the treadmill for 1 0 min at 1 5% grade starting at wk 3 . The running speed and
duration were continuously increased during the course of exercise to maximize at 1 8 ml
min for 25 min/d. The 2 x 2 factorial design was scheduled as follows: wk 1 , all rats
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consumed the nonsupplemented diet; wk 2, one-half of the rats consumed the
nonsupplemented diet and one-half did the supplemented diet; wk 3, one-half of the
nonsupplemented and supplemented rats were made to exercise on a treadmill 5 d/wk; wk
4, the diet and exercise regimen continued; and wk 5, the same treatments as in wk 4.
Sample collection and assays

At the end of the 5-wk experimental period, rats were anesthetized with
methoxyflurane (Pitman-Moore, Mundelein, IL) and killed by exsanguination after
cardiocentesis using 1 0-mL syringes fitted with 23-gauge, 1 .9 cm disposable needles.
The blood samples were immediately centrifuged at 2000 X g for 10 min at 4 ° C. Serum
was removed and stored at - 80 ° C until used for determination of glucose, triglycerides,
free fatty acids and leptin concentrations. Following blood collection, regional fat pads of
epididymal, perirenal and inguinal fat were quickly excised from the carcasses, weighed,
rinsed with saline, blotted dry, frozen in liquid nitrogen and stored at - 80 ° C until used
for triglycerides and total lipid determination. Glucose was determined by glucose
oxidase method using Sigma kit no. 5 1 0 (Sigma, St Louis, MO). Triglycerides, total
lipid, nonesterified fatty acids and lactate were determined by the methods of Giegel et al.
(1 975), Ellefson and Caraway (1 976) Novak (1 965) and Gutmann and Wahlefeld (1 974),
respectively. Serum leptin concentrations were determined using a commercial
radioimmunoassay kit (Linco Research, St Louis, MO).
Statistical analysis

All results are presented as group means ± SEM. Data were analyzed using two
way ANOVA to test the effects of exercise, supplementation and their interaction using
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SAS ( 1997). The main effects of diet and exercise were tested using specific linear
contrasts, as was the interaction. Pearson correlation coefficients were calculated using .
data from all 20 rats. Statistical significance level was set at P < 0.05.

RESULTS

Nonsupplemented rats consumed no caffeine, but consumed about 45 mg choline
and 0.66 mg camitine/d, because the nonpurified diet, Teklad 22/5, contains 2. 1 g choline
and 30 mg camitine/kg of diet (Table 3-1). Supplemented rats consumed in their diets
-2. 1, 105 and 240 mg/d caffeine, camitine and choline, respectively. The final body
weight and weight gain of the exercised rats were significantly lower (P = 0.00 1) than
those of nonexercised rats with or without supplement (Table 3- 1). There were no
significant differences in food intakes of the groups.
Fat pad weights generally were affected by exercise as well as by the supplement
(Table 3-2). The weights of epididymal fat pad of supplemented and nonsupplemented

rats with exercise were significantly lower than their nonexercised counterparts. The
weight of inguinal fat pads of exercised rats with and without supplementation were
significantly lower than their paired nonexercised rats. The weights of perirenal fat pads
of exercised rats were significantly lower than their nonexercised counterparts. The
perirenal fat pad weights of the supplemented, nonexercised rats were lower than those of
the nonexercised, nonsupplemented rats. Total fat pad weight (sum of the three) showed
a pattern similar to that of the other three fat pads, particularly the inguinal fat pad weight.
Although the duration and intensity of exercise were the same in the two exercised
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TABLE 3-1
Body weight andfood; caffeine, carnitine and choline intakes in exercised or nonexercised male rats with and without
caffeine, carnitine and choline supplementation 1
Nonsupplement

Supplement

Statistical significance2

--

Nonexercise

Exercise

Nonexercise

Exercise

Supplement

Exercise

S x E3

Initial body weight, g

21 8 ± 2.7

220 ± 7.8

2 1 6 ± 7.3

2 1 8 ± 5.6

NS4

NS

NS

Final body weight, g

377 ± 5.9a

349 ± 8.8

365 ± 9.28

332 ± 6.5

NS

0.00 1 2

NS

Total weight gain, g

1 58 ± 5. l a

129 ± 8.9

1 49 ± l l a

1 1 4 ± 7.2

NS

0.00 1 3

NS

2 1 .8 ± 0.4

2 1 . 1 ± 0.4

22.2 ± 0.5

20.7 ± 0.4

NS

NS

NS

2. 1 1 ± 0.04

2.07 ± 0.04

1 05 ± 2.0

1 04 ± 1 .8

0.000 1

NS

NS

Food intake, g/d
Caffeine intake, mg/d
Carnitine intake, mg/d

0.65 ± 0.01

0.67 ± 0.01

44 ± 0.8c
45 ± 0.9b
242 ± 4.6
238 ± 4. 1
Choline intake, mg/d
0.000 1
NS
NS
1
Values are means ± SEM, n = 5. The diets were supplemented with caffeine, carnitine, and choline at 0. 1 , 5, 1 1 .5 g/kg
diet. The nonsupplemented diet contained 2. 1 g choline and 30 mg carnitine per kg of diet. The energy distribution of diet:
22% protein, 5% fat, 73% carbohydrate. The diet provides 1 6.7 kJ/g (3 .99 kcal/g) and 3.8% fiber.
2
P values from 2-way ANOVA, using the factors supplementation and exercise.
3
S x E, supplement and exercise interaction.
4
NS, not significant, P < 0.05.
a Significant differences between nonexercised and exercised rats of a dietary group, tested by specific linear contrasts.
b
Significant differences between nonexercised rats with and without supplement, tested by specific linear contrasts.
c
Significant differences between exercised rats with and without supplement, tested by specific linear contrasts.

TABLE 3-2

Three regional fat pads and totalfat pad weights in exercised or nonexercised male rats with and without caffeine,
carnitine, and choline supplementation 1

Nonsupplement

-

00

Statistical significance2

Nonexercise

Exercise

Nonexercise

Exercise

Supplement

Exercise

S x E3

Epididymal fat, g

4.2 ± 0.2

3 .7 ± 0.48

3 .7 ± 0.3 b

2.9 ± 0.4

0.0350

0.01 69

NS4

Inguinal fat, g

4.6 ± 0.3 b
3 .7 ± 0.3 b,c

3 . 1 ± 0.5

3 . 7 ± 0.2b

2.2 ± 0.3

0.0 1 4 1

0.0003

NS

2.5 ± 0.4

2.6 ± 0.3

1 .9 ± 0.3

0.0245

0.0 1 4 1

NS

Perirenal fat, g

0

Supplement

0.00 1 9
NS
0.0 1 40
7.0 ± 1 .4
9.3 ± 2.6
1 0. 1 ± 1 .8 b
Total fat pad5 , g
1 2.4 ± 1 .6b
1
Values are means ± SEM, n = 5. The diets were supplemented with caffeine, carnitine, and choline at 0. 1 , 5, 1 1 .5 g/kg
diet. The nonsupplemented diet contained 2. 1 g choline and 30 mg carnitine per kg of diet. The energy distribution of
diet: 22% protein, 5% fat, 73% carbohydrate. The diet provides 1 6.7 kJ/g (3.99 kcal/g) and 3 . 8% fiber.
2
P values from 2-way ANOVA, using the factors supplementation and exercise.
3
S x E, supplement and exercise interaction.
4
NS, not significant, P < 0.05.
a Significant differences between nonexercised and exercised rats of a dietary group, tested by specific linear contrasts.
b
Significant differences between nonexercised rats with and without supplement, tested by specific linear contrasts.
c Significant differences between exercised rats with and without supplement, tested by specific linear contrasts.

groups, total fat pad reductions due to exercise were 25% in nonsupplemented rats and
44% in supplemented rats compared to the nonsupplemented, nonexercised rats.
However, there was not a significant interaction between diet and exercise.
Dietary supplement and exercise independently affected total lipids of the regional
fat pads (Table 3-3). The total lipid of epididymal and perirenal fat pad was significantly
lower in exercised, supplemented rats, reflecting the difference in the corresponding fat
pad weight (Table 3-2). The effects of both supplement and exercise on total lipid were
remarkable in the inguinal fat pad as there was 62% less of total lipid in the
supplemented, exercised rats compared to the nonsupplemented, nonexercised rats.
However, the interactive effects of supplement and exercise were not significant. The
triglycerides of epididymal fat pads were affected by exercise, however, those of the
inguinal and perirenal fat pads were not significantly affected by either supplementation
or exercise. The total lipids made up - 80-90% of the fat pad weights and 70-80 % of the
total lipids were triglycerides.
Differences in serum and muscle triglycerides were produced by the supplement
in exercised and nonexercised rats. Serum triglycerides were significantly lower in the
supplemented rats, but their muscle triglycerides were significantly higher than in the
nonsupplemented groups (Table 3-4). Serum leptin concentration was significantly
lower in the supplemented, exercised rats compared to any other group. Supplementation
and exercise did not significantly affect serum glucose, lactate or free fatty acids.
There were significant correlation between body weight and fat pad weights as
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TABLE 3-3

Total lipid and triglycerides ofthree regionalfat pads in exercised and nonexercised male rats with and without
caffeine, carnitine, and choline supplementation 1

Nonsupplement
Total lipid, g

......
......

N onexercise

Epididymal fat pads

3 .5 ± 0. 1

Inguinal fat pads

2.6 ± 0.2 b,

Perirenal fat pads

2.5 ± 0.2 b,

Exercise

Supplement
N onexercise

Exercise

Statistical significance2

Supplement

Exercise

S x E3

3.2 ± 0.3 a

3 .5 ± 0.3 b

2.5 ± 0.2

NS

0.01 65

NS4

c

1 .8 ± 0.2 a

1 .8 ± 0.2b

1 .0 ± 0. 1

0.0001

0.0001

NS

c

1 .6 ± 0.2

1 .7 ± 0.2

1 .3 ± 0.2

0.01 73

0.0082

NS

Triglycerides,
mmol/gfat
Epididymal fat pads

7.89 ± 0.3

8.63 ± 0.3

7.94 ± 0.3 b

9.22 ± 0.3

NS

0.0039

NS

Inguinal fat pads

7.73 ± 0.2

7.55 ± 0.5

6.93 ± 0.4

6.43 ± 0.5

NS

NS

NS

Perirenal fat pads
9.25 ± 0.4
8.66 ± 0. 1
8.67 ± 0. 1
8.79 ± 0.2
NS
NS
NS
Values are means ± SEM, n = 5. The diets were supplemented with caffeine, camitine, and choline at 0. 1 , 5, 1 1 .5 g/kg
diet. The nonsupplemented diet contained 2. 1 g choline and 30 mg camitine per kg of diet. The energy distribution of
diet: 22% protein, 5% fat, 73% carbohydrate. The diet provides 1 6.7 kJ/g (3 .99 kcal/g) and 3.8% fiber.
2
P values from 2-way ANOVA, using the factors supplementation and exercise.
3
S x E, supplement and exercise interaction.
4
NS, not significant, P < 0.05.
a Significant differences between nonexercised and exercised rats of a dietary group, tested by specific linear contrasts.
b
Significant differences between nonexercised rats with and without supplement, tested by specific linear contrasts.
c Significant differences between exercised rats with and without supplement, tested by specific linear contrasts.
1

TABLE 3-4
Effect ofsupplement and exercise on blood metabolites and muscle triglycerides in male rats fed the nonsupplemented diet
or supplemented diet with caffeine, carnitine and choline 1

Nonsupplement
Nonexercise

--

Exercise

Supplement
Nonexercise

Statistical significance2

Exercise

Supplement

Exercise

S x E3

Serum glucose, mmol/L

9.26 ± 0.57

9. 1 0 ± 0. 1 9

9. 1 8 ± 0.36

7.94 ± 0.28

NS

NS

NS4

Serum lactate, mmol/L

1 .42 ± 0.25

2.67 ± 0.65

1 .3 6 ± 0. 1 1

1 .89 ± 0.24

NS

NS

NS

Serum triglycerides,
mmol/L

0.76 ± 0.043

0.69 ± 0.09b

0.41 ± 0.06

0.46 ± 0.04

0.0003

NS

NS

Muscle triglycerides,
µmol/g ofwet muscle

32. l ± 2.73

34. 1 ± 4.7b

6 1 .2 ± 5.2

62.2 ± 6.2

0.0001

NS

NS

Serum free fatty acids,
µmo/IL

282 ± 30.9

290 ± 3 8.9

284 ± 29.4

NS

NS

NS

1 95 ± 24.4

1 .69 ± O. l l c
Serum leptin, µg/L
1 . 1 9 ± 0. 1 5
2.24 ± 0. 1 7a,c 1 .73 ± 0. 1 5 b
0.00 1 8
0.0032
NS
1
Values are means ± SEM, n = 5. The diets were supplemented with caffeine, camitine, and choline at 0. 1 , 5, 1 1 .5 g/kg diet.
The nonsupplemented diet contained 2. 1 g choline and 30 mg camitine per kg of diet. The energy distribution of diet: 22%
protein, 5% fat, 73% carbohydrate. The diet provides 1 6. 7 kJ/g (3.99 kcal/g) and 3 .8% fiber.
2
P values from 2-way ANOVA, using the factors supplementation and exercise.
3
S x E, supplement and exercise interaction.
4
NS, not significant, P < 0.05.
a Significant differences between nonexercised and exercised rats of a dietary group, tested by specific linear contrasts.
b
Significant differences between nonexercised rats with and without supplement, tested by specific linear contrasts.
c
Significant differences between exercised rats with and without supplement, tested by specific linear contrasts.

well as between body weight and concentrations of serum leptin and free fatty acids
(Table 3-5). Serum leptin concentrations were correlated with serum glucose but not
with food intake.

DISCUSSION

Since choline and carnitine have been used as lipotropic agents in number of
studies, we hypothesized that their combined effect on fat metabolism may be greater
than each alone, and may even be enhanced by exercise where energy demand is
increased. Our earlier studies had shown that choline supplementation promoted
carnitine conservation in both humans and guinea pigs but not in rats (Daily and Sachan
1995, Dodson and Sachan 1996). This conservation of carnitine in guinea pigs resulted in
accretion of carnitine in all tissues, especially skeletal muscle, where the differences were
significant (Daily and Sachan 1995). The exercise regimen is difficult to impose upon
guinea pigs because they do not run very well on a treadmill. Rats, on the other hand,
will run on a treadmill which enhances adipose tissue turnover rate (Askew et al. 1977).
However, rats do not conserve carnitine as do humans or guinea pigs at equivalent dosage
of choline (Daily and Sachan 1995). This was believed to be due to very high activity of
choline oxidase in rat liver compared to that in guinea pigs or humans (Sidransky and
Farber 1960). We speculated that high choline oxidase activity may be counterbalanced
by high levels of choline supplementation in the rat diet. Therefore, supplementary
choline level in the nonpurified diet was about 5-fold endogenous levels and that used in
earlier rat studies by us (Daily and Sachan 1995) and others (Rein et al. 1997). After
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TABLE 3-5

Correlations between body weight, three regional and total fat pad weights, food intake, blood metabolites, and muscle
triglycerides in exercised and nonexercised male rats with and without choline, caffeine and carnitine supplementation 1 •

2

Variable BW

-

EF

IF

PF

TF

FI

LP

GLU

LA

EF

0.76#

IF

0.71 * *

0.86#

PF

0.64**

0.86#

0.84#

TF

0.74#

0.95#

0.96#

0.64**

FI

0.77#

0.54*

0.51 *

0.40

0.50*

LP

0.5 5* *

0.78#

0.80#

0.75#

0.82#

0.29

GLU

0.24

0.34

0.51

0.43

0.46*

0.21

0.51 *

LA

-0.33

-0.03

-0.15

0.07

-0.05

-0.49*

-0.06

STG

0.21

0.17

0.31

0.29

0.28

-0.31

0.32

0.22

0.19

FFA

0.48*

0.40

0.49*

0.25

0.41

0.37

0.13

0.23

0.19

STG

FFA

0.26

-0.40
-0.41
0.06
MTG
-0.39
-0.3 8
-0.3 1
-0.34
-0.36
-0.21
-0.41
-0.41
Values are correlation coefficients, n = 20.
2
Abbreviation used: BW, body weight; EF, epididymal fat; IF, inguinal fat; PF, perirenal fat; TF, total fat; FI, food intake;
LP, leptin; GLU, nonfasting serum glucose; LA, lactic acid; STG, serum triglycerides; FFA; serum free fatty acids; MTG,
skeletal muscle triglycerides.
* P < 0.05, * * P < 0.01, # P < 0.001.
1

taking into account the daily food consumption by the rats (Table 3-1) it is estimated that
caffeine, carnitine and choline intakes were 6, 300 and 800 mg/kg of body weight. The
pharmacological doses of caffeine, carnitine and choline in humans are 7- 1 4, 40-45 and
1 50-200 mg/kg body weight, respectively. Thus choline and carnitine were 4-6 fold
higher than usual dosage but far below toxic dosage (LD 50 of choline in rat is 3 .4-6. 7 g/kg
body weight and none established for carnitine). It was anticipated that this amount of
choline may be more than sufficient to compensate for the high activity of rat choline
oxidase and therefore, may induce significant carnitine conservation. Choline
supplemented at 1 0 g/kg diet (seven- to tenfold higher than normal) and fed for 1 - 42 d
increased urinary excretion of choline 1 9-fold in rats just after 1 d of feeding the diet
(Rein et al. 1 997). In guinea pigs, choline supplementation (3 g choline/kg diet) over and
above the normal dietary choline concentration (1 .8 mg/kg), resulted in eight- to ninefold
higher choline excretion in the uririe. These observations indicate that supplementary
choline must get into the systemic circulation before it can be filtered into urine at these
high concentrations. We can only assume that enough choline escapes choline oxidase to
bring about anticipated conservation of carnitine.
The combination of choline, carnitine and caffeine superimposed with mild
exercise was hypothesized to enhance oxidation of fat by skeletal muscle and as a
consequence reduce the amount of body fat. Mild exercise preferentially promotes fat
oxidation for meeting energy needs over and above the basal energy requirements
(Romijn et al. 1 993 ). The results of this study support this hypothesis as there was
significant loss of adipose fat mass in the supplemented as well as exercised rats in 4 wk
1 14

(Table 3-2). This is important because camitine alone had no significant effect on
perirenal fat pad weight of rats fed 0.5% camitine-supplemented diet and trained on
treadmill for 5 wk (Askew et al. 1977). Diets supplemented with camitine alone have
produced variable responses regarding substrate utilization and muscle fatigue in exercise
(Brass and Hiatt 1994, Decombaz et al. 1992, Lennon et al. 1983, Neumann 1996).
Similarly, choline alone is not known to alter energy substrate utilization (Spector et al.
1995) or reduce body weight (Tsai et al. 1974). Likewise, caffeine alone has been shown
to increase plasma free fatty acid concentration without altering substrate preference for
oxidation in running exercise (Casal and Leon 1985). Caffeine by itself at a dosage of
200 mg, three times a day for 24 wk had no effect on body weight in obese patients.
However, when combined with 20 mg of ephedrine, it caused a significant decrease in
body weight (Astrup et al. 1992).
The reduction in body fat is supported by reduction in the endogenous marker of
adiposity, leptin, which was significantly lower in the supplemented as well as exercised
rats (Table 3-4). The leptin concentrations were positively correlated with body fat (r =
0.82, P < 0.001) and body weight (r = 0.55, P < 0.01) as shown in Table 3-5 and has been
seen elsewhere (Ahren, et al. 1997, Frederich, et al. 1995). Factors other than adipose
tissue mass influence leptin secretion (Havel 1998). For example, the decrease in
circulating leptin concentration during energy restriction in human is closely related to the
decrease in plasma glucose (Dubuc, et al. 1998). However, in the rats of our study, feed
intake was not affected by any of the treatments (Table 3-1), and serum concentration of
leptin was positively correlated with serum glucose (r = 0.51, P < 0.05).
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The differences in the concentrations of the metabolites presented in Table 3-4
suggest that supplementation favored partitioning of triglycerides from serum t_o skeletal
muscle because there was 33-46% lower concentration in serum and 82-90% greater level
in the muscle. Increased esterification and increased permeability of muscle membranes
to fatty acids are possible (Marconi et al. 1 985, Neumann, 1 996). Lower concentrations
of serum glucose ( 1 3 %) and free fatty acids (3 1 %) in the supplemented, exercised group
also suggests a promotion of energy substrate utilization by supplementation under the
conditions of mild exercise. Mild exercise has been -shown to promote preferential use of
fat for energy needs over and above the basal requirements (Romijn et al. 1 993 ). The rise
in serum lactate concentration due to exercise (88%) was buffered by the supplements
where it rose less than half (39% ), which may be due to decreased glycogen utilization or
increased renal loss of lactate.
We thought it was relevant to characterize the chemical nature of the adipose fat
mass which was found to be 80-90 % total lipids of which 70-80% were triglycerides
(Table 3 -3). These values are close to the upper end of the range of lipid contents of
adipose tissue. Adipose tissue is, on the average, 80% fat, 1 8% water and 2% protein
(Heymsfield et al. 1 999). The protein contents of the adipose tissues were not different
among the groups (data not shown).
From these data, clearly, the combination of choline, camitine and caffeine with
or without mild exercise reduces body fat, as indicated by decrease in fat pad weights and
total lipids as well as serum leptin in rats. We conclude that the dietary supplement used
in this study promotes fat loss as much as does the exercise, and there is no significant
1 16

interactive effect. This does not preclude reassessment of individual effects of the

components of this supplement. These results may or may not be applicable to humans,

and further research is necessary to determine whether similar effects would result in

other species.
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CHAPTER IV
INCREASES IN V0 2max AND METABOLIC MARKERS OF FAT OXIDATION
BY CAFFEINE, CARNITINE AND CHOLINE SUPPLEMENTATION IN RATS

This chapter is a slightly revised version of a manuscript published with co-author Dileep
S. in the Journal of Nutritional Biochemistry in 2000.
Dileep S. Sachan and Nobuko Hongu (2000) Increases in V02max and metabolic
markers of fat oxidation by caffeine, camitine and choline supplementation in rats. J.
Nutr. Biochem. 1 1 : 521 -526, 2000.

ABSTRACT

We have previously shown that the combination of caffeine, camitine and choline
supplementation decreased body fat and serum leptin concentration in rats and this was
attributed to increased fat utilization for energy. As a result, it was hypothesized that the
supplements may augment exercise performance including physiological and biochemical
indices. Twenty, 7 -wk-old male Sprague-Dawley rats were given free access to a
nonpurified diet with or without supplementation of caffeine, camitine and choline at
concentrations of 0. 1 , 5 and 1 1 .5 g/kg diet, respectively. One-half of each dietary group
was exercised on a motor-driven treadmill for 3 wk and maximal aerobic power
(V02max) was determined on l 81h day of exercise. Rats were killed 24-h postexercise,
and blood, regional fat pads and skeletal muscle were collected. The V02max was
increased (P < 0.05) in the supplemented, exercised group; however, the respiratory
quotient (RQ) was not affected. Postexercised concentrations of serum triglycerides were
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decreased but P-hydroxybutyrate, acylcamitine and acetylcamitine were increased in the
supplemented rats. The changes in serum metabolites were complemented by the
changes in the muscle and urinary metabolites. The magnitude of increase in urinary
acylcamitines (34- 45-fold) is a unique effect of this combination of supplements.
Cumulative evidence indicates enhanced P-oxidation of fatty acids without a change in
the RQ because acetyl units were excreted in urine as acetylcamitine and not oxidized to
carbon dioxide. For this phenomenon, we propose the term "fatty acid dumping". We
conclude that supplementation with caffeine; camitine and choline augments exercise
performance and promotes fatty acid oxidation as well as disposal in urine.

INTRODUCTION
Professional and nonprofessional athletes seek nutritional supplements that will
enhance exercise performance. These substances theoretically improve exercise capacity
by enhancing lipid oxidation and slowing rates of muscle glycogen depletion (Essig, et al.
1 980, Hawley et al. 1 998), therefore reducing fatigue (Green 1 99 1 ). Substantial research
has been done on the use of a single substance (or nutrient) to enhance endurance
performance, but only a few studies have been carried out to determine favorable effects
of a combination of ergogenic substances on metabolic processes (Decombaz et al. 1 987).
It is well known that athletes supplement their diets not only with single but multiple
nutritional factors (Clarkson 1 996, Short and Marquart 1 993). Therefore, a study using a
combination of three popular dietary supplements (caffeine, camitine and choline) was
envisioned, where the parameters of energy substrate utilization and exe.rcise could be
1 19

determined.
It has been suggested that caffeine enhances lipolysis and fat oxidation and
reduces glycogen breakdown (Costill et al. 1 978, Essig, et al. 1 980, Pasman et al. 1 978)
However, the results of studies on the ergogenic effects of caffeine are equivocal.
Carnitine is essential for translocation of long-chain fatty acids into mitochondrial matrix
as well as for the shuttling of acyl groups out of the mitochondria (Bremer 1 997).
Clinical studies have shown that carnitine supplementation improves muscle function and
exercise capability in peripheral arterial disease and hemodialysis patients (Brass and
Hiatt 1 998). Yet, it is not clear whether camitine supplementation benefits normal
healthy individuals. Choline supplementation has been shown to enhance acetylcholine
synthesis (Zeise! and Blusztajn 1 994). A decline in plasma and urinary choline
concentrations has been observed in athletes after running a marathon (Buchman et al.
1 999, Conlay et al. 1 992). This has lead to the hypothesis that choline supplementation
may prevent decrement in physical performance. However, the mechanism by which
choline could affect exercise performance has not been clearly established.
Recently, nutrient-nutrient interactions between choline and camitine have been
reported in healthy humans and animals (Daily and Sachan 1 995, Daily et al. 1 998,
Dodson and Sachan 1 996, Hongu and Sachan 2000, Rein et al. 1 997). Choline
supplementation promotes tissue carnitine conservation, especially in skeletal muscle,
which may have positive functional consequences in terms of exercise performance
(Daily and Sachan 1 995, Daily et al. 1 998). However, choline-supplemented exercised
guinea pigs showed no change in RQ even though their carcass fat was significantly
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reduced (Daily et al. 1 998). Adult rats did not produce carnitine conservation, when
choline dosage similar to that given to humans and guinea pigs were administered (Daily
and Sachan 1995, Rein et al. 1 997). In the previous study we found that relatively higher
doses of choline in combination with caffeine plus carnitine given to rats for 4 wk
significantly reduced their body fat and serum leptin concentration (Hongu and Sachan
2000). We report now the effects of the combination of caffeine, carnitine, and choline
supplementation on RQ, V02max and relevant metabolic and biochemical markers of
fatty acid oxidation.

MATERIALS AND METHODS
Animals and treatment

The experimental protocol was approved by the University of Tennessee
Institutional Review Board. Twenty, 7-wk-old male Sprague-Dawley rats (Harlan
Sprague-Dawley, Indianapolis, IN), weighing 21 0-230 g, were individually housed in
wire mesh cages in a room with controlled temperature (20-22 °C), relative humidity
(50%), and light cycle (1 2-h light/dark cycle). The rats were randomly divided into two
dietary groups to receive either a nonsupplemented or supplemented diet with caffeine,
camitine and choline at concentrations of 0. 1 , 5 and 1 1 .5 g/kg nonpurified diet,
respectively. Food intake and body weight were determined daily throughout the 5-wk
experimental period.
After 1 wk of dietary treatment, one-half of each dietary group (n = 5) was put to
exercise on the rodent treadmill (Columbus Instruments International, Inc., Columbus,
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OH) for 1 0 min at 1 5% grade, 6 cl/wk. The running speed and duration were gradually
increased during the experiment to maximize at 1 8 m/min for 25 min/day. Expired
gasses were continuously analyzed using an Ametek S-3A oxygen analyzer and CD-3A
carbon dioxide analyzer (Ametek, Inc., Paoli, PA). The expired gases were monitored to
calculate RQ. Resting RQ of each rat was measured on the first day of exercise period
(wk 3), after a rat was sitting quietly in the metabolic chamber for 20 min. On the 1 8 th
day of exercise, the V02max was determined according to the method described by
Bedford et al. (1 979). The exhaustion RQ was measured at the time a rat stopped
running, and the running time was recorded as the exhaustion time. A tail-vein blood
sample was taken at exhaustion for lactate determination.
Sample collection and assays

At the end of the experimental period, rats were anesthetized with methoxyflurane
(Pitman-Moore, Mundelein, IL) and killed by exsanguination after cardiocentesis. In the
exercised rats, blood (cardiac) and tissue collections were done 24 hr after the last bout of
exercise. The blood samples were immediately centrifuged and serum was stored at
- 80 ° C. Following blood collection, regional fat pads and skeletal muscle
(gastrocnemius) samples were collected and frozen in liquid nitrogen, and stored at
- 80 ° C. The samples were assayed for the concentrations of lactate (Gutmann and
Wahlefeld 1 974), triglycerides (Giegel et al. 1 975), free fatty acids (Novak 1 965) and
carnitine fractions (Cedarblad and Lindstedt 1 972, Sachan et al. 1 984) according to the
established procedures. Glucose and P-hydroxybutyrate were determined by using Sigma
kits no. 5 1 0 and 3 1 0, respectively (Sigma, St.Louis, MO).
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Statistical analysis
Data are reported as means ± SEM (n = 5). The differences between exercise
groups at exhaustion were tested with Student' s t test. Two-way ANOVA was used to
determine the effects of exercise, supplementation and their interaction on serum and
skeletal muscle metabolites and urinary carnitine excretion. Statistics were performed
using SAS ( 1 997). A value of P < 0.05 was considered to be significant.

RESULTS
There were no significant differences in food intakes of the groups (Table 3-1).
Final bo.dy weight was significantly affected by exercise (Table 3-1), but total fat pad
weight was affected by exercise as well as by the supplement (Table 3-2). The mean total
fat pad weight of supplemented, exercised rats was 25% lower than nonsupplemented,
exercise rats (Table 3-2).
No significant differences were observed in the mean RQ values of the groups at
rest and at exhaustion between the two exercised groups (Table 4-1). The V02max of the
supplemented rats was significantly higher than that of the nonsupplemented rats, which
is indicative of the enhanced exercise capacity of the supplemented rats. Although
exhaustion time and blood lactate were not statistically significant, the 70% longer time
to exhaustion and 29% lower blood lactate concentration in the supplemented, exercised
rats are physiological changes too large to be easily ignored (Table 4- 1 ).
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TABLE 4-1

Effects ofcaffeine, carnitine and choline supplementation on RQ at rest and exhaustion,
V02max, exhaustion time, and blood lactate concentrations at exhaustion in exercised
rats1
Nonsupplement
Parameters

Nonexercise

Exercise

Supplement
Nonexercise

Exercise

RQ
At rest

0.879 ± 0.02

0.875 ± 0.02

0. 866 ± 0.02

0.847 ± 0.0 1

----------

0.920 ± 0.02

----------

0.906 ± 0.03

V02max
(ml/kg/min)

----------

47.80 ± 1 . 1 2

----------

52. 1 3 ± 1 .28*

Exhaustion time
(min)

----------

32.26 ± 9.3

----------

54.72 ± 1 5 .8

Lactate at
exhaustion
(mmol/L)

----------

2.66 ± 1 .46

----------

1 .89 ± 0.53

At exhaustion

Values are mean ± SEM, n = 5 .
Rats were fed diet without supplemented or supplemented with caffeine, carnitine,
and choline at concentrations of O . 1 , 5, and 1 1 . 5 g/kg diet, respectively. The energy
distribution of diet: 22% protein, 5% fat, and 73% carbohydrate. The diet provides
1 6.7 kJ/g (3 .99 kcal/g) and 3 .8% fiber.
* P < 0.05.
1
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One day after the last bout of exercise, cardiac blood and tissues were collected.
Triglycerides were significantly lower in serum (Table 4-2) but significantly higher in
skeletal muscle (Table 4-3) of both supplemented groups. There were no significant
differences in serum glucose and free fatty acids. Serum P-hydroxybutyrate was affected
by exercise, even though it was determined in the blood samples collected 24 hr after
exercise periods (Table 4-2). All fractions of serum carnitine were significantly higher in
the supplement rats with or without exercise (Table 4-2). Serum camitine fractions of the
nonsupplemented, exercised rats were 20-29% lower compared with the
nonsupplemented, nonexercised rats. There was significant interactive effect of
supplement and exercise on total carnitine (TC), nonesterified carnitine (NEC) and acid
soluble acylcarnitine (ASAC) in serum.
The supplementation resulted in significantly higher concentration of
triglycerides, TC, NEC and ASAC in skeletal muscle (Table 4-3). There was 1 8% less
TC in the nonsupplemented, exercised rats compared to nonsupplemented, nonexercise
rats; however, TC concentration remained the same in the two supplemented groups with
or without exercise. The muscle free fatty acids and total lipid were significantly higher
in the exercised rats with or without supplements (Table 4-3).
Urinary excretion of TC and all fractions of carnitine were significantly higher in
the supplemented groups (Table 4-4). There was 34- 45-fold increase in ASAC and
56- 80-fold increase in acid-insoluble acylcarnitine (AIAC) in the- urine of the
supplemented rats. There were no differences between the nonexercised and exercised
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TABLE 4-2

Effects of supplement and exercise on serum metabolites at rest in male rats fed the nonsupplemented diet or supplemented
diet with caffeine, camitine and choline 1 •2
Nonsupplement

Supplement

Supplement
--

Exercise

S x E4

NS5

NS

NS

0.46 ± 0.04

0.0003

NS

NS

1 .3 1 ± 0.38

2.20 ± 0.44

NS

0.0 1 53

NS

284 ± 29.4

1 95 ± 24.4

NS

NS

NS

1 1 7.6 ± 4.9

0.000 1

NS

0.0003

85.6 ± 2.0

95.0 ± 3 . 5

0.000 1

NS

0.0007

1 0.2 ± 1 .7

1 6. 1 ± 1 . 1

1 8.3 ± 1 .2

0.0035

NS

0.0380

3 .0 ± 0.2

2.4 ± 0.3

5 .2 ± 0.3

4.3 ± 0.5

0.000 1

NS

NS

42.7 ± 1 . 1

34.3 ± 0.7

7 1 .9 ± 5.68

73 .7 ± 4.66

0.000 1

NS

NS

Metabolites

Nonexercise

Exercise

Nonexercise

Exercise

Glucose, mmollL

9.26 ± 0.57

9. 1 0 ± 0. 1 9

9. 1 8 ± 0.36

7.94 ± 0.28

Triglycerides, mmo!IL

0.76 ± 0.04

0.69 ± 0.09

0.4 1 ± 0.06

P-Hydroxybutyrate mgldL

0.6 1 ± 0. 1 5

1 .57 ± 0.32

Free fatty acids, µmo/IL

282 ± 30.9

290 ± 3 8.9

82. 1 ± 1 .6

66.5 ± 0.9

1 06.9 ± 0.9

NEC, µmo/IL

64.8 ± 2.3

53 .7 ± 1 .4

ASAC, µmo/IL

1 4.4 ± 1 .7

AIAC, µmo/IL

N TC, µmo/IL

AC, nmo!IL
1

Statistical significance3

Values are means ± SEM, n = 5. Rats were fed diet without supplemented or supplemented with caffeine, camitine, and
choline at concentrations of 0. 1 , 5 and 1 1 .5 g/kg diet, respectively. The energy distribution of diet: 22% protein, 5% fat,
and 73% carbohydrate. The diet provides 1 6.7 kJ/g (3.99 kcal/g) and 3 . 8% fiber.
2
Abbreviation used: AC, acetylcamitine; AIAC, acid-insoluble acylcamitine; ASAC, acid-soluble acylcarnitine;
NEC, nonesterified carnitine; TC, total camitine.
3
P values from two-way ANOVA, using the factors, supplementation and exercise.
4
S X E; supplement and exercise interaction.
5
NS: not significant, P > 0. 0 5 .

TABLE 4-3

Effects of supplement and exercise on skeletal muscle metabolites at rest in male rats fed the nonsupplemented diet or
supplemented diet with caffeine, carnitine and choline 1 •2
Metabolites
(units/g wet tissue)

Nonexercise

Exercise

Supplement
Nonexercise

Exercise

Statistical significance2
Supplement

Exercise

s X E3

32. 1 ± 2.7

34. 1 ± 4.7

6 1 .2 ± 5 .2

62.2 ± 6.2

0.0001

NS

NS

Free fatty acids,
µmo!

2. 1 ± 0. 1

2.8 ± 0.3

2.3 ± 0. 1

2.8 ± 0. 1

NS

0.0050

NS

Total lipid, mg

1 3 .6 ± 0.8

20.2 ± 1 .2

1 1 .2 ± 1 .2

1 9. 1 ± 2. 1

NS

0.000 1

NS

TC, nmol

1 025 ± 35.4

966 ± 59.6

1 270 ± 26.2

1 282 ± 56.5 .

0.000 1

NS

0.0002

NEC, nmol

576 ± 32.2

542 ± 3 3 .7

637 ± 3 1 .4

727 ± 49.8

0.000 1

NS

NS

ASAC, nmol

270 ± 29.8

295 ± 24. 5

533 ± 3 0.6

4 1 9.2 ± 24.0

0.000 1

NS

0.02 1 8

AIAC, nmol

1 64 ± 1 6.5

1 3 8 ± 6.3

1 47.8 ± 5.6

NS

NS

0.0 1 65

AC, nmol
-

245 ± 14.9

204 ± 1 9.9

254.3 ± 22. 1

NS

NS

NS

Triglycerides,
µmo!

.......

Nonsupplement

1

1 09.8 ± 8.7
276 ± 1 5.6

Values are means ± SEM, n = 5. Rats were fed diet without supplemented or supplemented with caffeine, camitine, and
choline at concentrations of 0. 1 , 5 and 1 1 .5 g/kg diet, respectively. The energy distribution of diet: 22% protein, 5% fat, and
73% carbohydrate. The diet provides 1 6.7 kJ/g (3 .99 kcal/g) and 3 . 8% fiber.
2
Abbreviation used: AC, acetylcarnitine; AIAC, acid-insoluble acylcarnitine; ASAC, acid-soluble acylcamitine;
NEC, nonesterified camitine; TC, total carnitine.
3
P values from two-way ANOVA, using the factors, supplementation and exercise.
4
S X E; supplement and exercise interaction. 5NS: not significant, P > 0.05.

TABLE 4-4
Effects ofsupplement and exercise on urinary carnitine excretion in male rats fed the nonsupplemented diet or
supplemented diet with caffeine, carnitine and choline 1 •2

......

Nonsupplement

Supplement

Statistical significance2

Carnitine
µmol/day

Nonexercise

Exercise

Nonexercise

Exercise

Supplement

Exercise

S x E3

TC

0.99 ± 0.26

0.87 ± 0.08

100.4 ± 7.9

105.6 ± 8.7

0.000 1

NS

NS

NEC

0.57 ± 0.2

0.48 ± 0.04

85.2 ± 7.2

87.5 ± 9.2

0.000 1

NS

NS

ASAC

0.4 ± 0.06

0.36 ± 0.04

13 .6 ± 3 .2

16.4 ± 2.2

0.000 1

NS

NS

AIAC

0.02 ± 0.00

0.03 ± 0.0 1

1.6 ± 0. 1

1.7 ± 0. 1

0.000 1

NS

NS

AC

0.66 ± 0. 1 6

0.56 ± 0.06

13 .4 ± 2.5

14.4 ± 2.8

0.000 1

NS

NS

Values are means ± SEM, n = 5. Rats were fed diet without supplemented or supplemented with caffeine, carnitine,
and choline at concentrations of 0. 1, 5 and 1 1.5 g/kg diet, respectively. The energy distribution of diet: 22% protein, 5%
fat, and 73% carbohydrate. The diet provides 16.7 kJ/g (3 .99 kcal/g) and 3.8% fiber.
2
Abbreviation used: AC, acetylcarnitine; AIAC, acid-insoluble acylcarnitine; ASAC, acid-soluble acylcarnitine;
NEC, nonesterified carnitine; TC, total carnitine.
3
P values from two-way ANOVA, using the factors, supplementation and exercise.
4
S X E; supplement and exercise interaction.
5
NS: not significant, P > 0.05.
1

rats. The majority (88-98%) of the urinary ASAC was acetylcarnitine (AC) in the
supplemented groups.

DISCUSSION

The known biochemical and physiological effects of caffeine, carnitine and
choline formed the basis of our hypothesis that coadministration of these agents should
augment exercise endurance and provide energy from fat oxidation in muscle. The
conceptual model was that caffeine will promote fatty acid release from adipose tissue,
choline will readily allow entry of carnitine into skeletal muscle cells, and carnitine will
enhance translocation of fatty acids (as acylcarnitine) into the mitochondrial matrix of
muscle. As a result, there should be a shift in the indices of exercise and fat oxidation.
Measurements of V02max, RQ, enzyme activities and substrate or metabolite
concentrations are often chosen as endpoints in exercise studies to assess aspects of
physical performance. V02max, provides an assessment of maximal exercise capacity
(Wasserman and Whipp 1975) and is an accepted index of the functional limit of the
cardiovascular system (Rowell 1974). Also, it has been used to evaluate the effect of the
ergogenic aids including nutritional supplements (Marconi et al. 1985, Spector et al.
1995). RQ is a convenient and general guide to the relative rates of glucose and fat
oxidation during steady state exercise below the lactate threshold (Jansson 1982).
The results of this study show that the combination of supplements augmented
exercise performance as indicated by 8% increased V02max, 70% longer time to
exhaustion, and 29% lower blood lactate concentration (Table 4-1 ). These results are
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consistent with those reported by Marconi et al.(1985) who found a significant increased
in the V02 max after camitine loading (4 g/d for 2 wk) of the competitive athletes engaged
in training programs. However, the results of other studies in humans supplemented with
carnitine are contradictory (Greig et al. 1987, Wyss et al. 1990). Some of the
contradiction may be related to variations in camitine loading. For example, we gave
carnitine at the rate of 105 mg/d for 4 wk, which was 150-fold higher than that of the
nonsupplemented rats and 5- 10-fold greater than the dosage used in humans (2-4 g/d).
Further, the polypharmacy nature of the supplement (combination of choline, carnitine
and caffeine) may lend a unique advantage to the system not present in other studies.
The RQ range (0.84-0.87) of the rats (Table 4-1) suggests that energy substrates
were both fat and carbohydrates (50:50), according to the published reports (McArdle et
al. 1986). The RQ was not altered by the supplement in our study; similar results have
been reported by Marconi et al. (1985). This means that fat was not the major energy
substrate under these conditions, which is difficult to reconcile with the significant loss of
body fat in supplemented, as well as in exercised rats (Table 3-2) (Hongu and Sachan
2000). We have argued that the loss of body fat was due to fat being used as the energy
substrate, as feed composition and intakes were not different among the groups (Table 31 ). Therefore, markers of fatty acid oxidation other than RQ needed closer examination.
The lower serum lactate concentration in the supplemented, exercised rats
compared to nonsupplemented, exercised rats (Table 4- 1) is suggestive of lesser glucose
catabolism and more fatty acid oxidation to provide energy for exercise (Sugden and
Holness 1994). A more direct evidence of fatty acid oxidation is seen in the higher P130

hydroxybutyric acid ( > 40% ), lower triglycerides (40%) and free fatty acids (3 1 %) in the
serum of the supplemented, exercised rats compared to the nonsupplemented, exercised
rats (Table 4-2). Additional evidence is presented by the changes in short-chain
acylcamitine (ASAC) and AC, both being markers of fatty acid oxidation (Bremer 1 997).
The serum ASAC and AC are nearly doubled in the supplemented rats (Table 4-2). A
decrease in ASAC (29%) and AC (20%) in the exercised rats without supplement
(nonsupplemented, exercised vs. nonsupplemented, nonexercised) suggests limited
production of these metabolites due to lack of supplement. The lower concentrations of
ASAC and AC in the nonsupplemented, exercised rats could not be explained by
complete oxidation of acetyl groups because RQ was not decreased in the rats (Table 41 ).

The changes in the markers of fatty acid oxidation in serum were complimentary
to the changes in skeletal muscle where supplement increased accretion of triglyceride
and camitine, particularly the ASACs, which are indicators of fatty acid oxidation (Table
4-3). The ASACs were increased about 1 .4-fold by the supplement and by exercise in the
gastrocnemius muscle, which is consistent with the changes in serum and urine, and
supports the argument that the supplement promoted fatty acid oxidation.
So why there was no decrease in the RQ of the supplemented animals if fatty acid
oxidation was enhanced? To reconcile the lack of concert between the RQ and
biochemical markers of fat .oxidation, we postulate the "fatty acid dumping" hypothesis
with the following rationale. The activation and subsequent oxidation (via P-oxidation)
of fatty acids produces acyl-CoAs of various chain lengths, including acetyl-CoA
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(Hiatt et al. 1 989). As the ratio of acetyl-CoA/CoA rises in muscle mitochondria after
exercise (Friolet et al. 1 994, Hiilsmann et al. 1 964), the acetyl moiety is readily
transferred to carnitine (Harris et al. 1 987, Sahlin 1 990) in the presence of readily
available carnitine in the muscle, promoted by choline in the supplement, as reported
elsewhere (Daily and Sachan 1 995, Daily et al 1 998). The AC is not a substrate for
condensing enzyme, therefore it can not enter the tricarboxylic acid (TCA) cycle, and
must exit mitochondria (Bremer 1 997). The cytosolic AC enters blood and is filtered out
in urine. This is supported by the rise in AC concentrations by 2-fold in serum (Table 42) and 25-fold in urine (Table 4-4) but not in the muscle (Table 4-3) of the supplemented
rats. The AC did not accumulate in the muscle, as it was allowed to exit into serum and
urine where it makes up 88-98 % of ASAC (Table 4-4). A similar scenario holds true for
the fatty acids of various chain lengths, particularly the short-chain fatty acids (ASAC).
The rise of ASAC content of skeletal muscle (2-fold), serum (2-fold) and urine (35- 45fold) of the supplemented rats (Tables 4-2- 4-4) is consistent with our hypothesis. Thus,
a significant amount of fatty acid carbons do not get oxidized to CO2 and the RQ remains
unchanged. Instead, the fatty acid carbons are loaded on to carnitine and dumped in urine
as ACs.
Could this be an effect of caffeine or carnitine alone? Caffeine promotes release
of fatty acids from adipose tissue, which does not necessarily mean that it enhances fatty
acid oxidation. There is paucity of clean biochemical data resulting in a great deal of
controversy about the promotion of fat oxidation by caffeine alone (Astrup et al. 1 992,
Casal and Leon 1 985). With regard to carnitine alone, there is reasonable evidence that it
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promotes fatty acid oxidation in intact animals; however, the magnitude of the effect is
small and controversial. Negrao et al. (1 987) found no significant increase in plasma
ASAC of rats given i.p. camitine for 8 wk. In one of our studies (Sachan and Mynatt
1 992), we fed 0.5% camitine-supplemented diet to rats for 5, 1 0, 20, 30 and 40 d and
found no significant increase in serum ASAC at any of these time points; however, there
was about 2-fold increase in serum ASAC and AIAC after 40 d of treatment. In another
study (Berger and Sachan 1 992), when rats were fed diets supplemented with various
doses of camitine for 1 0 d, there was about 2- and 1 0-fold increase in the ASAC
concentrations of blood and urine, respectively. So camitine alone brings about
respectable increases in urinary ASAC (1 0-fold) but nowhere near the 34- 45-fold
increase in ASAC and 56- 80-fold increase in AIAC seen in the current study (Table 4-4).
The magnitude of ASAC and AC loss in urine by the combination of camitine, caffeine
and choline compared to that by camitine alone is a very important point. A sustained
loss of fatty acid carbons, even in smaller amounts, are analogues to a dripping water
faucet. Thus, we call this phenomenon "fatty acid dumping". The shift in the normal
direction of flow of fatty acid carbons must perturb the metabolic pathways and modulate
normal homeostasis and regulation of energy substrate utilization.
In conclusion, the combination of caffeine, camitine and choline supplement
increases aerobic work capacity by enhancing fatty acid oxidation in the skeletal muscle.
The simultaneous presence of caffeine, camitine and choline is the key for promotion of
facilitated availability and transport of fat to the site of oxidation as well as disposal of
the end products of P..oxidation of fatty acids, i.e., acetyl groups. The loss of fatty acids
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as ASAC or AC leaves RQ unchanged, even though fatty acids are oxidized but not to
CO 2 as conventionally expected.
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CHAPTER V
TISSUE CARNITINE ACCRETION AND FAT METABOLISM IN RATS
SUPPLEMENTED WITH CARNITINE, CHOLINE AND CAFFEINE
REGARDLESS OF EXERCISE

This chapter is a slightly revised version of a manuscript, whish has been accepted for
publication with co-author Dileep S. Sachan in the Journal of Medical Sciences 2: 2002
(in press).

ABSTRACT

The objective of this study was to determine if a combination of carnitine, choline
and caffeine supplementation would alter the concentrations of camitine in various rat
tissues (i.e. liver, heart, kidneys, brain, and testes) with or without exercise. Male, 7-wk
old Sprague-Dawley rats were given free access to a nonpurified diet with or without
supplementation of carnitine, choline and caffeine at concentrations of 5, 1 1.5, and 0. 1
g/kg diet, respectively for 4 wk. One-half of each dietary group was assigned to exercise
on a treadmill for 3 wk. Results showed that the concentration of nonesterified and total
camitine was higher in serum, urine and all tissues of the supplemented rats. Exercise
further promoted this effect in the liver and kidneys. There were variable effects of
supplement and exercise on the other fractions of camitine in tissues. However, short
chain acylcamitines were consistently higher in the skeletal and cardiac muscles and
reflected in the serum and urine of the supplemented rats. Serum aspartate amino
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transferase (AST) and alanin amino transferase (ALT), liver proteins and DNA were not
adversely altered by the supplement. In conclusion, oral feeding of camitine, choline, and
caffeine (CCC) supplement to rats promotes camitine influx in all tissues and changes in
acylcamitines of skeletal and cardiac muscles, indicating enhanced fatty acid oxidation.
This is supported by the changes in serum and urinary acylcamitine profiles and loss of
adipose tissue mass.

INTRODUCTION

Camitine is an endogenous quaternary amine that is synthesized from the essential
amino acids, lysine and methionine (Cox and Hoppel 1 973). It is present in all
mammalian tissues, with higher concentrations in heart, skeletal muscle, and with lower
concentrations in blood plasma, liver and kidney (Bieber 1 988). Camitine is essential in
the oxidation of fatty acids, serving as a "carrier" of activated fatty acids, fatty acyl-CoA
esters, across the mitochondrial inner membrane to the site of P-oxidation. Camitine is
also necessary for maintaining intramitochondrial acyl-CoA/CoA ratio by accepting acyl
moieties from acyl-CoA (Bieber et al. 1 982). A positive outcome of this process is the
removal of toxic acyl-CoAs generated from the catabolism of branched chain amino acids
(Bieber 1 988).
Camitine is present in tissues as free (NEC) and as esterified camitine
(acylcamitine). Many pathophysiological conditions affect serum and tissue camitine
concentrations and their excretion in urine. Exercise training has been reported to
increase NEC and short-chain acylcamitine or ASAC in skeletal muscle and heart of
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swim-trained female rats (Lennon and Mance 1 986). There was an increase in NEC in
skeletal muscle and long-chain acylcarnitine (AIAC) in plasma and liver of treadmill
trained male Sprague-Dawley rats (Negrao et al. 1 987). Experiments in humans indicate
increased camitine concentrations in serum and skeletal muscle of trained individuals
(Lennon and Mance 1 986, Arenas et al. 1 99 1 ). A number of studies have shown
increased carnitine concentrations in different tissues as a result of carnitine
supplementation and/or exercise; however, the magnitudes of the changes have been
highly variable in some studies (Negrao et al: 1 987, Paulson et al. 1 984, Simi et al. 1 990).
We have reported that choline supplementation promotes tissue carnitine
conservation in humans and animals (Daily and Sachan 1 995, Daily et al. 1 998, Dodson
and Sachan 1 996). Choline supplementation causes significant accumulation of carnitine
in the skeletal muscle of guinea pigs; where it was associated with leaner body
composition, improved exercise performance, but showed no change in RQ (Daily et al.
1 998). A dosage of choline similar to that given to humans and guinea pigs did not result
in camitine conservation in adult rats (Daily and Sachan 1 995, Daily et al. 1 998).
However, relatively higher doses of choline in combination with caffeine plus camitine
given to rats for 4 wk resulted in significant increase in carnitine status of serum, skeletal
muscle and urine (Sachan and Hongu 2000). Functional consequences of the changes due
to the supplementation were significant loss of fat pad mass (Hongu and Sachan 2000),
increase in V02max and enhanced fat oxidation (Sachan and Hongu 2000). The present
report addresses distribution of carnitine, acylcarnitine and acetylcarnitine among the
tissues of rats fed diets supplemented with CCC under sedentary or exercising regimen.
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MATERIALS AND METHODS
Animals and treatment

The study was conducted at the University of Tennessee and all animal procedures
were approved by the Institutional Animal Care and Use Committee, and were in
accordance with the NIH guidelines (National Research Council, 1 985). Twenty, 7-wk
old, male Sprague-Dawley rats (Harlan Sprague-Dawley, Indianapolis, IN), weighing
2 1 0-230 g, were individually housed in wire mesh cages in a room with controlled
temperature (20-22 ° C), relative humidity (50%), and light cycle (12-hr light/dark cycle)
for the entire 5 wk study period. The rats were randomly divided into two dietary groups
to receive either the nonsupplemented or supplemented diet with caffeine, carnitine and
choline at concentrations of 0. 1 , 5 and 1 1 .5 g/kg nonpurified diet, respectively. Food
intake and body weight were determined daily. Average food intake (Table 3-1 ) was
calculated by using the daily food intake throughout the 4 wk.
After 1 wk of dietary treatment, one-half of each dietary group (n = 5) were put to
exercise on the rodent treadmill (Columbus Instrument Internationals, Inc., Columbus,
OH) for 1 0 min at 1 5% grade, 6 cl/wk. The running speed and duration were increased
gradually during the experimental period (3 wk) to maximize at 1 8 m/min for 25 min/d.
Sample collection and assays

In all animals 24-h urine was collected after 3 wk of the dietary treatment by
placing rats in the stainless steel metabolic cages. For the exercised rats urine was
collected after completing the last bout of the 2-wk exercise period even though they were
kept on the exercise regimen for another week, i.e. 24-h prior to being killed. Urine
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samples were quantified, centrifuged, and an aliquot was stored at - 80 ° C for later
analysis. After 4 wk of dietary treatment and 3 wk of the exercise regimen, the rats were
anesthetized with methoxyflurane (Pitman-Moore, Mundelein, IL) and killed by
exsanguination after cardiocentesis. The blood samples were immediately centrifuged
and serum was stored at - 80 ° C (Hongu and Sachan 2000). The tissues were removed
and immediately frozen in liquid nitrogen and stored at - 80 ° C. Only the heart samples
were freeze-dried and stored at - 80 ° C. In the exercise groups, blood and tissue were
collected 24-hr after the last bout of exercise "(Sachan and Hongu 2000).
Camitine concentrations in tissues, serum and urine were determined by a
radioenzymatic assay originally described by Cederblad and Lindstedt (1 972) and
modified by Sachan et al. (1 984). All samples were fractionated in perchloric acid (PCA)
to allow determination of NEC, acid soluble camitine (ASC) and AIAC.
In brief, the deproteinization of samples with PCA separates the TC content into
an acid-soluble fraction and an acid-insoluble fraction, which are removed by
centrifugation (1 500 X g for 1 0 min). NEC and ASC remain in the soluble fraction,
while AIAC is precipitated with its protein. Following a PCA deproteinization, both the
supernatant (acid-soluble fraction) and the pellet (acid-insoluble fraction) are alkalinized
using potassium hydroxide (KOH) to release NEC from it's ester linkage. The samples
are incubated in a water bath for the hydrolysis at 37 ° C for 30 min or at 65 ° C for 60 min.
After PCA or KOH treatment, samples are neutralized prior to assay. The neutralized
samples are added to the reagent mix, which contains [ 1 - 1 4C] acetyl-CoA, unlabelled
acetyl-CoA, and other buffer solutions. The reaction is started by adding camitine acetyl
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transferease (CAT) (EC 2.3 . 1 .7). Camitine in a sample can incorporate the acetyl moiety
to [ 1 -1 4C] acetyl-CoA to form the [ l - 14C] acetyl-camitine. The unreacted, negatively
charged [ 1 -1 4C] acetyl-CoA is then separated by means of anion exchange resin (column).
Camitine esters carrying the positive charge of the quaternary ammonium are not retained
by the resin. The radioactivity of the solution due to the eluted [ l - 14C] acetylcamitine
from the anion exchange column is measured (Figure 6-2). This assay gives the fraction
values of NEC, ASC and AIAC. The ASAC fraction is calculated by subtracting NEC
from the ASC. TC refers to the sum of the NEC, ASAC and AIAC. AC in all samples
was determined according to the method of Pantle and Caramancion ( 198 1 ). Detailed
procedure of AC assay is described in Appendix A.
Tissue protein was determined using the Bio-Rad Coomassie dye binding assay
(Hercules, CA) with bovine serum albumin as the standard (Bradford, 1976). The
concentration of DNA in a liver sample was determined using bisbenzimide dye with a
calf thymus DNA standard (Sigma, St. Louis, MO). The DNA-dye complex was
measured at 425 nm by DyNAQuant 200 fluorometer (Pharmacia Biotech, Piscataway,
NJ ). The activities of serum AST and ALT were determined spectrophotometrically
using Sigma diagnostic kit no. 1 5 8 and 1 59, respectively (Sigma Diagnostics®, St. Louis,
MO).
Statistical analysis

All results are presented as group means ± SEM. Data were analyzed using two
way ANOVA to test the effects of exercise, supplementation and their int�raction using
SAS (SAS Institute, 1 998). The main effects of diet and exercise were tested using
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specific linear contrasts, as was the interaction. Statistical significance level was set at P
< 0.05.

RESULTS

The concentration of all carnitine fractions including the AC in serum and urine
were higher in the supplemented rats with or without exercise (Table 5-1 ). Significant
supplement and exercise interactions were observed in the serum TC, NEC and ASAC.
These camitine fractions were lower in the exercised, nonsupplemented rats but higher in
the serum of exercised, supplemented rats; however, the differences were not statistically
significant.
Supplement and exercise resulted in lower liver weight (Table 5-2). However, no
significant difference was found when liver weight was expressed as a percentage of the
body weight (data not shown). Therefore, the liver weight may be simply reflecting the
body weight, which was significantly affected only by exercise (Table 3-1 ). Total protein
in liver was not affected by either supplement or exercise. DNA concentration in liver
was significantly higher in the exercise group, and there was significant interaction
between supplement and exercise, but the supplement alone had no significant effect on
hepatic DNA concentration. Although no differences were observed in AST activities,
supplement and exercise resulted in significantly lower ALT activity (Table 5-2). The
concentrations of TC, NEC and AIAC in liver were markedly higher in the
supplemented rats (Table 5-2). There was no significant difference in the ASAC of the
groups, even though the ASAC was 53% higher in the supplemented, exercised rats
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TABLE 5-1

Serum and urinary carnitine profiles ofrats with or without supplement and exercise'-2

Nonsupplement

Supplement

Statistical significance3

Carnitine

Nonexercise

Exercise

Nonexercise

Exercise

Supplemen
t

Exercise

S x E4

Serum TC (µmol/L)

82. 1 ± 1 .6

66.5 ± 0.9

1 06.9 ± 0.9

1 1 7.6 ± 4.9

0.000 1

NS5

0.0003

Serum NEC (µmol/L)

64.8 ± 2.3

53.7 ± 1 .4

85.6 ± 2.0

95.0 ± 3 .5

0.000 1

NS

0.0007

Serum ASAC (µmol/L)

1 4.4 ± 1.7

1 0.2 ± 1.7

1 6. 1 ± 1 . 1

1 8.3 ± 1 .2

0.0035

NS

0.0380

Serum AIAC (µmol/L)

3.0 ± 0.2

2.4 ± 0.3

5.2 ± 0.3

4.3 ± 0.5

0.000 1

NS

NS

42.7 ± 1 . 1

34.3 ± 0.7

7 1 .9 ± 5.7

73.7 ± 4.7

0.000 1

NS

NS

Urine TC (µmol/d)

1.0 ± 0.3

0.9 ± 0. 1

1 00.4 ± 7.9

1 05.6 ± 8.7

0.000 1

NS

NS

Urine NEC (µmol/d)

0.6 ± 0.2

0.5 ± 0.0

85.2 ± 7.2

87.5 ± 9.2

0.000 1

NS

NS

Urine ASAC (µmol/L)

0.4 ± 0. 1

0.4 ± 0.0

1 3 .6 ± 3.2

1 6.4 ± 2.2

0.000 1

NS

NS

Urine AIAC (µmol/L)

0.02 ± 0.00

0.03 ± 0.0 1

1 .6 ± 0. 1

1 .7 ± 0. 1

0.000 1

NS

NS

0.7 ± 0. 1

0.6 ± 0.03

1 3.4 ± 1. 1

1 4.4 ± 1 .2

0.000 1

NS

NS

Serum AC (nmol/L)

Urine AC (µmol/L)
1

Values are means ± SEM, n = 5. Rats were fed diet without supplemented or supplemented with caffeine, carnitine
and choline at concentrations of 0. 1 , 5 and 1 1 .5 g/kg diet, respectively.
2
Abbreviation used: AC, acetylcamitine; AIAC, acid-insoluble acylcarnitine; ASAC, acid-soluble acylcamitine; NEC,
nonesterified carnitine; TC, total camitine. 3P values from two-way ANOVA, using the factors, supplementation and
exercise. 4 S X E; supplement and exercise interaction. 5NS: not significant, P > 0.05.

TABLE 5-2
Serum enzymes, liver weight, protein, DNA and carnitine profiles ofrats with or without supplement and exercise 1-2

Nonsupplement

Statistical significance3
Supplemen
t

Exercise

S x E4

Nonexercise

Exercise

Nonexercise

Exercise

Serum AST (U/L)

40.0 ± 4.7

31.9 ± 1.9

42.4 ± 8.6

29.0 ± 1.1

NS6

NS

NS

Serum ALT (U/L)

35.7 ± 1.5

26.8 ± 3.4

27.7 ± 2.0

22.0 ± 2.1

0.0158

0.0071

NS

Weight of liver (g5 )

13.6 ± 0.5

12.2 ± 0.1

12.5 ± 0.4

11.2 ± 0.4

0.0123

0.0030

NS

Liver protein (mg/g)

109.7 ± 8.8

145.6 ± 7.9

128.2 ± 8.4

126.9 ± 14.5

NS

NS

NS

Parameters

w

Supplement

Liver DNA (mg/g)

0.66 ± 0.02

0.99 ± 0.04

0.85 ± 0.06

0.84 ± 0.08

NS

0.0085

0.0051

Liver TC (nmol/g)

290.2 ± 16.3

316.7 ± 14.2

356.3 ± 30.4

452.2 ± 30.0

0.0006

0.0205

NS

Liver NEC (nmol/g)

256.0 ± 9.0

265.2 ± 15.4

309.2 ± 26.5

383.9 ± 21.0

0.0004

0.0431

NS

Liver ASAC (nmol/g)

28.0 ± 8.5

46.7 ± 12.5

39.3 ± 14.2

59.3 ± 8.1

NS

NS

NS

Liver AIAC (nmol/g)

6.2 ± 0.9

4.9 ± 0.7

7.9 ± 0.9

9.0 ± 1.1

0.0054

NS

NS

10.2 ± 2.4

21.4 ± 2.6

11.4 ± 1.6

25.6 ± 6.8

NS

0.0050

NS

Liver AC (nmol/g)

Values are means ± SEM, n = 5. Rats were fed diet without supplemented or supplemented with caffeine, carnitine and
choline at concentrations of 0.1, 5 and 11.5 g/kg diet, respectively.
2
Abbreviation used: AC, acetylcarnitine; AIAC, acid-insoluble acylcarnitine; ASAC, acid-soluble acylcarnitine;
AST, aspartate aminotransferase; ALT, alanine aminotransferase; NEC, nonesterified carnitine;TC, total carnitine.
3
P values from two-way ANOVA, using the factors, supplementation and exercise.
4
S X E; supplement and exercise interaction. 5 g: gram of wet weight of tissue. 6NS: not significant, P > 0.05.
1

compared to the nonsupplemented, nonexercised rats. AC in liver was higher in the
exercised rats with or without supplement. Both exercise groups had twice as much AC
concentration compared to their nonexercised counterparts.
Supplementation resulted in significantly higher concentration of TC, NEC and
ASAC in the skeletal and cardiac muscles (Table 5-3). In the skeletal muscle,
supplement and exercise interaction was significant for the ASAC and AIAC. Exercise
without supplementation produced slightly lower concentration of AIAC, but exercise
with supplementation had the opposite effect. In the· cardiac muscle, supplement caused
significantly higher concentrations of TC, NEC and ASAC but there was no significant
supplement and exercise interaction. The AIAC in cardiac muscle of the exercised rats
increased 48-84% compared to their nonexercised counterparts; however, these were
statistically not significant. In contrast to skeletal muscle, the AC in cardiac muscle was
significantly higher in the exercise groups particularly in the supplemented groups, where
it was almost doubled. The decrease in the ASAC in the cardiac muscle of exercised rats
without supplement was proportional to the increase in the AC, which amounted to more
than 90 % of the entire ASAC.
Supplement resulted in significantly higher concentration of TC and NEC in the
testes, brain (Table 5-4) and kidney (Table 5-5), and AC in the testes (Table 5-4) and
kidney (Table 5-5). There were no significant differences in ASAC and AIAC of the
testes, brain or kidney (Table 5-4 & Table 5-5).
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TABLE 5-3

Skeletal and cardiac muscle carnitine profiles ofrats with or without supplement and exercise 1-2

Carnitine (nmol/g of
wet wt. (Skeletal) or
nmol/g of freezedried wt. (Cardiac)

t,.,,..A

Nonsupplement
Nonexercise

Exercise

Statistical significance3

Supplement
Nonexercise

Exercise

Supplement

Exercise

S x E4

Skeletal m. TC

1024.8 ± 35.4

965.8 ± 59.6

1269.6 ± 26.2

1282.0 ± 56.5

0.0001

NS5

NS

Skeletal m. NEC

576.4 ± 32.2

541.8 ± 33.7

636.8 ± 31.4

727.0 ± 49.8

0.0001

NS

NS

Skeletal m. ASAC

270.0 ± 29.8

295.4 ± 24.5

533.0 ± 30.6

419.2 ± 24.0

0.0001

NS

0.0218

Skeletal m. AIAC

164.4 ± 16.5

138.0 ± 6.3

109.8 ± 8.7

147.8 ± 5.6

NS

NS

0.0165

Skeletal m. AC

244.7 ± 14.9

204.4 ± 19.9

275.6 ± 15.6

254.3 ± 22.1

NS

NS

NS

Cardiac m. TC

1725.6 ± 128

1465.9 ± 100

2101.5 ± 28.9

2573.1 ± 172

0.0001

NS

0.0075

Cardiac m. NEC

1236.2 ± 73.2

1113.8 ± 68.4

1590.4 ± 21.6

1930.0 ± 168

0.0001

NS

0.0318

Cardiac m. ASAC

453.8 ± 70.9

286.6 ± 59.1

475.5 ± 45.3

578.5 ± 48.0

0.0200

NS

0.0350

Cardiac m. AIAC

35.6 ± 8.1

65.5 ± 11.0

43.3 ± 8.2

64.6 ± 12.9

NS

NS

NS

Cardiac m. AC

216.6 ± 50.1

265.3 ± 52.3

207.8 ± 25.5

399.1 ± 63.2

NS

0.0245

NS

Values are means ± SEM, n = 5. Rats were fed diet without supplemented or supplemented with caffeine, carnitine and
choline at concentrations of 0.1, 5 and 11.5 g/kg diet, respectively.
2
Abbreviation used: AC, acetylcarnitine; AIAC, acid-insoluble acylcarnitine; ASAC, acid-soluble acylcarnitine; m., muscle;
NEC, nonesterified carnitine; TC, total carnitine.
3
P values from two-way ANOVA, using the factors, supplementation and exercise.
4
S X E; supplement and exercise interaction. 5 NS: not significant, P > 0.05.
1

TABLE S-4
Testes and brain carnitine e.ro'!J.les ofrats with or without SU[![!_lement and exercise

Nonsupplement

Statistical significance3

Exercise

Nonexercise

Exercise

Supplement

Exercise

S x E4

1 85.5 ± 4.2

1 84.7 ± 6.9

204.9 ± 1 4.7

23 5.8 ± 6.6

0.00 1 2

NS5

NS

1 37.5 ± 4. 1

1 34.9 ± 2.5

1 58.8 ± 1 2.3

1 8 8.7 ± 7.0

0.0001

NS

0.0442

Testes ASAC

45.4 ± 2.7

47.5 ± 7.7

43.9 ± 4.8

43 .7 ± 5.7

NS

NS

NS

Testes AIAC

2.6 ± 0.6

2.2 ± 0.7

2.2 ± 0.4

3 .4 ± 0.3

NS

NS

NS

32.7 ± 1 . 1

30.0 ± 2.0

47.2 ± 3.4

46.3 ± 1 .7

0.000 1

NS

NS

1 1 0.5 ± 6. 1

1 03.4 ± 2.6

1 60.5 ± 3.5

1 65.8 ± 9.7

0.000 1

NS

NS

Bram NEC

88.0 ± 4.8

79. 1 ± 2.2

1 3 5.9 ± 1 .0

1 4 1 .8 ± 9.5

. 0.000 1

NS

NS

Brain ASAC

1 6.7 ± 4.6

1 7.6 ± 5.2

1 8. 1 ± 2.4

1 5.9 ± 3 . 1

NS

NS

NS

Brain AIAC

5 . 8 ± 1 .3

6.7 ± 0.9

6.5 ± 0.6

8 . 1 ± 0.8

NS

NS

NS

1 4.9 ± 2.2

1 7. 8 ± 3.0

1 7.7 ± 2. 1

1 9.8 ± 1 .6

NS

NS

NS

Carnitine
(nmol/g wet weight)

Nonexercise

Testes TC
Testes NEC

Testes AC
_. Brain TC

°'

. Supplement

1-2

.

Brain AC
1

Values are means ± SEM, n = 5. Rats were fed diet without supplemented or supplemented with caffeine, carnitine and
choline at concentrations of 0. 1 , 5 and 1 1 .5 g/kg diet, respectively.
2
Abbreviation used: AC, acetylcarnitine; AIAC, acid-insoluble acylcarnitine; ASAC, acid-soluble acylcarnitine;
NEC, nonesterified carnitine; TC, total carnitine.
3
P values from two-way ANOVA, using the factors, supplementation and exercise.
4
S X E; supplement and exercise interaction.
5
NS: not significant, P > 0.05.

TABLE 5-5
Kidney carnitine profiles ofrats with or without supplement and exercise 1-2

Nonsupplement

......

Supplement

Statistical significance3

Carnitine
(nmol/g wet
weight)

Nonexercise

Exercise

Nonexercise

Exercise

Supplemen
t

Kidney TC

874.1 ± 52.1

873.1 ± 36.9

1307.1 ± 62.4

1607.0 ± 19.8

Kidney NEC

743.8 ± 48.2

732.8 ± 32.3

1172.1 ± 47.6

Kidney ASAC

119.1 ± 13.4

130.0 ± 8.5

Kidney AIAC

11.2 ± 1.4

Kidney AC

90.7 ± 2.3

1

Exercise

S x E4

0.0001

0.0036

0.0034

1454.2 ± 26.8

0.0001

0.0071

0.0041

126.5 ± 22.8

139.8 ± 17.8

NS5

NS

NS

10.2 ± 1.7

8.5 ± 0.8

13.0 ± 1.7

NS

NS

NS

88.3 ± 6.2

122.2 ± 2.3

126.1 ± 3.9

0.0001

NS

NS

Values are means ± SEM, n = 5. Rats were fed diet without supplemented or supplemented with caffeine, carnitine
and choline at concentrations of 0.1, 5 and 11.5 g/kg diet, respectively.
2
Abbreviation used: AC, acetylcarnitine; AIAC, acid-insoluble acylcarnitine; ASAC, acid-soluble acylcarnitine;
NEC, nonesterified carnitine; TC, total carnitine.
3
P values from two-way ANOVA, using the factors, supplementation and exercise.
4
S X E; supplement and exercise interaction.
5
· NS: not significant, P > 0.05.

DISCUSSION
In our earlier reports it was shown that a combination of choline, camitine and
caffeine (CCC) supplementation produced camitine conservation and fat oxidation in
intact rats (Hongu and Sachan 2000, Sachan and Hongu 2000). We now report that the
CCC supplementation produced positive camitine balance in all tissues examined (Table
5-3 - Table 5-5) and the dosages did not have a toxic effect (Table 5-2). Further, the
supplementation increased tissue content of short-chain and/or AC, which are considered
to be the biochemical markers of fatty acid mobilization and oxidation (Bremer 1 997).
It is important to recognize that unlike any other study reported in the literature
outside of our laboratory exogenous CCC were fed in the diet simultaneously. Most of
the camitine was concentrated in skeletal muscle of these rats very much like that
reported by other investigators, suggesting normal transport and redistribution of the
supplemented camitine (Rebouche 1 977, Paulson et al. 1 984 ). The difference we found
was that the concentrations of camitine were consistently higher in muscles of the
supplemented rats {Table 5-3). The muscle camitine pool exists in free and acylated
forms through a rather complex equilibrium with the camitine pools of serum, liver,
kidney and other tissues. It has been suggested that camitine fractions of the body
compartment change in size, because of the increased esterification of the muscle-free
camitine (Lennon et al. 1 983). The muscle and other tissue camitine pools remained at a
high state of repletion (Table 5-2- Table 5-5) in the supplemented rats in spite of the
significant losses in the urine (Table 5- 1 ) of these rats. The size of acylcamitine pools
within the muscle tissue must depend on its metabolic activity and supply of fatty acids to
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this tissue. The supplemented rats put on exercise regimen showed significant interactive
effect on size of the acylcarnitine (ASAC, AIAC) pool under the conditions of our study
(Table 5-3). The presence of caffeine in the supplement promoted lipolysis and therefore,
supply of fatty acids.
The AC pool was increased in serum, urine and kidney of the supplemented
animals and in the liver and heart of the exercised animals (Table 5- 1 - Table 5-3 & Table
5-5). The sources of acetyl moiety can be pyruvate and/or fatty acids depending on the
fed or unfed state (Harris et al. 1 987, Bremer 1 997, Sachan and Hongu 2000). As the rate
of acetyl-CoA production exceeds the rate of its utilization, the camitine acetyl
transferase facilitates transfer of acetyl moiety of acetyl-CoA to carnitine (Bieber et al.
1 982, Harris et al. 1 987). This process can be augmented by enhanced lipolysis induced
by hormones or chemicals, supply of carnitine, and energy demands of animals. These
conditions were present in our supplemented, exercised rats. It is apparent that the
supplement also promotes formation of ASAC and AIAC in tissue specific manner.
These metabolites appear in serum and are excreted in urine, a process termed "fatty acid
dumping" (Sachan and Hongu 2000). None of these rats were starved, and only a half of
them were exercised and yet there was an increase in the pool size of acylcarnitine in all
rats. These observations suggest that there are undefined points of control of fat
metabolism that can be manipulated by dietary means.
The supplement enlarged pools of total and acylcarnitine in liver similar to that
seen in livers of trained female rats (Lennon and Mance 1 986) and Streptozotocin
diabetic rats (Fogle and Bieber 1 979). Exercise also enlarged carnitine pools particularly
1 49

the AC pools of liver (Table 5-2). An increased cardiac TC pool of exercised rats has
been reported (Ciman et al. 1 980, Lennon and Mance 1 986), however; in the heart of our
rats, this was not the case unless they were supplemented with CCC (Table 5-3). This is
perhaps because of the differences in the type and intensity of exercise regimen (Lennon
and Mance 1 986) or the strain of animals (Ciman et al. 1 979). The supplement prevented
a fall in the size of cardiac NEC pool, in spite of the enlargement of acylcarnitine (ASAC)
pool (Table 5-3) which is contrary to the fall in NEC pool observed in starved and
diabetic rat hearts (Fogle and Bieber 1 979, Bremer 1997). The enlargement of cardiac
AC pool by exercise especially in the supplemented rats suggests up-regulation of fatty
acid oxidation in this tissue. This and possible modulating of camitine carrier proteins of
cardiac myocytes (Cantrell and Borum 1 982) by the supplement remains to be
investigated. In any case the supplement may be of benefit to ischemic and aged hearts,
where reduced camitine concentrations have been observed (Shug et al. 1 978, Costell and
Grisolia 1 993).
Camitine is important for reproductive system in males, where it has been shown
that oral carnitine supplementation improved total number of spermatozoa per ejaculate
and sperm motility in men (Costa et al. 1 994, Vitali et al. 1 995). The supplement
significantly enlarged the TC, NEC and AC pools in the testes (without epididymus) of
the supplemented rats, but the exercise had no effect on testicular carnitine fraction
(Table 5-4). The improved reproductive functions in the CCC supplemented males is
entirely speculative at this time.
The role of carnitine in brain function has been vigorously investigated because
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carnitine is found in the brain (Bresolin et al. 1 982, Shug et al. 1 982); it crosses blood. brain barrier (Mroczkowska et al. 1 996, Mroczkowska et al. 2000); and it has a novel
camitine transport protein in cerebral cortex neurons (Wawrzenczyk et al. 200 1). There
is some evidence that carnitine may play different roles in the central nervous system,
where the fatty acid oxidation is relatively lower than in the peripheral tissues (Warshaw
and Terry, 1 976). Clinical studies have shown that carnitine and AC are effective in
slowing down the progression of mental deterioration in Alzheimer's disease (Forloni et
al. 1 994 ). The mechanisms of the therapeutic properties are unknown, except the
postulate that it provides activated acetyl moiety for the synthesis of acetylcholine
(Rebouche 1 992, Nalecz and Nalecz 1 996). Addition of carnitine and choline together
has been shown to promote acetylcholine synthesis in rat cerebral cortex cells
(Wawrzenczyk et al. 1 995). The supplement augmented only brain TC and NEC pools in
our study, where acylcarnitines were essentially unchanged (Table 5-4). Relative
concentrations of ASAC plus AIAC in all groups were about 1 5-20 % of TC, which is in
accord with 1 0% reported in the supplemented animals (Wawrzenczyk et al. 1 995).
Kidney participates in the biosynthesis, acylation and excretion of carnitine
(Carter and Frenkel 1 979, Guder and Wagner, 1 990). The CCC supplement enlarged the
pool of NEC and AC (Table 5-5) similar to the streptozotocin-diabetic rats kidney (Fogle
and Bieber 1 979). Kidney TC and NEC pools were also enlarged not only by the
supplement, but also by the exercise regimen. There was also significant supplement and
exercise interaction on these carnitine species. Such an effect on kidney is not produced
by choline alone in rats (Rein et al. 1 997) or guinea pigs (Daily et al. 1 998). As a matter
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of fact, choline supplementation decreased carnitine concentration in the kidneys and
urine of rats and guinea pigs (Daily and Sachan 1 995, Daily et al. 1998, Rein et al. 1 997),
and urine of humans (Daily and Sachan 1 995, Dodson and Sachan 1 996). It is unlikely
that the 5 fold higher dosage of choline (Table 3-1) in the present study compared to the
earlier reports (Daily and Sachan, 1 995, Daily et al. 1 998, Rein et al. 1 997) would have
caused this shift. Perhaps the caffeine of the supplement mixture may contribute to the
change in the carnitine profile of kidney. There is no carnitine data on caffeine
supplemented animals, however there are a few reports of a close relative of caffeine,
theophylline, being studied (Al-Jafari et al. 1 996, Alhomida 1 998). In these studies, there
was a significant increase in NEC, ASAC, AIAC and TC in the kidney (Alhomida 1 998),
and in the heart and skeletal muscle (Al-Jafari et al. 1 996) of the adult male rats given
theophylline. There is little explanation of the data except that it indicates enhanced
transport and oxidation of fatty acids, however no clear mechanism has been proposed.
Of course, there can be other functions of carnitine in tissues, such as protection against
lipid peroxidation (Dayanandan et al. 200 1 ) and the like.
In conclusion, we found that oral supplementation of carnitine, choline and
caffeine did not influence dietary intake and produced normal growth of rats, but
decreased the fat pad weight. The combination of supplementation increased the total
carnitine concentrations in all tissues, serum and urine.
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CHAPTER VI
EFFECTS OF CARNITINE-CHOLINE SUPPLEMENTATION ON CARNITINE
PROFILES AND INDICES OF FAT METABOLISM IN HEALTHY ADULTS

Some parts of this Chapter has been prepared for manuscripts for publication with co
author Dileep S. Sachan in the American Journal of Clinical Nutrition and Journal of the
American College of Nutrition.

ABSTRACT

We have previously shown that dietary choline supplementation promotes
camitine conservation in humans by decreasing daily urinary camitine excretion.
However, there were no consistent changes in the serum camitine concentration and there
was no determination of functional consequence of choline-induced camitine
conservation. Studies in the animal models showed choline-camitine interactions similar
to those seen in humans and allowed the determination of tissue accretion and functional
significance such as altered body composition and fatty acid oxidation. The aim of this
study was to determine the effects of choline or camitine pre-loading, followed by a
combination of the two and exercise on serum and urinary camitine fractions, lipid
profiles, body weight, percentage body fat (%BF) and indices of fatty acid oxidation in
healthy humans. Twenty-three healthy adults, 5 men and 1 8 women, were given placebo
or choline or camitine for 1 wk; and placebo or choline plus camitine for an additional
wk. Body weight, dietary analysis, serum lipids, camitines, ketones, leptin, and urinary
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carnitine were determined before and after each treatment. While there was no change in
the placebo group, serum and urinary carnitine and acylcarnitine were decreased in the
choline supplemented group. Introduction of carnitine to the choline group improved the
serum carnitine profile, but the daily urinary carnitine excretion continued to fall. On the
contrary, serum and urinary carnitine and acylcarnitine increased in the carnitine
supplemented group and introduction of choline to the camitine group decreased serum
carnitine, but the urinary camiti�e excretion remained high. The concentrations of _serum
P-hydroxybutyrate and serum and urinary acetylcarnitine were elevated by the
supplements and accentuated, particularly by the introduction of camitine. The
supplements reduced the concentrations of serum leptin which was correlated with the
body weight, body mass index (BMI; in kg/m2 ), percentage body fat (%BF) and serum
triglyceride. A mild exercise regimen further increased concentration of serum P
hydroxybutyrate and serum and urinary acetylcarnitines, and decreased leptin levels
across the groups. It is concluded that a choline-induced decrease in serum and urinary
carnitine is buffered by carnitine pre-loading. The combination of carnitine and choline
supplementation promotes fat mobilization, oxidation and disposal of acetylcamitine in
urine and this effect of the supplements is accentuated by a mild exercise regimen as well
as sustained until 2 wk following cessation of supplement and exercise interventions.

INTRODUCTION
In our earlier discourse, we have introduced essentiality of carnitine for fatty acid
translocation (Bremer 1 997), muscle function (Brass and Hiatt 1 994) and exercise
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performance (Decombaz et al. 1992, Lennon et al. 1983, Neumann 1996). We have
talked about choline being a lipotropic agent (Best et al. 1935, Leiber et al. 1994),
promoter of synthesis and release of acetylcholine (Zeisel and Blusztajn 1994,
Buyukuysal et al. 1995) and need for supplementation in athletes running a marathon
(Conlay et al. 1992). We also addressed usage of caffeine as a general stimulant, fatty
acids mobilizer from adipose tissues (Bellet et al. 1968, Costill et al. 1978, Denadai 1994)
and booster of endurance exercise (Nehlig and Debry 1994).
Recently, we have reported interactive effects of choline and camitine in normal
healthy humans and animals. Choline supplementation resulted in significant
conservation of camitine in humans and guinea pigs (Daily and Sachan 1995, Dodson and
Sachan 1996); however, this effect of choline was not seen in the adult rats given choline
dosage similar to that of humans and guinea pigs (Daily and Sachan 1995, Rein et al.
1997). When rats were given relatively higher doses of choline in combination with
caffeine plus carnitine for 4 wk, there was significant conservation of camitine (Sachan
and Hongu, 2000, Hongu and Sachan 2002). The functional consequences of choline
mediated camitine accretion in tissues have been studied in animal models. Choline
supplementation alone resulted in a significant increase in camitine concentration in
skeletal muscle of guinea pigs (Daily and Sachan 1995) and loss of carcass fat (Daily et
al. 1998). In rats, choline plus camitine along with caffeine supplementation resulted in
significant reduction in fat pad mass, serum leptin concentration (Hongu and Sachan
2000), and other biochemical markers indicative of enhanced fatty acid oxidation to
acetate (Sachan and Hongu 2000). While exercise endurance was increased in both
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guinea pigs and rats by the respective supplements, the RQ was not significantly affected
to support fat being energy substrate; for which a novel explanation has been postulated
(Sachan and Hongu 2000).
In light of these observations, it was logical to ask if humans respond in a manner
akin to animal models when their diets are supplemented with choline and camitine with
or without caffeine. As early as 1 988, Sachan and his associates (Mynatt et al. 1 988,
Dodson and Sachan 1 992) reported effects of choline plus pantothenic acid on reduced
urinary camitine excretion in humans which was later documented to be due to choline
and not pantothenic acid supplementation. These observations went unappreciated
resulting in the delay of the full length publication in 1 996, wherein it was clearly
demonstrated that choline reduced carnitine excretion in urine without significantly
affecting serum camitine concentrations in all subjects (Dodson and Sachan, 1 996). This
was especially significant because the subjects were international, multiethnic, free-living
who are eating their traditional foods. In one of the studies described in the paper
(Dodson and Sachan, 1 996), subjects were given a supplement of choline for the first 7 d
followed by addition of camitine for 3 d to see if the urinary camitine excretions would
be restored to normal. The urinary camitine concentrations were restored, but only to
about 40% of the control values. This suggested that there was deficit of camitine due to
choline, and perhaps a longer duration of camitine supplementation was needed to fully
replete the system. This is all the literature on the choline-camitine interactions in
humans and many questions remain to be addressed. Therefore, the main objective of
this segment of our studies was to determine effects of choline and camitine
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supplementation with and without exercise on carnitine status, body weight, body fat,
lipid profiles and biochemical markers of fat oxidation in free-living men and women.

Subjects

SUBJECTS AND METHODS

The participants were 5 men and 1 8 women who met the inclusion criteria of the
study protocol approved by the Institutional Review Board for the Protection of Human
Subjects in Research. Most of the participants were from the faculty and student
population of the University of Tennessee, Knoxville, only 4 subjects from the
community of Knoxville, TN. They had a mean (± SEM) age of 28.7 ± 2.2 y (range 1 8 to
54 y), body weight of 72.4 ± 3.6 kg (range 47.5 to 1 09.3 kg), BMI (kg/m2 ) of 25 .7 ± 1 .0,
%BF of 25.7 ± 1 .6 %, and waist to hip ratio (WHR) of 0.79 ± 0.02 {Table 6- 1). All of
the participants were apparently healthy individuals according to the criteria of the
American College of Sports Medicine (2000).
Expected participants were verbally screened to ensure that they were willing to
maintain their extra-physical activity during the exercise intervention period. They met
the following inclusion criteria: 1 ) no clinical diagnosis of cancer, cardiovascular,
gastrointestinal, hepatic, renal disease, hypertension or diabetes; 2) no current use of
antibiotic, prescription medication; 3) no use of vitamin or mineral supplements within 2
wk of the start of the experimental periods; 4) no specific dietary practice for weight loss,
such as low fat diet or reduced calorie intakes within the past year. Further, women were
specifically excluded from the study if they were pregnant, lactating, or using exogenous
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TABLE 6-1

Anthropometric measurements ofparticipants in three groups 1-2

Variables

Day

Age (y)
Height (cm)

Supplement 1
=
(n 8) _

Supplement 2
{t1 ==_ 8)

28. 1 ± 5.0

29.3 ± 3.5

28.8 ± 3 .6

NS 5

NS

NS

1 63 .9 ± 3 .2

1 66.0 ± 3 .2

1 70.7 ± 2.9

NS

NS

NS

Weight (kg)

0-d
2 1 -d
3 5-d

69. 1 ± 6.4
69.5 ± 5 .7
68.4 ± 6.0

72.3 ± 6.8
72.2 ± 6.5
7 1 . 1 ± 6.6

76.8 ± 6.6
76.3 ± 6.7
75.8 ± 6.8

NS

0.0 1 76

NS

BMI (kg/m2)

0-d
2 1 -d
3 5-d

25.4 ± 1 .5
25.4 ± 1 .4
25.3 ± 1 .4

25.5 ± 1 .6
25.3 ± 1 .8
25.0 ± 1 .8

26.3 ± 2. 1
26. 1 ± 2. 1
26.7 ± 2. 1

NS

NS

NS

Sum skinfold
(mm)

0-d
2 1 -d
3 5-d

1 00.6 ± 1 0.9
1 01 . 1 ± 1 2.9
1 04.4 ± 14.3

1 09.6 ± 1 0.6
1 06.5 ± 1 0.8
1 05.4 ± 1 0.8

1 05.2 ± 1 4.7
1 00.4 ± 1 4.9
1 0 1 .3 ± 1 4.8

NS

NS

NS

00

1

Statistical Significance3
Grou_E
Time
G x T4

Placebo
(n = 7)

Values are expressed as mean ±SEM. 2Abbreviation used: BIA, bioelectrical impedance analysis; BMI, body mass index;
WHR, waist to hip ratio. 3P values from 2-way ANOVA, using the factors group and time. 4G x T, group and time
interaction. 5NS, no significant differences, P > 0.05.

TABLE 6-1

Anthropometric measurements ofparticipants in three groups'-2 (Continued)

Variables

Day

Placebo
(n = 7)

Supplement 1
(n = 8)

Supplement 2
(n = 8 )

Statistical Significance3
G x T4
Time
Group

% body fat
(Skinfold)

0-d
2 1 -d
35-d

26.9 ± 2.5
27.0 ± 2.6
27.2 ± 2.9

26.0 ± 1 .9
25.5 ± 1 . 8
25.0 ± 1 .8

23.3 ± 3.8
22. 1 ± 3 .9
22.6 ± 3.7

NS5

NS

NS

% body fat
(BIA)

2 1 -d
35-d

27.8 ± 1 .7
27.6 ± 1 .6

25.4 ± 1 .7
25.8 ± 1 .9

23 .3 ± 3.9
23.5 ± 3.8

NS

NS

NS

Waist (cm)

0-d
2 1 -d

80.4 ± 4.8
79.7 ± 4.9

83 .5 ± 7.7
83 .5 ± 7.6

83.5 ± 5 . 1
83 .4 ± 5. 1

NS

NS

NS

WHR

0-d
2 1 -d

0.77 ± 0.03
0.77 ± 0.03

0.79 ± 0.04
0.79 ± 0.04

0.80 ± 0.03
0.80 ± 0.03

NS

NS

NS

\0

Values are expressed as mean ±SEM. 2 Abbreviation used: BIA, bioelectrical impedance analysis; BMI, body mass index;
WHR, waist to hip ratio. 3P values from 2-way ANOVA, using the factors group and time. 40 x T, group and time
interaction. 5NS, no significant differences, P > 0.05.
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hormones. Subjects who met eligibility requirements participated in an orientation
meeting. Each subject was informed about the nature and the purpose of the study and
was required to provide written informed consent to participate in the study.
Study design
The randomized placebo-control study with 3 groups lasted a period of 3 5 d
during which interventions were carried out as shown in Figure 6-1 . At baseline,
habitual dietary intake was assessed an? anthropometric measures were taken. Fasting
venous blood and 24-hr urine samples from 2 consecutive days were collected before the
intervention. All participants were specifically instructed to follow their usual dietary and
life-style patterns, including exercise, work and recreation; but not to indulge in sexual
intercourse a day before or during the 24 h urine collection. They were also asked not to
introduce unusual foods to their diets or any nutrient supplements for the duration of the
experiment. Following the baseline period, participants were randomly assigned to the
placebo (n = 7) or supplement groups. Supplement groups were randomly divided into
two subgroups; supplement 1 (S 1 ) and supplement 2 (S2). The S 1 group (n = 8) received
only choline supplementation for the 1 st wk followed by addition of camitine supplement
in the 2"d through 3 rd wk. The S2 group (n = 8) received only camitine supplement for the
1 st wk followed by addition of choline in the 2nd through 3 rd wk. Neither group received
any supplement in 4th and 5 th wk (wash out period). Choline was supplied as choline
bitartrate (Pharmachem Laboratories, South Hackensack, NJ) and administered at the
dosage of 7.8 mmol (0.94 g) choline/d. Camitine was L-camitine L-tartrate (Lonza,
Switzerland) supplied by Daily Manufacturing, Inc. (Rockwell, NC) and administered at
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Study Design
Baseline/pre-treatment

Placebo

t Placebo

•

•

Placebo

•

Choline +

Sl
S2

Choline,
Carnitine
Camitine ,
Choline

Choline
Carnitine
Supplement Supplement

•
1

•

l Camitine
Supplement

•

0-day

•

7-day

•

Placebo +
Exercise

Choline+
Carnitine+
Exercise

•

No treatment

Choline+
Carnitine+
Exercise

•

No treatment

Carnitine +
Choline
Supplement

•

•

No treatment

14-day

21-day

w-up
I

Follow-up

•l

Follow-up
�

3 5-day

-••
• : Blood and 24-hr urine collection

FIGURE 6-1 Schematic presentation ofstudy design showing dietary and exercise
intervention time periods. S 1: supplement group 1, S2: Supplement group 2.

the dosage of 4.2 mmol (0.68 g) carnitine/d (Dodson and Sachan 1996). Both
supplements were taken with daily meals. The supplements are US Pharmacopeic (USP)
grade and have purity �98.6%. Each supplement was dissolved in distilled water and 1
wk supply dispensed in amber-colored bottles with a coded label and dosing instruction.
The placebo bottle contained citric acid (0.2 mmol, 1 g/d) in equivalent dosage. All
participants were given daily-supplement sheets and asked to record timing of taking the
contents of given bottles and return the sheets and empty bottles on the following visit.
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The coordinator of the program reviewed the sheet and bottles at weekly visits to the
clinical study facility. From d 7 until d 2 1 , both choline and carnitine were taken by both
S 1 and S2 groups, so the difference was pre-loading with choline or carnitine in the first
wk of the trial.
At the 3 rd week of the d 1 4 to d 2 1 period, all groups were instructed to perform
light to moderate exercise training to increase their daily energy expenditure
approximately 1 00 to 300 kcal/wk above the pre-exercise intervention period regardless
of dietary supplementation. All participants were given an exercise log sheet and an
electronic pedometer (Yamax Inc., Japan) to record their daily steps, distance and calorie
output. The last 2 wk were the follow-up or washout period in which they were asked to
go back to their normal activity level and not to take the placebo or supplement.
Physical activity intervention

The physical activity intervention consisted of light to moderate exercise as
recommended by American College of Sports Medicine for cardiorespiratory fitness in
healthy adults (Pollock et al. 1 998). All participants were asked to have � 20 min of
aerobic activity such as walking, jogging, stair-climbing, 3-5 d/wk over and above their
normal activity, which may equal to an extra 300-500 kcal energy output per wk. In the
2nd wk of this study, before starting exercise intervention, all subjects were instructed how
to record their baseline physical activity by using an electronic pedometer, the Yamax
Digi-Walker SW-70 1 (Yamax Inc., Japan) for 5-7 d. They recorded daily estimated
calorie output (based on their body weight), walking distance (estimated from their
strides) and walking steps, including non-exercise related physical activities, such as
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occupational and household activities. All participants were asked to wear a pedometer
all the time during the 3 wk to keep track for their daily physical activity. There was no
rd

attempt made to monitor exercise intensity.
Assessment of body composition

The assessments of body composition were made after an overnight fast on d 1, 2 1
and 35. Body weight was measured at each visit with a Physician Mechanical scale.
Barefoot standing height was measured to the nearest 0. 1 cm with a vertical height scale.
BMI was calculated by dividing weight in kg by height in meters squared.
Skinfold thicknesses were measured 3 times to the nearest 0. 1 mm with a Lange
skinfold caliper (Cambridge Scientific Industries, Inc., Cambridge Maryland ) on the one
side of the body at the triceps, subscapular, suprailiac, thigh, abdomen in both men and
women, and chest in only male subjects. These sites are described in the Health Fitness:
Instructor's Handbook (Bubb 1992). The skinfold thickness values from all these sites
were added up and termed the "sum of skinfold thickness".
Percentage BF was estimated using the mean of 3 times reading of triceps,
abdomen and suprailiac measurements for women, and triceps, chest and subscapular for
men, as described by Jackson and Pollock (1985). Percentage BF was also estimated by
bioelectrical impedance analysis (BIA) only on d 21 and 35. Bioelectrical impedance was
measured using a BIA-RJL system analyzer (RJL-systems, Detroit) with a 50 kHz, 800
µA device. Two signaling electrodes were placed on the dorsal surface of the right foot at
the space between the metatarsal-phalangeal joints of the great and second toes, as well as
on the dorsal right hand at the space between the metacarpal-phalangeal joints of the
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index and middle fingers. The 2 detecting electrodes were placed between the styloid
processes of the right radius and ulna and between the medial and lateral malleoli of the
right ankle (Heitmann 1 990). During the measurement, subjects remained still in a
supine position with their hands and feet slightly abducted from the midline to ensure that
no contact was made between the extremities and the torso. Percentage BF was
calculated by using an equation of Segal et al. (1 988). Equation: BF = a BW
Ht2/resistance- b Ht + c Age + 1 4.94 1 , where fractions varies by gender.
Waist circumference was measured, with a measuring tape, midway between the
inferior angle of the ribs and the suprailiac crest, whereas hip circumference was
measured at the outermost points of the greater trochanters (WHO 1 995). The waist-to
hip ratio (WHR) was then calculated. All the anthropometric measurements described
above were performed by the same trained investigator throughout the study.
Dietary assessment

All subjects were interviewed and completed a questionnaire about the type of
diet consumed, the length of time they had been following the diet, reasons motivating
their choice of diet, nutritional supplement use, smoking habits, oral contraceptive use
and whether they had received dietary advice. Dietary intake was assessed at baseline and
every wk of the intervention by 3-d dietary records. Each of the five 3-d periods
consisted of the 1 weekend day and 2 weekdays to control for day-of-the-week effects.
At the baseline period each participant was given food record sheets and instructed, by a
registered dietitian, how to keep dietary intake. Subjects were asked to record the exact
description of all food and drink consumed during each of the 3-d period. Food portion
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sizes were estimated by using standard household measures. All completed dietary
records were reviewed by the dietitian, and were discussed with the subject, if necessary,
to resolve any ambiguities regarding accuracy or completeness. Food records were
coded, entered, and analyzed using the Nutritionist IV program (version 4.1, 1997, First
Data Bank, San Bruno, Calif).
Blood collection and analysis

Venous blood samples (13 ml) were collected following overnight fasting (8-12
hr) at the beginning of baseline (0 day) and at each visit (Figure 6-1). Whole blood was
collected in vacutainer tubes without anticoagulants and kept on ice. After clotting,
serum was separated by centrifugation at 1500 X g for 10 min at 4 ° C and stored at - 80 ° C
until used for determination of cholesterol, triglycerides, free fatty acids,

P

hydroxybutyrate, leptin and camitine concentrations.
Total serum cholesterol was determined by a enzymatic procedure using the
Sigma kit no.352 (Sigma, St. Louise, MO). Briefly, cholesterol esters are first hydrolyzed
by cholesterol esterase (EC 3.1.1.13) to cholesterol, which is then oxidized by cholesterol
oxidase (EC 1.1.3.6) and the resulting hydrogen peroxide. The produced hydrogen
peroxide is then coupled with the 4-aminoantipyrine and hydroxybenzenesulfonate in the
presence of peroxidase (EC 1.11.1.7) to yield a quinoneimine dye which has an
absorbance at 500 run. The intensity of the color produced is proportional to the total
cholesterol concentration in the sample. This is a modification of the method of Allain et
al. (1974).
Serum high density lipoprotein (HDL) was determined by the same enzymatic
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method (Sigma kit no.352, Sigma, St. Louise, MO). First, VLDL and LDL (low density
lipoprotein) cholesterol were precipitated, leaving the HDL fraction in solution by using
phosphotungstic acid and magnesium chloride (Assmann et al. 1 983). The LDL
concentration was calculated using the following equation (Friedewald et al. 1 972):
LDL (mg/dL) = total cholesterol - HDL - [triglycerides/5]
This equation loses accuracy when the serum triglyceride concentration exceeds 400
mg/dL. However, in this study, there was no individual, whose TG was over 400 mg/di.
Serum triglycerides and nonesterified fatty acids were determined by the methods of
Giegel et al. ( 1 975) and Novak (1 965) respectively.
Serum leptin concentration was deter,mined using a commercial
radioimmunoassay kit (Linea Research, St. Louis, MO). The assay use

1 25

1-labeled

human leptin and a human leptin antiserum to determine the level of leptin in serum.
Serum P-hydroxybutyrate was determined spectrophotometrically at 340 nm by
NAD linked enzymatic reactions (Sigma kit no.3 1 0, Sigma, St. Louise, MO). All serum
samples used for P-hydroxybutyrate went through one freeze-thaw cycle during a 1 .5 y of
storage at - 80 °C before P-hydroxybutyrate was measured.
Serum carnitine was determined by the radioisotopic-enzymatic procedure
originally described by Cederblad and Lindstedt ( 1 972) as modified by Sachan et al.
( 1 984). When carnitine is quantified, NEC and acylcarnitine must be distinguished in
order to evaluate the metabolic nature of carnitine. First, serum samples were treated
with 0.6 M PCA and centrifuged at 1 500 X g for I O min at 4 °C to extract acid soluble
forms of carnitine, i.e. free or NEC and short-chain or acid soluble acylcarnitines
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(ASAC). The long-chain or acid insoluble acylcarnitines (AIAC) remained with the
pellet. An aliquot of the supernatant is assayed for the NEC concentration. Another
aliquot of supernatant alkalinized with 0.5 N KOH is assayed for the ASC, which is
incubated in a water bath for 30 min at 37 ° C, thus releasing all carnitine from its ester
linkage to the fatty acids. For AIAC concentration, the pellet was treated with 0.5 N
KOH to about pH 1 0 and hydrolysis carried out at 65 ° C for 60 min for the release of
carnitine from the long-chain fatty acid esters. After PCA and KOH treatments, the
samples were neutralized with the 3-[N-morpholino] propanesulfonic acid (MOPS) buffer
prior to the radioenzymatic assay. Enzymatic assays for carnitine involve the use of the
enzyme, CAT, which facilitates transfer of acetyl moiety of [ l - 14C]acetyl-CoA (Moravek
Biochemicals, Brea, CA) to carnitine, resulting in radioactive carnitine species. The
unreacted negatively charged [ l - 1 4C]acetyl-CoA is then removed from the reaction
mixture by running through anion exchange resin (Dowex 1X8, 200-400 mesh, c1- form)
(Doe & Ingalls, Durham, NC). Carnitine esters carrying the positive charge of the
quaternary ammonium are not retained by the resin and are collected into scintillation
vials. The radioactivity of samples, the eluted [ l - 1 4C]acetyl-CoA from the anion
exchange column, was determined using a Beckman LS-3801 liquid scintillation counter
(Beckman, Fullerton, CA). Four different carnitine fractions are determined by this
procedure: 1) NEC; 2) ASAC, total acid soluble minus the NEC ; 3) AIAC; and 4) Total
carnitine, the sum of NEC, ASAC and AIAC (Figure 6-2).
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FIGURE 6-2 Radioenzymatic assay ofthe various carnitinefractions.
Sample is treated with PCA to separate acid-soluble and acid-insoluble fraction of
camitine. NEC and ASC remain in supernatant (SN), but AIAC is precipitated with
pellet. KOH releases NEC from it ester linkage. After hydrolysis, a neutralized sample is
added to reaction mix, which contains [ l - 14C] acetyl-CoA. The reaction is started by
adding camitine acetyl transferase (CAT). Camitine in a sample forms [l -14 C] acetyl
camitine, which is eluted from the column that is packed with anion exchange resin.
Four different values can be obtained: 1) NEC, 2) ASAC = ASC - NEC, 3) AIAC and
4)TC = NEC + (ASC-NEC) + AIAC.
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Acetylcamitine (AC) was determined separately according to the method of Pande
and Caramancion (198 1) and the modification described below. In the procedure, the
acetyl portion of acetylcamitine is converted to [U- 14C]citrate, using an excess of [U14C]oxaloacetate generated from [U- 14C]aspartate and citrate s thase (CS) (EC 4. 1.3.7).
yn
The radioactivity of the citrate formed is measured after removal of the leftover [U14C]oxaloacetate which is converted to [U- 1 4C]aspartate by the addition of glutamate
oxaloacetate transaminase (GOT) (EC 2.6. 1. 1) plus glutamate. The [U- 14C]aspartate
formed is removed from the solution by the adding of a cation exchange resin and leaving
the [U- 14C]citrate for scintillation counting (Figure 6-3).
For estimation of serum acetylcamitine, samples were first deproteinized by 0.6M
PCA and centrifugation as described in the method for carnitine determination. The
supernatant of PCA extracts were neutralized with 0.5 M Hepes-KOH and 3M KHC03
and centrifuged at 2000 X g for 10 min at 4 °C. The supernatant was then transferred to
the microcentrifuge tube containing 0.5 M Hepes-KOH-6mM EDTA, pH 7.0. This
mixture was again transferred to the glass tubes (12 x 75 mm) containing 0.5 M Hepes
KOH, pH 8.5. About 200 mg of anion exchange resin, Dowex 1X8 (200-400 mesh, c1·
form) (Doe & Ingalls, Durham NC) with methanol and double distilled water (DDW)
were added to the glass tubes and vortex 2-3 times at room temperature, and then
centrifuged at 2000 X g for 5 min. Endogenous citrate was removed through anion
exchange resin and used for acetylcarnitine assay. The reaction mixtures containing
freshly prepared CoASH, dithiothreitol, cx-ketoglutarate, GOT, and [U- 14C]aspartate in
Hepes-KOH-EDTA buffer solution was added to the supernatant for starting the reaction
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FIGURE 6-3 Radioenzymatic assay of acetylcarnitine. Bold arrows indicate the reactions directly involved in the
formation of [ 14C]Citrate from acetylcamitine.

of [U- 14C]aspartate to form [U- 14C]oxaloacetate. Subsequently, CAT and CS were added
and incubated at room temperature for 20 min. At the end of the incubation, glutamate
and GOT mixture was added and incubated for an additional 20 min. Then, a slurry of
cation exchange resin, Dowex 50X8 (200-400 mesh, H+ form, Bio-Rad, Hercules, CA)
was added. The tubes were vortexed and placed on ice for 2-3 time over 20 min. After
the vortex, the tubes were centrifuged at 2000 X g for 5 min at 4 ° C. The supernatant was
transferred to scintillation vials and count by a Beckman LS counter (Beckman, Fullerton,
CA). A detailed procedure is shown in Appendix 1 .
Urine collection and analysis

All subjects collected two 24-hr urine samples during the baseline period and one
24-hr urine sample every wk thereafter. Oral and written instructions on the collection of
24-hr urine samples were given to the subjects before and during the study. They were
asked to record the date and time of collections. They were instructed to exclude the first
morning void of the first day and include the first morning void of the second day.
Polyethylene collection bottles containing thymol as a preservative were provided. The
volume of urine was measured, then throughly mixed and portions of urine were
centrifuged at 1 500 X g for 1 0 min at 4 ° C and placed in 1 3 ml of plastic tubes, stored
immediately at - 80 ° C until analyzed.
The 24-hr urine was analyzed for creatinine and camitine. Urinary creatinine was
determined by the alkaline-picrate method (Henry 1 967, Taussky 1 954 ). Creatinine
produces a certain definite color in the presence of an alkaline picric acid solution. This
reaction is due to the formation of a red tautomer of creatinine picrate, which has an
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absorbance at 520 run.
Carnitine in urine was determined by the same method as used for the serum
(Cederblad and Lindstedt 1 972, Sachan et al. 1 984). Samples of 20- 30 µl urine were
added to the tubes containing 200 µl 0.6 M PCA. In order to form pellets, 1 00 µl of 8%
bovine serum albumin and enough DDW to make the total volume of 400 µl were added.
The tubes were centrifuged at 1 500 X g for 1 0 min at 4 °C. An aliquot of supernatant and
pellets were used for carnitine assay as described above. Four different carnitine fractions
were also obtained in the urine. For the assay of the urinary acetylcarnitine the urine
samples of carnitine supplemented subjects were diluted 2 to 1 0 times, depending on the
concentration of the acetylcarnitine in urine.
Statistical analysis
All statistical analyses were done using the Personal Computer Statistical
Analysis System for Windows (Version 8e, 2000, SAS Institute, Cary, NC). Two-way
ANOVA with repeated measures was performed to determine whether there were any
significant differences on variables listed in the Tables. If there was a significant main
effect (group, time, interaction of group and time), Duncan' s multiple range test was
performed to determine how the groups differed. To evaluate treatment effects on each
time point (0, 7, 14, 21 and 35 d) separately, two-way ANOVA without repeated
measures was also performed to determine whether there were any significant differences
(group, gender, interaction of group and gender) on all the variables listed in the Tables,
except anthropometric measurement, across three dietary intervention groups. The data
in all tables are expressed as means ± standard error of means (SEM). Simple regression
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analysis was performed to calculate correlations between the serum leptin concentration
and anthropometric parameters. Statistical significance was set at P < 0.05.

RESULTS

Initially, 23 biologically unrelated subjects (5 men and 20 women), who met the
inclusion criteria, were recruited. Two of these subjects withdrew from the study prior to
completion due to the illness in their family. Thus, a total of 23 subjects completed the
study as a part of 3 groups: placebo, all women (n=7); supplement-I (S 1 ), 6 women and 2
men (n=8); and supplement-2 (S2), 6 women and 2 men (n=8). Anthropometric
measurements, 24-h urine collection, 3-d diet diary, exercise log, and supplement intake
were recorded in all subjects. The anthropometric parameters are shown in Table 6- 1.
Age and height were recorded only on day O and were not significantly different among
the groups.
The body weights were not significantly different among the groups; however,
there was a significant time effect on body weight between O and 35 d when the subjects
of the 3 groups were taken together (Table 6-1). The net change in body weights of the
groups at 3 different time points is shown in Table 6-2 . After wk 3 of treatment (at 21d), the SI and S2 groups lost on an average 0. 14 and 0.45 kg body weight, respectively,
and the placebo group lost 0.03 kg body weight. All groups showed loss of body weight
between 2 1 and 35 d (wash out period). Neither group nor time showed significant
effects on the remaining parameters listed in Table 6- 1, i.e. BMI, sum of skinfold
thickness, %BF, waist circumference and WHR.
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TABLE 6-2
Net changes in body weight of the groups at 3 time points'

Day
Weight (kg) (2 1 -d) - (0-d)
(35-d) - (2 1 -d)
(3 5-d) - (0-d)

Placebo
- 0.03
- 0.65
- 0.68

Supplement 1

Supplement 2

-0. 14
- 1 .07
- 1 .21

- 0.45
- 0.49
- 0.94

1

Values are mean differences of two time points. No statistical analysis was applied due
to the too large individual differences to make any prediction.

Nutrient and caffeine intakes at the pre-treatment (0-d) and on days 7, 1 4, 2 1 , and
35 are summarized in Table 6-3 and Table 6-4, respectively. Two-way ANOVA with
repeated measures showed no significant differences in mean nutrient intakes including,
energy intakes of the groups throughout the experiment. To determine if there were any
differences across the groups due to the total calorie and body size of subjects, intakes of
the macro-nutrients (protein, carbohydrate, fat) were calculated on the basis of per 1 000
kcal and per kg body weight of each subject. However, there were no significant group
differences on any of the macro-nutrients per 1 000 kcal and kg of their body weight
(Appendix D).
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TABLE 6-3
Mean nutrient intakes ofparticipants in three groups 1
Variables

Placebo

%kcal

Energy (kcal)
0-d
1 748 ± 88
1 840 ± 1 53
7-d
1 4-d
1 658 ± 1 64
2 1 -d
1 758 ± 335
35-d
1 857 ± 1 54
Protein (g)
0-d
6 1 ± 6.0
14 ± 0.9
80 ± 1 3
1 7 ± 1 .7
7-d
1 4-d
59 ± 8.8
14 ± 0.9
2 1 -d
59 ± 1 0
14 ± 0.5
70 ± 9.4
1 5 ± 1 .8
35-d
Carbohydrate (g)
258 ± 22 59 ± 2.5
0-d
7-d
239 ± 1 1 53 ± 3.6
1 4-d
224 ± 1 4 5 6 ± 4. 1
226 ± 42 52 ± 2.5
2 1 -d
253 ± 28 55 ± 5 .6
35-d
Fat (g)
50 ± 4.8 25 ± 1 .6
0-d
61 ± 8.7 30 ± 2.2
7-d
29 ± 3 .7
55 ± 1 1
1 4-d
±
34 ± 2.2
69 1 5
2 1 -d
59 ± 9.5 28 ± 2.9
35-d
Cholesterol (mg)
142 ± 22
0-d
202 ± 36
7-d
1 4-d
1 3 8 ± 58
1 77 ± 67
2 1 -d
1 63 ± 37
35-d
1

Supplement 1

%kcal

Supplement 2

%kcal

2007 ± 278
2223 ± 1 36
2296 ± 235
2085 ± 262
2 1 22 ± 1 53

1 879 ± 1 85
1 925 ± 264
1 826 ± 386
2 1 86 ± 383
1 974 ± 1 99
7 1 .± 7. 8
70 ± 8.0
72 ± 1 5
80 ± 1 3
69 ± 9.0

15 ±
15 ±
16 ±
15 ±
15 ±

1 .5
1 .9
1 .0
1 .4
1 .8

75 ± 1 0
75 ± 9.3
78 ± 9.6
76 ± 1 3
78 ± 1 0

1 5 ± 1 .6
1 3 ± 1 .5
14 ± 1 . 1
1 5 ± 2.0
1 5 ± 1 .9

260 ± 30
27 1 ± 39
26 1 ± 4 1
307 ± 4 1
285 ± 34

55 ± 2.7
56 ± 3 .2
61 ± 3 .5
5 8 ± 3.3
57 ± 4.3

278 ± 3 8
322 ± 25
307 ± 25
280 ± 43
29 1 ± 33

5 6 ± 2.2
58 ± 2.9
55 ± 4.8
52 ± 4.2
54 ± 2.8

67 ± 1 2
76 ± 7.5
87 ± 18
78 ± 1 0
75 ± 6.7

29 ± 1 .8
3 1 ± 2.0
33 ± 3 .5
3 5 ± 2.7
32 ± 2.6

64 ± 6. 8
66 ± 1 3
56 ± 1 9
69 ± 1 9
64 ± 1 1
1 96 ± 42
1 62 ± 28
1 45 ± 48
24 1 ± 83
1 1 4 ± 27

Values are expressed as mean ± SEM.
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3 1 ± 2.5
3 0 ± 2.3
24 ± 3.8
26 ± 2.8
29 ± 3.9

1 70 ± 42
212 ± 42
256 ± 65
222 ± 57
1 99 ± 22

TABLE 6-3

Mean nutrient intakes ofparticipants in three groups1 (continued)
Variables

Placebo

Saturated fat (g)
0-d
1 5 ± 1 .9
7-d
20 ± 3.3
1 4-d
1 6 ± 2.6
2 1 -d
20 ± 4.9
35-d
1 8 ± 2.8
Monounsaturated fat (g)
0-d
1 2 ± 1 .4
7-d
1 5 ± 1 .8
14-d
1 7 ± 4.4
2 1 -d
1 7 ± 5 .6
35-d
14 ± 2.4
Polyunsaturated fat (g)
0-d
7.2 ± 1 . 1
7-d
14 ± 3 .8
1 4-d
1 0 ± 1 .9
2 1 -d
1 6 ± 4.7
35-d
1 1 ± 2.4
Dietary fiber (g)
0-d
1 0 ± 2.2
7-d
1 0 ± 1 .5
14-d
1 0 ± 1 .6
2 1 -d
1 0 ± 2.0
35-d
12 ± 1 .7
Sugar (g)
0-d
91 ± 15
7-d
85 ± 1 0
14-d
60 ± 14
2 1 -d
72 ± 1 8
35-d
74 ± 1 4
1

%kcal

Supplement 1

%kcal

Supplement 2

%kcal

7.5 ± 0.8
9.4 ± 1 .0
8.2 ± 0.9
9.8 ± 1 .3
8.6 ± 1 .3

17 ± 1.1
22 ± 4.8
16 ± 5 .5
20 ± 5.2
20 ± 3.8

8.5 ± 0.9
10 ± 1 .5
7.0 ± 1 .4
7.7 ± 0.9
9.0 ± 1 .5

21 ± 4.7 9.0 ± 1 .0
23 ± 3 . 1 9 . 1 ± 0.8
29 ± 7.7 1 1 ± 1 .6
26 ± 5 .2 1 1 ± 1 .4
22 ± 3 .2 9.3 ± 1 . 1

3 .7 ± 0.5
6.5 ± 1 .3
5.7 ± 0.9
7.4 ± 1 .5
4.9 ± 0.8

18 ± 3.2
12 ± 4.6
1 1 ± 4.3
1 0 ± 3.5
13 ± 5.4

8.5 ± 1 .5
5 . 1 ± 1 .2
4.3 ± 1 .2
3.9 ± 0.6
5.8 ± 2. 1

1 3 ± 2.9
1 9 ± 3 .0
1 6 ± 3 .9
1 4 ± 2.0
1 3 ± 2.5

6.3 ± 0.6
7.5 ± 0.6
9.2 ± 1 .8
8.0 ± 1 .3
7.0 ± 1 .0

17 ± 1 .9.
1 2 ± 1 .3
1 6 ± 7.4
1 7 ± 8.0
1 9 ± 2.4

1 1 ± 2.5
1 3 ± 2.5
1 1 ± 1 .9
12 ± 2.8
14 ± 2.7

69 ± 1 5
1 1 2 ± 22
77 ± 14
1 00 ± 1 2
89 ± 1 7

Values are expressed as mean ± SEM.
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8.4 ± 0.7
5.8 ± 1 .0
6.0 ± 1 .8
6. 1 ± 1 .7
8.5 ± 0.7

16 ± 1 .5 7.6 ± 0.8
1 8 ± 3 . 1 7 . 3 ± 1 .2
26 ± 2.3 1 1 ± 0.8
23 ± 3 .0 1 0 ± 1 . 1
22 ± 2.9 9.5 ± 1 . 1

13 ± 1 .8
13 ± 2.0
1 5 ± 2.2
1 2 ± 2.3
13 ± 2.3

89 ± 22
1 35 ± 28
92 ± 29
97 ± 1 9
93 ± 22

6.0 ± 0.7
7.6 ± 1 . 1
6. 1 ± 1 .2
6.2 ± 1 .0
5.5 ± 1 .0

TABLE 6-3
Mean nutrient intakes ofparticipants in three groups1 (continued)

Variables

Placebo

Vitamin A (µg RE)
0-d
795 ± 1 59
7-d
537 ± 8 1
1 4-d
72 1 ± 1 57
2 1 -d
908 ± 209
35-d
847 ± 45 1
P-carotene ( µ g)
0-d
55 ± 34
7-d
92 ± 3 1
1 4-d
1 23 ± 50
2 1 -d
47 ± 28
35-d
22 1 ± 80
Thiamin (mg)
0-d
1 . 1 ± 0.2
1 .3 ± 0.2
7-d
1 4-d
1 .2 ± 0.2
2 1 -d
1 .6 ± 0.4
35-d
1 .2 ± 0.3
Riboflavin (mg)
0-d
1 .4 ± 0.2
7-d
1 .4 ± 0.2
1 4-d
1 .3 ± 0. 1
2 1 -d
1 .7 ± OJ
3 5-d
1 .4 ± 0.2
Niacin (mg)
0-d
1 6 ± 2.0
27 ± 3.6
7-d
1 4-d
1 6 ± 1 .9
2 1 -d
1 7 ± 2.2
35-d
19 ± 5.1
1

Supplement 1

Supplement 2

744 ± 1 0 1
483 ± 1 1 8
62 1 ± 254
888 ± 244
1 1 26 ± 253

848 ± 1 32
73 8 ± 1 3 9
597 ± 1 1 6
940 ± 346
1 068 ± 570

1 .6 ± 0.2
1 .3 ± 0.3
1 .2 ± 0.3
1 .6 ± 0.3
1 .4 ± 0.3

1 .7 ± 0.3
1 .6 ± 0.3
2.3 ± 0.8
1 .2 ± 0. 1
2.5 ± 0.8

1 64 ± 68
1 6 1 ± 92
224 ± 1 73
1 32 ± 53
225 ± 1 02

1 .6 ± 0.2
1 . 1 ± 0.3
1 .2 ± 0.4
1 .6 ± 0.3
1 .6 ± 0.2

19 ± 3 .0
20 ± 2.2
1 7 ± 4.4
19 ± 3.8
1 9 ± 2.6

Values are expressed as mean ± SEM.
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336 ± 1 07
212 ± 141
65 ± 20
1 26 ± 48
346 ± 2 1 5

1 .7 ± 0.2
1 . 8 ± 0.3
1 .5 ± 0. 1
1 .5 ± 0.2
1 .7 ± 0.3

2 1 ± 2.8
20 ± 3.0
25 ± 4.3
22 ± 4. 1
22 ± 2.9

TABLE 6-3

Mean nutrient intakes ofparticipants in three groups 1 (continued)
Variables

Placebo

Vitamin B6 : pyridoxine (mg)
0-d
1 .0 ± 0.2
7-d
1 .4 ± 0.2
1 4-d
1 .0 ± 0.2
2 1 -d
1 . 1 ± 0. 1
35-d
1 .2 ± 0.3
Vitamin B 1 2 ( µ g)
0-d
2.7 ± 0.7
7-d
3.4 ± 0.7
1 4-d
1 . 8 ± 0.3
2 1 -d
3.6 ± 0.9
35-d
1 . 8 ± 0.4
Vitamin C (mg)
0-d
99 ± 1 5
7-d
83 ± 1 7
1 4-d
80 ± 3 1
2 1 -d
84 ± 21
35-d
77 ± 1 8
Vitamin D ( µg)
0-d
2.2 ± 0.9
7-d
1 . 8 ± 0.7
1 4-d
1 . 1 ± 0.4
2 1 -d
2.9 ± 0.9
35-d
1 .5 ± 0.5
Vitamin E (mg a-TE)
0-d
3.7 ± 1 .3
7-d
1 2 ± 3.3
1 4-d
7.7 ± 3 .3
2 1 -d
1 4 ± 4.8
35-d
5 .5 ± 3.3
1

Supplement 1

Supplement 2

1 .4 ± 0.2
1 . 1 ± 0.2
1 .0 ± 0.2
1 . 1 ± 0.2
1 .5 ± 0.3

1 .3 ± 0.2
1 .3 ± 0.2
1 .7 ± 0.3
1 .3 ± 0. 1
1 .7 ± 0.4

2.9 ± O.(j
2.7 ± 0.8
2.5 ± 1 . 1
2.6 ± 0.7
2.3 ± 0.6

2.7 ± 0.6
2.4 ± 0.5
3 . 1 ± 1 .0
2.6 ± 0.5
2.4 ± 0.9

79 ± 1 3
1 14 ± 18
5 8 ± 27
94 ± 35
1 09 ± 28

77 ± 1 6
90 ± 1 8
1 03 ± 25
141 ± 56
1 1 1 ± 38

3.1 ± 1 .3
1 . 1 ± 0.6
2.5 ± 1 .7
3.5 ± 1 .4
2.4 ± 0.9

2.7 ± 1 .0
1 .8 ± 0.9
1 .6 ± 0.5
1 .9 ± 0.4
2.2 ± 1 .3

1 3 ± 2.9
6.6 ± 1 .5
6. 1 ± 2.0
3.4 ± 1 .2
8.6 ± 2.5

5 .4 ± 1 .9
9.6 ± 3 .0
1 1 ± 4. 1
8.4 ± 2.2
4.3 ± 1 .2

Values are expressed as mean ± SEM.
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TABLE 6-3

Mean nutrient intakes ofparticipants in three groups1 (continued)

Variables

Placebo

a-Tocopherol (mg)
0-d
2.4 ± 0.6
7-d
4.3 ± 0.6
14-d
3 .9 ± 0.8
2 1 -d
4.3 ± 1 .2
35-d
3.4 ± 1 .2
Folate (µg)
0-d
2 1 3 ± 45
7-d
1 86 ± 40
14-d
214 ± 44
2 1 -d
232 ± 37
35-d
1 83 ± 28
Pantothenic acid (mg)
0-d
2.0 ± 0.4
7-d
2.8 ± 0.2
14-d
2.0 ± 0.4
2 1 -d
2.7 ± 0.7
35-d
1 .9 ± 0.4
Biotin (µg)
0-d
4.3 ± 1 .8
7-d
7.2 ± 2.2
14-d
6.5 ± 1 .9
1 2 ± 3.2
2 1 -d
35-d
4.4 ± 1 .5
Vitamin K (µg)
237 ± 104
0-d
7-d
240 ± 68
1 78 ± 44
14-d
234 ± 48
2 1 -d
161 ± 61
35-d
1

Supplement 1

Supplement 2

1 1 ± 4.6
4. 1 ± 0.9
3.8 ± 1 .2
4.4 ± 1 .6
9.2 ± 5 .7

3.2 ± 0.8
6. 1 ± 1 .4
3.8 ± 0.8
4.0 ± 0.8
4.0 ± 0.8

2 14 ± 45
204 ± 22
1 70 ± 44
241 ± 77
242 ± 40

1 86 ± 39
201 ± 28
233 ± 44
1 84 ± 33
228 ± 57

4. 1 ± 0.7
2.0 ± 0.3
2.5 ± 0.7
3.2 ± 1 .0
4.2 ± 0.7

2.4 ± 0.5
2.5 ± 0.4
3.5 ± 0.5
2.8 ± 0.6
3.3 ± 1 .0

7.6 ± 2.5
5 . 1 ± 1 .7
4.7 ± 1 .8
1 2 ± 4.9
5.7 ± 1 .6

7.8 ± 2.7
8.9 ± 2.5
1 4 ± 4.4
9.0 ± 3 . 1
6.5 ± 2.7

1 3 8 ± 61
122 ± 2 1
148 ± 42
227 ± 59
171 ± 42

1 37 ± 62
1 3 8 ± 64
1 1 8 ± 50
143 ± 43
1 1 4 ± 54

Values are expressed as mean ± SEM.
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TABLE 6-3

Mean nutrient intakes ofparticipants in three groups 1 (continued)
Variables

Placebo

Sodium (mg)
0-d
2909 ± 397
7-d
2627 ± 269
14-d
2646 ± 227
2 1 -d
2579 ± 504
35-d
2978 ± 23 8
Potassium (mg)
0-d
2044 ± 244
7-d
2388 ± 273
14-d
1 848 ± 1 97
2 1 -d
1 989 ± 23 3
35-d
2209 ± 1 3 8
Iron (mg)
0-d
10 ± 1 . 1
7-d
1 2 ± 1 .5
14-d
1 1 ± 1 .3
2 1 -d
1 6 ± 2.5
35-d
14 ± 3.4
Calcium (mg)
0-d
664 ± 68
7-d
60 1 ± 1 09
14-d
545 ± 8 1
2 1 -d
750 ± 1 52
35-d
766 ± 74
Magnesium (mg)
0-d
1 89 ± 26
7-d
225 ± 27
1 4-d
1 86 ± 2 1
2 1 -d
1 97 ± 25
35-d
1 80 ± 25
1

Supplement 1

Supplement 2

2729 ± 2 1 2
2873 ± 48 1
2893 ± 563
341 5 ± 672
3690 ± 545

3877 ± 253
3437 ± 468
3075 ± 3 1 4
3058 ± 4 1 0
30 1 0 ± 369

1 2 ± 2.6
1 2 ± 2. 1
1 1 ± 3.0
14 ± 3.8
14 ± 1 .9

13 ± 1 .7
14 ± 1 .3
15 ± 2 . 1
1 1 ± 1 .2
14 ± 1 . 1

2 1 1 0 ± 320
2 1 58 ± 295
204 1 ± 466
2594 ± 592
2578 ± 3 5 8

779 ± 1 5 1
656 ± 202
70 1 ± 2 1 4
83 1 ± 1 98
743 ± 86
254 ± 40
1 95 ± 23
208 ± 57
25 1 ± 54
274 ± 33

Values are expressed as mean ± SEM.
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2402 ± 3 1 8
2594 ± 142
2465 ± 2 1 5
2468 ± 257
2538 ± 323

888 ±
856 ±
779 ±
788 ±
873 ±

119
1 03
1 14
1 04
191

22 1 ± 28
226 ± 20
273 ± 42
1 94 ± 28
257 ± 45

TABLE 6-3
Mean nutrient intakes ofparticipants in three groups1 (continued)
Variables

Placebo

Phosphorus (mg)
0-d
871 ± 1 1 7
1 1 06 ± 1 33
7-d
1 4-d
793 ± 78
2 1 -d
1 030 ± 1 66
35-d
746 ± 1 1 2
Zinc (mg)
0-d
6.0 ± 0.8
7.9 ± 1 .4
7-d
6.6
± 0.8
1 4-d
2 1 -d
9.5 ± 3.9
35-d
5 .4 ± 1 .0
Copper (mg)
0-d
0.7 ± 0. 1
1 .3 ± 0.4
7-d
1 4-d
0.7 ± 0. 1
2 1 -d
1 . 1 ± 0.3
0.8 ± 0.2
3 5-d
Selenium ( µg)
0-d
30 ± 7.9
51 ± 1 1
7-d
1 4-d*
23 ± 7.3
23 ± 6.0
2 1 -d
5 1 ± 23
35-d
Chromium ( µg)
42 ± 1 6
0-d
54 ± 7.6
7-d
1 4-d
33 ± 1 0
2 1 -d
77 ± 1 9
37 ± 1 6
35-d
1

Supplement 1

1 253 ± 142
977 ± 1 82
932 ± 228
1 285 ± 288
1215 ± 161

Supplement 2

1316 ±
1 1 40 ±
1 098 ±
1 1 86 ±
1 1 92 ±

1 89
1 59
118
1 89
1 47

8.6 ± 1 .3
6.0 ± 1 .2
6.2 ± 2. 1
7.2 ± 1 .7
7.9 ± 1 .2

7.7 ± 1 . 1
7.4 ± 1 .2
8.3 ± 0.9
1 3 ± 5.4
8.0 ± 1 .9

1 .4 ± 0.4
0.8 ± 0. 1
1 .0 ± 0.3
1 .0 ± 0.2
1 .3 ± 0. 1

0.9 ± 0. 1
0.9 ± 0.04
1 .2 ± 0.2
0.9 ± 0. 1
1 . 1 ± 0.2

92 ± 25
58 ± 15
35 ± 7.4
56 ± 1 7
1 1 9 ± 49

42 ± 1 4
33 ± 1 1
79 ± 20
53 ± 1 1
80 ± 24

47 ± 9.8
70 ± 1 5
36 ± 1 4
81 ± 19
33 ± 9.5

33 ± 1 3
33 ± 1 1
92 ± 3 1
5 0 ± 8.3
37 ± 1 5

Values are expressed as mean ± SEM.
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TABLE 6-4

Mean caffeine intakes ofparticipants in three groups1
Variables

Placebo

Caffeine (mg)
0-d
7-d
14-d
2 1 -d
35-d

234 ± 46
256 ± 3 8
269 ± 67
309 ± 69
268 ± 97

1

Supplement 1

Supplement 2

1 67 ± 55
1 74 ± 46
226 ± 67
297 ± 93
23 1 ± 71

1 96 ± 64
262 ± 5 8
2 3 6 ± 66
259 ± 73
223 ± 68

Values are expressed as mean ± SEM.

For all nutrient intakes, factorial analysis was used to evaluate gender differences
in the entire population (all 3 groups together). Results of energy and nutrients that are
significantly different between male (n = 5) and female (n = 1 7) subjects are summarized
in Table 6-5. Total energy, protein and carbohydrate intake were affected by gender at all
time periods, except on d 3 5. More nutrients were affected by the gender on d 14
and 2 1 than on any other time period. The gender differences were eliminated by d 3 5,
except for the sugar and sodium. On d 7 and 14 there were some nutrients that were
significantly different among the groups, when excluding the values of males and only the
values of female subjects were compared.
Resting metabolic rate (RMR) of each subject was predicted using the equation
formulated by Harris and Benedict ( 1 9 1 9). The estimates of total energy expenditure
included the additional energy cost associated with activity which was based on ·
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TABLE 6-5

Gender differences on nutrient intakes
0-d

Energy
Protein
Carbohydrate
Fat

Sugar
Niacin

Calcium
Magnesium
Phosphorus

Caffeine

7-d

Energy
Protein
Carbohydrate*

14-d

21-d

Energy*
Protein
Carbohydrate*
Fat*

Energy
Protein
Carbohydrate
Fat
Cholesterol
Saturated fat
Mono-Fat
Poly-Fat
Sugar
Niacin
Sodium
Potassium
Iron
Calcium
Magnesium
Phosphorus

Saturated fat*
Mono- Fat*
Po.l y-Fat*
Niacin*
Sodium
Iron
Calcium
Phosphorus
Chromium

Niacin
Sodium
Potassium
Iron*
Calcium
Magnesium
Phosphorus
Zinc*
Copper

35-d

Sugar
Sodium

* Indicates significant differences (P< 0.05) between the groups when compared with
only female participants

individual activity level for sedentary to moderately active life style (Whitney et al. 1994).
Daily energy balance of each individual for each wk was estimated by subtracting energy
intake determined from 3-day food dietary and total energy expenditure. Estimated
energy balance of each group for d 0, 7, 14,21 and 35 is summarized in Table 6-6.
Energy balance was negative in the subjects of the placebo group throughout the study
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TABLE 6-6

Energy balance estimatedfrom total energy expenditure and calorie intake in three
groups1
Variables

Day

Energy Balance 0-d
7-d
(kcal)
14-d
2 1 -d
35-d

Placebo

Supplement 1
- 1 6 1 ± 74
23 ± 1 39
-357 ± 1 37
- 1 9 ± 1 28
71 ± 1 1 4

- 1 42 ± 99
-89 ± 154
-230 ± 161
-298 ± 200
-2 1 ± 1 1 1

Supplement 2
1 2 ± 160
205 ± 128
169 ± 1 66
-14 ± 213
96 ± 1 79

1

Values are expressed as mean ±SEM. No statistical analysis was applied due to the too
large individual differences to make any prediction.

period. There was negative energy balance of � 300 kcal in the SI group on d 1 4. The
estimates of energy balance were positive in the S2 group during the study period. The
difference in energy balance between the S 1 and S2 was more than 500 kcal on d 1 4 but it
was 25 kcal on d 35. The placebo group had the largest calorie deficit (-- 300 kcal)
following the exercise period (on d 2 1 ), but the estimated total energy expenditures and
calorie intakes were almost equal in the S 1 and S2 during the exercise period.
Serum lipid profiles of the subjects are shown in Table 6-7. Significant group
effects were observed for HDL on d 14, and for triglycerides on d 2 1 and 35. The
placebo group had significantly higher HDL than the 2 supplement groups on d 1 4.
Serum triglyceride of the S2 group was lower than that of the other two groups during the
entire study period, and the differences were statistically significant on d 2 1 and 35. Men
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TABLE 6-7
Serum U-e_ids ote.artici"e_ants in three 8!._0U(!/
Supplement 2
Statistical Significance2
Placebo
Supplement 1
{n = 8)
GrouE
GxG
Gender
{n = 8)
Variables
{n = 7)
Dax
1 74.2 ± 4.5
1 63 .2 ± 8. 1
1 97.5 ± 26.2
NS
NS
Total-C (mg/di) 0-d
NS
1 62. 1 ± 9.3
1 62.8 ± 6.0
NS
NS
NS
1 89.0 ± 9.7
7-d
NS
1 68.0 ± 5.5
178.4 ± 9.7
NS
1 95.7 ± 23 .2
1 4-d
NS
1 58.7 ± 5.3
1 84.2 ± 9.8
NS
NS
203.6 ± 25.3
2 1 -d
NS
1 79.7 ± 8.7
1 69.4 ± 8.5
NS
NS
NS
1 9 1 .0 ± 24. 8
35-d
104.4 ± 7.9
1 1 4.4 ± 5.4
NS
NS
LDL (mg/di)
1 22.4 ± 22.4
NS
0-d
103.0 ± 3 .9
NS
105.0 ± 1 1 .7
NS
NS
1 1 4.9 ± 2 1 .4
7-d
108.2 ± 6.2
NS
NS
1 1 9.0 ± 10.6
1 24.3 ± 22.0
NS
1 4-d
99.7 ± 6.3
1 1 9.6 ± 10.2
NS
1 25.3 ± 2 1 .6
NS
NS
2 1 -d
1 07.9 ± 9.4
1 1 2. 1 ± 10.2
NS
NS
NS
1 1 3.9 ± 20.9
35-d
41 .5 ± 4.3
39.5 ± 2.7
52.6 ± 4.9
NS
HDL (mg/di)
NS
NS
0-d
37.4 ± 1 .7
4 1 .3 ± 3 .7
49.5 ± 4.3
NS
NS
7-d
NS
37.2 ± 1 . 8
40.2 ± 4.0
0.0427
49.8 ± 3 .0
1 4-d
NS
NS
42.7 ± 4.5
40.0 ± 2.4
NS
54.2 ± 3 . 8
NS
2 1 -d
NS
43 . 1 ± 2.4
53.6 ± 4.7
44.4 ± 4.8
NS
35-d
NS
NS
96.
1
±
1
3
.5
1
1
2.7
±
1
9.2
9
1
.2
±
8
.4
0-d
NS
NS
NS
TG (mg/dl)
98.6 ± 1 8.7
92.6 ± 1 4.7
1 22.9 ± 20. 1
NS
7-d
NS
NS
99.6 ± 9.7
1 10.8 ± 1 8.4
1 4-d
107.9 ± 1 3 .3
NS
0.0 1 50
NS
1 23 .4 ± 1 3 .6
80.9 ± 8.8
0.037 1
2 1 -d
1 20.2 ± 1 7 . 1
NS
NS
1 1 6.2 ± 1 3 . 1
86.0 ± 8.3
35-d
1 1 7.3 ± 1 6.4
0.0347
NS
NS
423 .9 ± 35. 8
53 1 .4 ± 55.5
479.8 ± 23 .0
FFA (µmol/L) 0-d
NS
NS
NS ·
375.3 ± 26.3
498.7 ± 56. 8
584.7 ± 66.9
7-d
NS
NS
NS
396.2 ± 59.0
47 1 .5 ± 57.5
5 1 9.7 ± 49.8
1 4-d
NS
NS
NS
453 .8 ± 27.6
470.5 ± 58.6
32 1 .2 ± 48.5
2 1 -d
NS
NS
NS
453 .4 ± 33.4
427.3 ± 30.2
35-d
494.0 ± 55.0
NS
NS
NS
1
Values are expressed as mean ± SEM. 2P values from 2-way ANOVA. Abbreviation used: FFA, free fatty acids; NS, no
significance differences, P> 0.05; TG, triglycerides; Total-C, total cholesterol; GxG, group and gender interaction.

had higher serum triglycerides (134. l ± 15.0 mg/dl, n = 5) than women (97 .5 ± 8 . 1, n =
17) on d 14. Two-way ANOVA with repeated measures showed significant group
differences in HDL (P = 0.044) and FFA (P = 0.033). The placebo group had higher
HDL than the SI group throughout the study. Duncan's multiple range test revealed that
the serum FFA was significantly lower in the S 1 than S2 group, although there were no
significant group differences from week to week.
Serum concentrations of P-hydroxybutyrate and leptin are shown in Table 6-8.
The S2 group, after having been on camitine supplementation for 7 d, showed higher
concentration of P-hydroxybutyrate compared to other treatments. Two-way ANOVA
with repeated measures also showed group and time effects on the serum concentration of
P-hydroxybutyrate. The Duncan Multiple range test revealed that the placebo group was
significantly different from the S2 group, and the baseline was significantly different from
the d 21. The placebo and S 1 group had a peak of P-hydroxybutyrate on d 2 1, that is after
the exercise intervention. The S2 group on the other hand had a peak P-hydroxybutyrate
concentration after carnitine supplementation (d 7) and the concentration remained higher
than other groups throughout the study period.
No significant group effects were found on serum leptin concentration after any
treatment. However, two-way ANOVA with repeated measurements revealed that there
was significant time effect in all group (P = 0.0001), indicated by reduced serum leptin
concentration after 1 wk of exercise intervention. Serum leptin concentration showed
significant positive correlations to all the anthropometric measurement, except the WHR,
before and after the treatment (Table 6-9). Serum leptin concentration was not
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TABLE 6-8

Serum /J-hydroxybutyrate and leptin concentrations in three groups 1
Variables

.....

......:J

Day

Placebo
(n = 7)

Supplement 1
(n = 8)

P-Hydroxybutyrate
(µmol/L)
0-d
27.6 ± 13.1
25.2 ± 7.3
35.7 ± 10.4
7-d
26.4 ± 6.6
41.2 ± 11.5
14-d
22.3 ± 7.0
65.0 ± 17.9
21-d
42.3 ± 4.8
28.0 ± 6.4
33.4 ± 10.2
35-d
2-way ANOVA repeated measure:
pa' SI a,b ' S2 b
Group: 0.0099 .....
O-d8' 7-dbc' 1 4 -dabc' 2 1 - db' 3 5 -dac
Week: 0.0198 .....
Group x Week: NS
Leptin
28.8 ± 5.4
0-d
25.2 ± 5.6
(ng/ml)
27.7 ± 5.7
28.7 ± 4.3
7-d
14-d
21.7 ± 3.8
27.2 ± 4.7
11.0 ± 2.7
21-d
12.8 ± 3.0
35-d
2-way ANOVA repeated measure:
Group: NS
Week: 0.0001 .... O-d8, 7-d8, 14-d8, 21-db
Grou2 x Week: NS
1
4

Supplement 2
(n = 8)
20.2 ± 4.5
81.1 ± 15.1
52.1 ± 14.1
61.8 ± 13.0
38.0 ± 9.5

24.5 ± 9.5
25.4 ± 10.7
21.0 ± 7.6
8.5 ± 3.6

Statistical Significance2
Group
Gender
GxG3

NS

NS4

NS
NS
NS

NS
NS
NS

NS

NS
NS

NS
NS
NS
NS

NS
NS
NS
NS

NS
NS
NS
NS

NS
0.0169

NS

Values are expressed as mean ± SEM. 2P values from 2-way ANOVA. 3GxG, group and gender interaction.
NS, no significance differences, P> 0.05.

NS

TABLE 6-9
Correlation between serum leptin, anthropometric measurements, serum
triglyceride andfree fatty acids before and after the exercise intervention

Measurements

Body Weight
before 1
after
BMI
before
after
Waist Circumference
before
after
Hip Circumference
before
after
WHR
before
after
Sum of skinfold thickness
before
after
% BF

before
after
Serum triglyceride
before
after
Serum free fatty acid
before
after

All subjects (n = 23)
r

P-value

0.587 0.0032
0.549 0.0066
0.690 0.0003
0.654 0.0007
0.493 0.01 68
0.496 0.0 1 60 .
0.735 0.000 1
0.730 0.000 1
0. 1 94 0.3755
0.236 0.278 1
0.7 1 3 0.0002
0.7 1 6 0.0002
0.723 0.000 1
0.779 0.000 1
0.343 0. 1 1 75
0.592 0.0036
0.398 0.0668
0.088 0.6979

Pearson correlation coefficients were calculated using data from all 23 subjects.
1
before: correlation at the beginning of the baseline (0-d),
2
after: correlation after the exercise intervention week (2 1-d).
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significantly correlated with serum triglyceride before the treatments (0-d), but it became
significantly correlated after the treatments (2 1 -d) in all subjects.
Serum camitine concentrations in the 3 groups after each treatment and the wash
out period are shown in Table 6 -10. On d O (base line) there were no significant
differences among the groups in any of the camitine fractions. There was a significant
gender effect on the ASAC. The mean serum ASAC concentrations in female and male
were 1 0.40 ± 1 .2 (n = 1 7) and 5.7 ± 0.5 (n = 3) µmol/L, respectively. Comparisons of the
pooled ASAC values of all female showed no significant differences among the groups.
After the first treatment period (d 7) all fractions of camitine, except AIAC, were
significantly different among the groups. The S2 group showed significantly higher
serum camitine concentrations after 7 d of camitine supplementation. After 7 d of the
combination of camitine and choline supplementation (d 1 4) the group effect disappeared
and no significance was found among the groups. After 1 wk of exercise intervention the
group effect was observed only in TC. Both supplement groups maintained significantly
higher serum camitine concentration than the placebo group, and the concentrations in the
supplemented groups had peaked after the exercise intervention period. The placebo
group maintained a very stable serum TC concentration, i.e. within about 2 µmol/L
throughout experimental period. After 2 wk of wash-out period (d 35) there was a
significant group effect on the AC in that the S2 group had significantly higher serum AC
than other 2 groups. Two-way ANOVA with repeated measures showed significant
group effect in all the fractions of serum camitine, except the AIAC.
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TABLE 6 -10
Serum carnitine concentrations in three groups 1

-

"°

Statistical Significance2
GxG
Gender
Group

Variables

Day

Placebo

Supplement 1

Supplement 2

Total camitine
(µmoVL)

0-d
7-d
1 4-d
2 1 -d
3 5-d

37.2 ± 2.8
35.9 ± 2.2
39.6 ± 3.3
39.2 ± 3.2
37.6 ± 4. 1

4 1 .3 ± 3.5
36. 1 ± 6.7
43.8 ± 2.0
53.5 ± 3.2
47.6 ± 3.8

44.6 ± 2.7
55.2 ± 4. 1
48. 1 ± 6.5
55.7 ± 5.3
50.8 ± 4.8

NS
0.0 1 08
NS
0.0 1 65
NS

NS
NS
NS
NS
NS

NS
NS
NS
NS
NS

NEC (µmoVL) 0-d
7-d
1 4-d
2 1 -d
3 5-d

25.6 ± 2. 1
25.5 ± 1 .7
3 0.3 ± 3.0
3 1 .2 ± 2.3
28. l ± 2.9

3 1 .2 ± 2.4
26.0 ± 5.9
32.0 ± 1 .6
4 1 .0 ± 3.6
36. 1 ± 3.5

3 1 .2 ± 2.4
39.5 ± 4. 1
35.9 ± 4.9
43.6 ± 4.7
36.3 ± 2.9

NS
0.04 1 3
NS
NS
NS

NS
NS
NS
NS
NS

NS
NS
NS
NS
NS

ASAC (µmoVL) 0-d
7-d
1 4-d
2 1 -d
3 5-d

9.2 ±
8.3 ±
7.2 ±
6.2 ±
7. 1 ±

8.9 ± 1 .5
8.0 ± 1 .4
1 0.0 ± 1.6
I O. I ± 2. 1
9.3 ± 1 .5

1 0.9 ± 1 .2
1 3.3 ± 1 .8
10.3 ± 2. 1
9.3 ± 1 . 1
1 1 .7 ± 2.5

NS
0.04 1 3
NS
NS
NS

0.0028
NS
NS
NS
NS

NS
NS
NS
NS
NS

AIAC (µmoVL) 0-d
7-d
1 4-d
2 1 -d
3 5-d

2.3 ± 0.30
2.0 ± 0.29
2. 1 ± 0.37
1 .9 ± 0.33
2.4 ± 0.43

NS
NS
NS
NS
NS

NS
NS
NS
NS
NS

NS
NS
NS
NS
NS

AC (µmoVL)

1.1
1 .0
1 .0
1 .2
1 .2

2.5 ± 0.24
2.0 ± 0.26
1 .8 ± 0. 1 4
2.5 ± 0. 1 7
2.2 ± 0.2 1

2.5 ± 0. 1 5
2.4 ± 0. 1 4
2.0 ± 0. 1 5
2.8 ± 0. 1 8
2.8 ± 0.3 1

0-d
3.9 ± 0.42
4.8 ± 0.44
4. 1 ± 0.38
NS
NS
7-d
7.8 ± 0.9 1
0.0465
NS
5.0 ± 0.50
4.9 ± 0.55
1 4-d
4.9 ± 0.53
6.3 ± 0.38
6.7 ± 0.60
NS
NS
2 1 -d
6.6 ± 0.63
5.2 ± 0.79
7.2 ± 0.73
NS
NS
3 5-d
4.9 ± 0.47
0.0346
NS
5.9 ± 0.43
8.2 ± 1 . 1
1
Values are expressed as mean ± SEM. 2P values from 2-way ANOVA. Abbreviation used: AC, acetylcamitine; AIAC, acid- insoluble
acylcamitine; ASAC, acid-soluble acylcamitine, NEC, nonesterified camitine; NS, no significance differences.

0.0246
0.0452
NS
NS
NS

Urinary excretions of camitine are shown in Table 6 -1 1 . There was no
significant difference in the fractions of camitine, except on AIAC, among the groups on
d 0. There were significant gender anq gender-and-group interactions on AIAC. The
mean daily AIAC excretion for females and males were 10.7 1 ±0.7 (n = 17) and 15.73 ±
1.3 (n = 3) µmol/d, respectively. However, there were no significant differences among
the groups if, analyzed without male subjects. As it was observed in the serum, the
urinary concentrations of all camitine fractions were significantly different among the
groups after the first treatment. The S2 group showed significantly higher urinary
camitine concentrations after 7 d of camitine supplementation and the magnitude of
changes are much greater (3-4- fold) than those in serum carnitine (1.2-fold). After 7 d of
the combination of carnitine and choline supplementation (d 14) the group effect
disappeared and no significance was found among the groups. After 1 wk of exercise
intervention the group effects and gender effects were observed for all camitine fractions.
The exercise reduced urinary total camitine excretion to more than half of the previous
weeks in the placebo group this effect continued at the wash-out period for fractions of
camitine (d 35). This decline in camitine excretion has magnified the difference between
the placebo and supplemented groups and the differences between the base line and wash
out period. Two-way ANOVA with repeated measures showed significant group effects
in the TC, NEC, and AC.
Mean walking steps, distance and estimated caloric output per wk before and
during the 1 wk of exercise intervention, including percentage changes of those
measurements between the two periods, are summarized in Table 6-12. Subjects in the
19 1

TABLE 6-1 1
DailJ!.. urinary carnitine excretions in three woup/

Variables

Day

Placebo

Supplement 1

Supplement 2

Statistical Significance
GxG
Gender
Group

Total camitine 0-d
(µmol/d)
7-d
14-d
2 1 -d
35-d

1 42. 1 ± 24.3
1 32.5 ± 20.7
1 44.3 ± 30.7
66.2 ± 14.8
55.9 ± 1 0.2

1 13.9 ± 14.6
57.7 ± 1 5.4
234.2 ± 56.8
1 95.4 ± 4 1 .0
2 1 9.2 ± 43.9

1 1 2.7 ± 24.9
427.9 ± 55.6
2 1 0.5 ± 53.5
2 1 8.7 ± 48.4
2 1 0.4 ± 38.2

NS
0.000 1
NS
0.0098
0.0 1 6 1

NS
NS
NS
0.029 1
NS

NS
NS
NS
NS
NS

NEC (µmol/d)

0-d
7-d
14-d
2 1 -d
35-d

76.2 ± 1 8.2
70.0 ± 1 6.0
90.3 ± 23.0
32.5 ± 8 . 1
24.8 ± 8.0

65.5 ± 6.5
1 8. 1 ± 8.3
1 63.6 ± 48.4
144.4 ± 33.3
129.2 ± 35.9

63.3 ± 1 7. 1
297.5 ± 48.3
149.8 ± 44.9
1 50.3 ± 42.3
1 5 1 . 1 ± 25.5

NS
0.000 1
NS
0.0 1 29
0.0 1 2 1

NS
NS
NS
0.04 1 2
0.0 1 1 1

NS
NS
NS
NS
NS

ASAC (µmol/d) 0-d
7-d
14-d
\0
2 1 -d
N
35-d

54.6 ± 8.9
50.6 ± 8. 1
42.5 ± 8.2
23.0 ± 5.8
22.8 ± 9.6

36.6 ± 7.0
30.5 ± 7.6
56.7 ± 7.7
33.4 ± 6.7
76.2 ± 20.6

3 8.7 ± 8.0
1 1 1 .7 ± 1 0.7
46.8 ± 7.2
50.5 ± 7.4
45.4 ± 20. 1

NS
0.0009
NS
0.022 1
NS

NS
NS
NS
NS
NS

NS
NS
NS
NS
NS

AIAC (µmol/d) 0-d
7-d
1 4-d
2 1 -d
35-d

1 1 .3 ± 1 .4
1 1 .8 ± 1 .8
1 1 .6 ± 2.2
1 0.7 ± 2.5
8.3 ± 1 .2

1 1 .8 ± 2.4
9. 1 ± 2. 1
1 3.9 ± 3 . 1
1 7.5 ± 3 .4
1 3.8 ± 0.9

1 1 .9 ± 0.86
1 8.7 ± 1 .7
1 3.9 ± 2.4
1 8.0 ± 2.4
1 3.9 ± 1 .7

NS
0.00 1 8
NS
NS
0.02 1 6

0.0007
0.03 8 1
NS
0.022 1
NS

0.0076
NS
NS
NS
NS

-

NS
NS
22.9 ± 5.2
NS
1 9.2 ± 2.3
19.5 ± 1 . 1
0-d
NS
NS
5. 1 ± 1 .8
0.000 1
1 9.4 ± 4.3
7-d
52.7 ± 5.9
NS
NS
14-d
28.0 ± 4.5
30.5 ± 8. 1
NS
22.9 ± 4.4
0.0 147
NS
0.0 1 26
2 1 -d
1 4.2 ± 5 . 1
35.6 ± 6.2
36.9 ± 8.0
NS
NS
0.0077
35-d
27.9 ± 4.9
1 2.5 ± 2.9
3 8.7 ± 3.5
1
Values are expressed as mean ± SEM. 2P values from 2-way ANOVA. Abbreviation used: AC, acetylcarnitine; AIAC, acidAC (µmol/d)

insoluble acylcarnitine; ASAC, acid-soluble acylcamitine, NEC, nonesterified carnitine; NS, no significance differences.

TABLE 6-12
Average walking steps, distance and estimated calorie outputs per day before and during
the exercise intervention in three groups1

Variables
Walking steps
before
during
% change
Walking distance (mile)
before
during
% change
Calorie output (Kcal)
before
during
% change

Placebo
(n = 7)

Supplement 1
(n = 8)

Supplement 2
(n = 8)

960 1 ± 2448
12829 ± 3845
25. 17

7794 ± 2573
12375 ± 2987
37.0 1

4436 ± 2408
8676 ± 2885
48.86

2.54 ± 0.4
3.25 ± 0.6
21.68

2.36 ± 0.9
3.85 ± 1.0
38.64

1.32 ± 0.8
2.41 ± 0.8
45.23

378.7 ± 92.8
515.5 ± 97. 1
26.52

327.4 ± 76.6
494.5 ± 78.9
38.80

181. 1 ± 94.2
358.2 ± 99.8
49.45

1

Values are expressed as mean ±SD. Daily walking steps, estimated walking distance and estimated calorie
output were determined by the Yamax Digi-Walker SW-70 1 (Yamax Inc., Japan) for 5-7 d , before
(between 7- 14 d) and during the exercise intervention week (between 12-2 1 d).

placebo group recorded more steps both before and during the exercise intervention
periods than the other 2 groups. The mean of steps taken by the supplemented groups
before exercise intervention were 46-81% of the steps taken by the placebo group.
However, after the exercise intervention the mean steps taken by the supplemented
groups was 68-96% of the steps taken by the placebo group. The percentages increase in
steps taken before and during exercise intervention were 49, 37 and 25 percent in S2, Sl
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and the placebo group, respectively (Table 6- 1 2).

DISCUSSION

This study was launched to determine if supplementary carnitine, choline and

caffeine with or without a mild exercise regimen would enhance fat oxidation and

thereby, reduce body fat in humans as seen in the animal model (discussed earlier).

Unlike in the rat study, caffeine was not a part of the supplement mixture given to the

human participants; however, the subjects in all 3 groups consumed 200-300 mg caffeine
daily from a variety of self-selected foods and beverages as indicated by the nutrient

intake data (Table 6-4). This amount of caffeine was slightly lower than that given to rats
(- 360 mg/d) in earlier study (Hongu and Sachan 2000). The drawback was that placebo

and treatment groups consumed about equal amounts of caffeine. Thus, the independent
variables remained camitine and choline and the combination of these two. The serum
(Table 6- 1 0) and urinary (Table 6- 1 1) carnitine concentrations were decreased by the

introduction of choline and increased by the introduction of carnitine as has been reported
in earlier human (Dodson and Sachan 1 996) and animal studies (Hongu & Sachan 2002).
So the effects of choline and carnitine independently (d 7), as well as in combination (d
14) are consistently reproducible; i.e. choline promotes carnitine conservation by

decreasing losses in urine and thus increasing carnitine concentrations in the tissues

(Chapter 5 ; Hongu & Sachan 2002).

Fatty acid mobilization, oxidation and disposal were augmented by the

supplements. For example serum concentrations of �-hydroxybutyrate (Table 6-8) were
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elevated and sustained by the supplements particularly by the introduction of camitine.
The concentration of another marker of fatty acid oxidation, acetylcamitine, was elevated
about 2-fold in serum (Table 6-10) and about 3-fold in urine (Table 6-1 1 ). Short-chain
acylcamitines (ASAC) were only modestly elevated in serum but greatly increased in the
urine by camitine supplementation. Serum leptin concentrations were reduced about 15%
by the combination of supplements (Table 6-8) and leptin was significantly correlated
with the BW, BMI, %BF and serum triglycerides. These changes, however modest,
support the hypothesis that dietary supplementation with carnitine and choline promotes
fat oxidation and disposal in free-living humans who consumed 200-3 00 mg caffeine
daily from their self selected diets .
Exercise intervention further accentuated choline-carnitine effect on fat oxidation
and disposal as evidenced by changes in the biochemical markers. The fall in the
concentration of serum leptin in all groups following exercise was quite dramatic (> 50%)
and this is particularly so in the S2 group (Table 6-8) where there was complimentary
decrease in the serum triglycerides and free fatty acids (Table 6-7). The concentrations of
serum P-hydroxybutyrate were elevated beyond the concentrations raised by the
supplements (d 21 vs d 14) in both supplemented groups, but not in the placebo group
(Table 6-8). The leptin concentration was reduced to less than half in the supplemented
(d 21) as well as the placebo groups. This indicates a very clear and strong effect of
exercise on serum leptin which is further magnified in the carnitine-primed (S2)
individuals (Table 6-8). The effect of exercise on AC was very small, but consistent with
the idea of enhanced fatty acid oxidation particularly in the camitine pre-loaded group.
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Whereas there were decreases in the urinary acetylcarnitine excretion in the placebo
group, there were 21-27% increases in the S 1 and S2 groups (d 21 vs d 14 in Table 6- 11 ).
The urinary loss of fatty acids in form of ASAC continued in the S2 group. The loss of
fatty acid carbons as ASAC and AC was not only enhanced by exercise in the S2 group,
but it was sustained for at lease 2 wk beyond (d 35) the cessation of supplementation
(Table 6-1 1). It can be argued that, in spite of increased demand for energy due to
exercise, the rate of fatty acid degradation is high enough to sustain the urinary loss of
fatty acids. This perturbation of the metabolic processes is of great significance, even
though the loss of energy as fatty acid carbons in quantitative terms is rather small. It
appears that the sequence of camitine-choline loading corrupts the metabolic regulators in
favor of energy wasting which is accentuated and sustained by mild exercise regimen.
It is interesting to note that the activity level (numbers of walking step) of the S2
group was lowest prior to the exercise intervention and it nearly doubled during exercise
intervention wk (Table 6-12). These changes were modest in the SI group and least in
the placebo group. On the contrary, the caloric intake was consistently higher in the S2
group followed by the SI and placebo group (Table 6-3). The body weights and BMI
reflected caloric intake and followed a similar pattern (Table 6- 1). On the contrary, the
sum of the skinfolds and percent body fat was lowest in the S2 group followed by the S 1
and placebo group (Table 6- 1). This suggests that the supplement and exercise regimen
reduced body fat without changing body weight and this effect was sustained for at least 2
wk following cessation of the treatments. In spite of fat loss the body weight is
maintained because carnitine in known to promote nitrogen accretion and protein/muscle
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mass (Daily and Sachan 1995, Daily et al. 1998).
The cumulative evidence presented here allows the conclusion that camitine
choline supplementation promotes fat mobilization, oxidation and disposal in urine
without fully capitalizing the energy content of the lost carbons in urine. This effect of
the supplements is accentuated by mild exercise regimen and is sustained for at least 2 wk
after the cessation of the interventions. The final verdict in support of this conclusion
must wait additional studies involving a larger sample size and controlled feeding
condition.
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CHAPTER VII
SUMMARY AND CONCLUSIONS

The interactive effect of a diet supplemented with carnitine, choline and caffeine
at concentrations of 0.1, 5, and 11.5 g/kg diet, respectively was first evaluated in a 2x2
factorial design in rats where one-half of each dietary group was put on exercise regimen
and the other half was sedentary. The mean food intake of the groups was not different,
however, the body weight was significantly reduced by exercise in both dietary groups.
Fat pad weights and total lipids of epididymal, inguinal and perirenal regions were
significantly reduced by the supplements as well as by exercise. Regardless of exercise,
supplements significantly lowered triglycerides in serum, but increased triglycerides in
the skeletal muscle. Serum leptin concentrations were equally lowered by supplements
and exercise. Serum leptin was correlated with body weight (r = 0.55, P < 0.01 ), fat pad
weight (r = 0.82, P < 0.001) and glucose (r = 0.51, P < 0.05).
V02max was increased in the supplemented, exercised group; however, RQ was
not affected at rest and exhaustion. Post-exercised concentrations of serum triglycerides
were decreased, but P-hydroxybutyrate, acylcarnitine and acetylcarnitine were increased
in the supplemented animals. The changes in serum metaboli�es were complemented by
the changes in the muscle and urinary metabolites. The magnitude of increase in urinary
acylcarnitiries (34-45-fold) is an unique effect of this combination of the supplements.
Cumulative evidence indicates enhanced P-oxidation of fatty acids without a
change in the RQ because acetyl units were excreted in urine as acylcarnitine and
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acetylcarnitine and not oxidized to carbon dioxide. Partially oxidized fatty acid carbons
are loaded on to carnitine and dumped in urine as acylcarnitine and acetylcarnitine. For
this phenomenon the term "Fatty acid dumping" was introduced.
The concentrations of nonesterified and total carnitine were higher in serum, urine
and all tissues of the supplemented rats. Exercise further promoted this effect in the liver
and kidney. There was variable effect of the supplement and exercise on the other
fractions of camitine in tissues, except that short-chain acylcarnitines were consistently
higher in the in skeletal and cardiac muscles and reflected in the serum and urine of the
supplemented animals. Serum AST and ALT as well as liver proteins and DNA were not
adversely altered by the supplement.
In humans, serum and urinary camitine and acylcarnitine were decreased in
choline supplemented group; but, this carnitine profile was improved by the introduction
of carnitine to the choline group. The concentrations of serum P-hydroxybutyrate and
serum and urinary acetylcarnitine were elevated by the supplements and accentuated by
the introduction of mild exercise. The supplements reduced the concentrations of serum
leptin which was significantly correlated with the body weight, BMI, %BF and serum
triglycerides. Mild exercise regimen further increased indices of fatty acid oxidation and
reduced leptin concentrations.
From this data it is concluded that the combination of carnitine, choline, and
caffeine supplementation promotes camitine influx in all tissues and changes in
acylcarnitines of skeletal and cardiac muscles of rats, indicating enhanced fatty acid
oxidation, which is supported by the changes in serum and urinary acylcarnitine profiles
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and loss of adipose tissue mass. The indices of body fat loss by dietary supplements were
similar to that by mild exercise and the supplements augmented fatty acid oxidation as
well as disposal of acylcarnitine in urine of rats and humans.
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APPENDIXES

APPENDIX A
ACETYLCARNITINE ASSAY
Principle
The acetyl portion of acetylcamitine is converted to

[14C]Citrate, with the aid of

camitine acetyltransferease (CAT) (EC 3 .2.1.7), citrate synthase (CS) (EC 4.1.3 .7), and
[

14

C]Oxaloacetate. Then, the unreacted [ 14 C]Oxaloacetate is converted to [ 14 C]Aspartate

by the addition of glutamate oxaloacetate transaminase (GOT) (EC 2.6. 1 .1) and
glutamate. A cation exchange resin is added to absorb the [ 14 C]Aspartate, and the
radioactivity of the solution due to [ 1 4C] Citrate is measured (Pande and Caramancion
1981).

Acetylcamitine +

CoASH

Camitine

+

( 14C]Citrate

+

Acetyl-CoA

(Reaction I)

CAT
Acetyl-CoA

•
+ ( 14C]Oxaloacetate ----

CoASH

(Reaction 2)

cs
[ 14C]Aspartate

+

a-Ketoglutarate ____•
411

[ 14C]Oxaloacetate +

Glutamate

(Reaction 3)

GOT

FIGURE A-1. Principal reactions in acetylcarnitine assay

In Reaction 1, CAT catalyses the transfer of the acetyl moiety from acetylcamitne
to CoA, forming camitine and acetyl-CoA. In Reaction 2, acetyl-CoA is then reacted
with labeled oxaloacetate to form [ 14 C]Citrate and CoASH, which is catalysed by CS .
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[

14

C]Oxaloacetate is produced from the reaction of [ 14C]Aspartate with

a-ketoglurarate in the presence of GOT. Unreacted [ 14C]Oxaloacetate is then
trasaminated back to the [ 14C]Aspartate with glutamate with the presence of GOT
(Reaction 3). This provides a means for separation of unreacted [ 14C]Oxaloacetate from
[

14

C]Citrate. Then, a cation exchange resin (i.e. Dowex 50X8, 200-400 mesh, H+ form) at

neutral pH allows the separation of [ 14C]Citrate from [ 14C]Aspartate. [ 14C]Citrate passes
through the column (or in supernatant of the reaction mixture) and positively charged
[

1

4

C]Aspartate is retained in the resin. The [ 14C]Citrate is counted by a Beckman LS

counter (Beckman, Fullerton, CA).
High specific activity of [U- 14C]Aspartate (> 200 mci/mmol) allows the
estimation of > 10 pmol acetylcamitine. The assay can determine acetylcamitine ranging
from 20-80 pmol. Thea assay is not affected by camitine even when the ratio of
camitine:acetylcamitine is > 500 (Di Lisa et al. 1992).
Reagents

Chemicals involved in the assay are as follows:
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.

0.6 M and I M PCA
0.5 M N-[2-Hydroxyethyl]piperazine-N' -[2-ethanesulfonic acid](HEPES)-KOH,
pH 8.5. (0.5 M HEPES neutralized with KOH to pH 8.5)
0.5M HEPES-KOH-6mM EDTA, pH 7.0
66.7 mM HEPES-KOH- 1.96 mM EDTA, pH 7.4
61.6 mM HEPES-KOH-9.87 EDTA, pH 7.4
37.5 mM HEPES-KOH, pH 7.4
3 M KHC03
CoASH (20 µg/µl = 5 mg CoA in 250 µL of DDW)
Use a 10 mg or 5 mg of vile and add DDW directly to the vile.
Dithiothreitol (DTT)
a-ketoglutarate
GOT
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12.
13.
14.
15.
16.
17.
18.
19.

cs

CAT
U- 1 4C-Aspartate (> 200 mci/mmol)
Sodium glutamate
Dowex 1X8, 200-400 mesh, er form
Dowex 50x8, 200 -400 mesh, H+ form
Methanol
Scintillation cocktail

Preparation of samples: PCA extraction

Plasma
1.
0.2 mL in 0.8 mL of 0.6 M HC104 , vortex, place on ice for 10 min.
Centrifuge at 2000 X g for 10 min at 4 °C. Use supernatant (SN) for
2.
acetylcamitine assay.
Note; Dilute samples, if supplemented animals or humans

Urine
1.
Thaw samples, vortex thoroughly.
2.
Take 0.1 mL urine, 0.1 mL DDW, and 0.8 mL of 0.6M PCA, vortex, place on ice
for 10 min.
3.
Centrifuge at 2000 X g for 1 0 min at 4 ° C. Use SN for acetylcamitine assay.
Liver
1.
100 mg wet liver added to 3 mL of 0.6 M PCA, polytron (place in ice water while
using polytron).
2.
Centrifuge at 10,000 X g for 5 min at 4 ° C . Use SN for acetylcamitine assay.
Muscle
1.
50 m g wet (or 10 mg freeze dried ) skeletal muscle added to 3 m L of 0 . 6 M PCA
in 1 mM Na-EDTA (i.e. 0.17 mL of70% PCA in 3mL of l mM Na-EDTA),
polytron (place in ice water while using polytron)
2.
Centrifuge at 10,000 X g for 5 min at 4 °C. Use SN for acetylcamitine assay.
Neutralizaiton
1.
2.

All PCA extracts (tissues, plasma, or urine) must be neutralized. Transfer 0.8 mL
of SN in glass test tubes (12 x 75 mm) containing 75 µL of 0.5 M Hepes-KOH,
pH 8.5.
Vortex, and neutralize with 125 µL 3 M KHC03 _ Need to be freshly prepared
each time use.
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3.
4.
5.
6.

Keep on ice for 1 0 min.
Centrifuge at 2000 X g for 10 min at 4 °C.
Transfer 0.45 mL of the SN to micro-centrifuge tube containing 20 µL of 0.5 M
Hepes-KOH-6mM EDTA, pH 7.0.
Mix well, capped and can be stored frozen until assayed for acetylcarnitine.

Anion exchange (remove anion, citrate, by using anion Dowex resin)

1.
2.
3.
4.
5.

Make anion exchange resin: 200 mg/1 .5 ml (0.5 ml methanol + 1 .0 mL
DDW/tube)
Example: 2 gm/5 ml methanol + 1 0 ml methanol
Take a 400 µL of sample into a glass tube and add 1 .5 mL of the mix resin, and
add 400 µL of DDW
Vortex and let stand for 2 min.
Centrifuge at 2000 x g for 5 min at 4 °C.
Take 1 98 µL of SN to a microcentrifuge tube containing 2 µL of 0.5M HEPES
KOH-6mM EDTA, pH 7.0.

Making Stock Standard:

Make 37.5 µM acetylcarnitine. First, make 375 µM acetylcarnitine. Dissolve
0.0898 gm acetylcarnitine-HCL (23 9.7g/mol) in 1 000 mL DDW, then take 5 ml of this
solution, and diluted with DDW to make the volume to 50 ml.
Dilution factor for a sample :
Because 1 00 µL of samples are diluted to 2.66 µL/Assay, dilution factor is 375
(1 000 µL+2 .66 µL = 375)
Example :
1 00 ul urine sample + 1 00 DDW + 800 µL PCA = Total volume: 1 000 µL ( 1 00
a.
µL of urine/1 000 µL )
Take 800 µL of SN (80 µL of urine) + 75 µL Buffer + 125 µL KHC0 3 = Total
b.
volume : 1 000 µL (80 µL of urine/1 000 ul)
c.
Take 450 µL of SN (36 µL of urine) + 20 µL buffer = Total voule: 470 µL (36 µL
of urine/470 µL)
d.
Take 400 µL of SN (30.63 µL of urine) for anion exchange +1 .5 mL resin mix +
400 µL DDW = Tv; 2300 µL (30.63 µL of urine/2300 µL)
e.
Take 200 µL of SN (2.66 µL of urine) for acetylcarnitine assay
1 000 µL + 2.66 µL =375
f.
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Preparation for reaction mixtures

a.

Reaction mixture A (Per 50 assay tubes)
1 .0 ml of 37.5 mM HEPES-KOH, pH 7.4
1.
2.
10 µl of CoASH (20 µg/µl; 5 mg CoA in 250 µl of DDW)
1 5 µl of DTT (20 µg/µl; 5 mg DTT in 250 µl of water; 1 0 mg DTT in 500
3.
µl of water)
Add 475 µl of 37.5 mM HEPES-KOH, pH 7.4 (Total volume is 1 .5 mL.)
4.
Vortex, let stand at room temperature for 2 0 min and place in ice bath until
5.
ready to use

b.

Reaction mixture B (Per 50 assay tubes)
277 µl of 66.7 mM HEPES-KOH- 1 .96 mM EDTA, pH 7.4
1.
2.
8 µl of a-ketoglutarate (2 1 .2 µg/µl: 5 mg in 234 µl of DDW)
1 µl of GOT
3.
40 µl of [U-1 4C]Aspartate (50 µCi/ 1 ml of DDW)
4.
Vortex and let stand at room temperature for 1 0 min.
5.
6.
Add, while vortexing, 37 µl of 1 M PCA.
Let stand on ice for 1 5 min, then add 668 µl of 6 1 .6 mM KOH-9.87
7.
EDTA.
8.
Vortex and use immediately.

c.

Reaction mixture C (Per 50 assay tubes)
Pipette 878 µl of DDW into a test tube.
1.
2.
Add 22.7 µl of citrate synthetase (CS) to equal 0.5 units/assay tube.
3.
Add 1 1 0 µl of carnitine acyl transferase (CAT) to equal 0.5 units/assay
tube.
4.
Mix and keep on ice until use.

d.

Reaction mixture D (Per 50 assay tubes)
1.
Pipette 1.3 5 1 ml of water in a test tube.
Add 37.5 mg of sodium glutamate.
2.
Vortex until glutamate is completely dissolved.
3.
Add 1 25 µl of 1 :22 diluted GOT (6 µl in 1 27 µl of water)
4.
Mix and keep in ice until use.
5.

Reactions

1.

Add reaction mixture A to reaction mixture B and mix. Immediately pipette 50 µI
of this mixture (A+B) into each assay tube.
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2.
3.

Add 20 µ 1 of the reaction mixture C and mix. Incubate at room temperature for
20 minutes.

Add 30 µ 1 of the reaction mixture D and mix. Incubate at room temperature for
an additional 20 min.

Cation Exchange Resin: Use Dowex 50x8, 200-400 mesh, H+ form.

1.
2.
3.
4.
5.

Count
1.

2.

Make Dowex slurry (4 gm resin: 6 ml DDW).
Add 0.75 ml of Dowex 50x8 slurry and cap.
Vortex and place on ice.
Vortex an additional 2 times over 20 min and a maximum time period of 90 min.
After the last vortex, centrifuge for 1 min in a micro-centrifuge tube.

Transfer 0.2 mL of the SN to scintillation vials. Add 4.5 ml of Fisher BD
Scintillation cocktail.
Count for 1 0 min or to 1 .0 % error in a Beckman LS counter.

References

1.
2.
3.
4.

Cederblad et al. (1 990)
Di Lisa et al. (1 992)
Jackson and Lee ( 1 996)
Pande and Caramancion ( 1 98 1 )
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APPENDIX B
FREE FATTY ACIDS ASSAY

Serum and tissue nonesterified fatty acids are determined by the method of Novak
(1965). The free fatty acids are extracted in Dole's Extraction Mixture (DEM) and
partitioned into heptane where they formed soaps with cobalt. A color complex was
formed with alpha nitroso-beta-naphthol.
Reagents

1.

Solution A:
a.
Prepare a saturated potassium sulfate solution by adding several grams of
the solute to 150 ml boiling water.
b.
Store the solution in the presence of the extra crystals overnight and filter
before use.
c.
In a 100 ml volumetric flask, add 6 g of cobalt nitrate and 0.8 ml of glacial
acetic acid and dilute to volume with the saturated potassium sulfate
solution .
d.
Store at room temperature.

2.

Solution B:
a.
Prepare a saturated sodium sulfate solution by adding several grams of
sodium sulfate to boiling water.
b.
Filter the solution next day and store at room temperature.

3.

Cobalt reagent: Must make fresh each analysis. (Use 500 µl /Assay)
Mix 1.35 volumes of triethanolamine, 10 volumes of solution A, and 7 volumes of
solution B.
Store at room temperature.

4.

Indicator:
A stock solution of indicator:
a.
Dissolve 400 mg of alpha nitroso-beta-naphthol in 96% (v/v) ethanol and
diluted to 100 ml.
b.
To make 96% of ethanol: Mix 96 ml of absolute ethanol and 4 ml of
DDW.
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Working indicator:(Vse 750 µI/Assay)
a.
Dilute the stock indicator by a factor of 1 2. 5 with 96% ethanol before use.
(Indicator: ethanol = 1 : 1 1 .5 )

5.

6.

Dole's Extraction Mixture (DEM) : (use 250 µ 1/Assay)
Mix:
a.
40 volumes of glass distilled isopropanol,
1 0 volumes of glass distilled heptane, and
1 volume 1 N sulfuric acid
b.
For the lN sulfuric acid: Add 14 ml of concentrated sulfuric acid to DDW,
and diluted to the final volume to 500 ml. Store at room temperature.
Store at refrigerator as an organic solvents.
c.

7.

Chloroform-heptane: (use 500 µ1/Assay)
Mix:
a.
5 volumes of glass distilled chloroform and
1 volume of glass distilled heptane
b.
Store at refrigerator for organic solvents in the hallway.

Palmitic acid standard; 0.4 mE q/L (Palmitic acid; 256.4 g/mol)
a.
Dissolve 1 0.2 mg palmitic acid in DEM and diluted to 1 00 ml.
b.
Store at a freezer.

Assay Procedure

1.

Prepare blank, standards and samples as following:

tube #

STD : Palmitic acid:
0.4 mEq/L
( µ l)

Blank

0

STD 1

25

Sample
STD 2

STD 3

STD 4

STD 5

0

75

250

50

275

0

175

0

250

(0.0 1 µEq)
(0.03 µEq)

225

1 25 (0.05 µEq)

175 (0.07 µEq)

125

250 (0. 1 µEq)

50
256

Water
(µl)

DEM
( µ l)
50

0
0
0

2.

Add 250 µl of Dole's Extraction Mixture (DEM) and 50 ul of serum (or tissue
homogenate) to 1 .5 ml micro-centrifuge tubes, mix, and cool in an ice bath for 10
mm.

3.

Add 400 µ l of heptane and 500 µl of water and vortex, develop a separation of
phases.

4.

Transfer 300 µl of the upper heptane phase to 2 ml micro-centrifuged tubes.

5.

Add 500 µl of chloroform-heptane and 500 µl of cobalt reagent. Mix. The tubes
were tightly capped, and placed in a shaker and vigorously mixed for 3 minutes.

6.

Centrifuge tubes at 1 500 X g for at least 15 min.

7.

Transfer 600 µl of upper chlorofom-heptane phase to new micro-centrifuge tubes
containing 750 µl of the working indicator. Be careful not to disturb the lower
dark phase.

8.

After a wait of 30 min measure absorbance of the samples and standards at 500
nm against the blank.

Calculations

Nonesterified fatty acids (mEq/L) = absorbance X inverse slope x dilution factor
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APPENDIX C
MEAN NUTRIENT INTAKES: FACTORIAL ANALYSIS
TABLE A-1
Mean nutrient intakes in three groups: Effects ofgroup, gender and their interaction 1
Variables

N

oo

Placebo

%kcal

Supplement 1

%kcal

Supplement 2

%kcal

Statistical Significance
Group Gender GxG

Energy (kcal)
NS
0.000 1
0-d
NS
2007 ± 278
1 879 ± 1 85
1 748 ± 8 8
NS
0.0 1 99
7-d
NS
2223 ± 1 36
1 925 ± 264
1 840 ± 1 53
NS
0.00 14*
1 4-d
NS
2296 ± 23 5
1 65 8 ± 1 64
1 826 ± 386
NS
0.0007
NS
2 1 -d
2085 ± 262
2 1 86 ± 3 83
1 75 8 ± 335
NS
NS
NS
2 1 22 ± 1 53
3 5-d
1 857 ± 1 54
1 974 ± 1 99
Protein (g)
NS
0.0340
NS
0-d
75 ± 1 0
1 5 ± 1 .6
14 ± 0.9
71 ± 7.8
1 5 ± 1 .5
6 1 ± 6.0
NS
0.0 1 26
7-d
NS
1 3 ± 1 .5
75 ± 9.3
1 5 ± 1 .9
80 ± 1 3
1 7 ± 1 .7
70 ± 8.0
NS
0.00 1 2
14 ± 1 . 1
1 4-d
78 ± 9.6
NS
72 ± 1 5
1 6 ± 1 .0
1 4 ± 0.9
59 ± 8.8
NS
1 5 ± 2.0
0.0004
2 1 -d
NS
80 ± 1 3
76 ± 1 3
1 4 ± 0.5
1 5 ± 1 .4
59 ± 1 0
NS
NS
1 5 ± 1 .9
35-d
78 ± 1 0
69 ± 9.0
NS
70 ± 9.4
1 5 ± 1 .8
1 5 ± 1 .8
Carbohydrate (g)
NS
0.000 1
NS
278 ± 38
56 ± 2.2
0-d
260 ± 30
258 ± 22
59 ± 2.5
5 5 ± 2.7
NS
5 8 ± 2.9
0.045 1 *
NS
322 ± 25
7-d
56 ± 3 .2
53 ± 3.6
271 ± 39
239 ± 1 1
NS
0.0278*
1 4-d
55 ± 4.8
NS
26 1 ± 4 1
307 ± 25
5 6 ± 4. 1
61 ± 3 . 5
224 ± 1 4
NS
NS
0.00 1 7
52 ± 4.2
2 1 -d
307 ± 4 1
280 ± 43
52 ± 2.5
226 ± 42
58 ± 3.3
54 ± 2.8
NS
NS
NS
3 5-d
285 ± 34
29 1 ± 33
55 ± 5.6
57 ± 4.3
253 ± 28
1
Values are expressed as mean ± SEM. GxG indicates a group and gender interaction. NS indicates no significant
difference (P > 0.05) * indicates significant difference between the groups (P < 0.05), when comparisons were made only
in female subjects.

TABLE A-1
Mean nutrient intakes in three groups: Effects ofgroup, gender and their interaction 1 (Continued)
Variables

Placebo

Fat (g)
0-d
50 ± 4.8
7-d
6 1 ± 8 .7
1 4-d
55 ± 1 1
2 1 -d
69 ± 1 5
35-d
59 ± 9.5
Cholesterol (mg)
0-d
1 42 ± 22
� 7-d
202 ± 36
"° 1 4-d
1 3 8 ± 58
2 1 -d
177 ± 67
35-d
1 63 ± 37
Saturated fat (g)
0-d
1 5 ± 1 .9
20 ± 3 . 3
7-d
1 4-d
1 6 ± 2.6
20 ± 4.9
2 1 -d
1 8 ± 2.8
3 5-d
Monounsaturated fat (g)
0-d
1 2 ± 1 .4
7-d
1 5 ± 1 .8
17 ± 4.4
1 4-d
17 ± 5.6
2 1 -d
1 4 ± 2.4
35-d
1
Values are mean ± SEM.
in female subjects.

%kcal
25 ± 1 .6
30 ± 2.2
29 ± 3.7
34 ± 2.2
28 ± 2.9

Supplement 1
64 ± 6.8
66 ± 1 3
56 ± 1 9
69 ± 1 9
64 ± 1 1

%kcal
3 1 ± 2.5
30 ± 2.3
24 ± 3 . 8
26 ± 2.8
29 ± 3 .9

1 96 ± 42
1 62 ± 28
1 45 ± 48
24 1 ± 83
1 1 4 ± 27
7.5 ± 0.8
9.4 ± 1 .0
8.2 ± 0.9
9.8 ± 1 .3
8.6 ± 1 .3

17 ± 1 . 1
22 ± 4.8
1 6 ± 5.5
20 ± 5.2
20 ± 3 . 8

Supplement 2
67 ± 1 2
76 ± 7.5
87 ± 1 8
78 ± 1 0
75 ± 6.7

%kcal

Statistical Significance
Group Gender GxG

2 9 ± 1 .8
3 1 ± 2.0
33 ± 3 .5
3 5 ± 2.7
32 ± 2.6

NS
NS
NS
NS
NS

0.0074
NS
0.0046*
0.0064
NS

NS
NS
NS
NS
NS

NS
NS
NS
NS
NS

NS
NS
NS
0.03 57
NS

NS
NS
NS
NS
NS

NS
NS
NS
NS
NS

NS
NS
0.0045*
0.01 95
NS

NS
NS
NS
NS
NS

170 ± 42
2 1 2 ± 42
256 ± 65
222 ± 57
1 99 ± 22
8.5 ± 0.9
1 0 ± 1 .5
7.0 ± 1 .4
7.7 ± 0.9
9.0 ± 1 .5

2 1 ± 4.7
23 ± 3 . 1
29 ± 7.7
26 ± 5.2
22 ± 3 .2

9.0 ± 1 .0
9. 1 ± 0.8
1 1 ± 1 .6
1 1 ± 1 .4
9.3 ± 1 . 1

6.3 ± 0.6
17 ± 1 .9
1 6 ± 1 .5
8.4 ± 0.7
7.6 ± 0.8
NS
NS
NS
7.5 ± 0.6
12 ± 1 .3
5.8 ± 1 .0
18 ± 3.1
7.3 ± 1 .2
NS
NS
NS
9.2 ± 1 .8
26 ± 2.3
1 6 ± 7.4
6.0 ± 1 . 8
1 1 ± 0.8
0.0032* NS
NS
8.0 ± 1 .3
17 ± 8.0
23 ± 3 .0
6. 1 ± 1 .7
10 ± 1 .1
0.009 1
NS
NS
22 ± 2.9
7.0 ± 1 .0
1 9 ± 2.4
8.5 ± 0.7
9.5 ± 1 . 1
NS
NS
NS
* indicates significant difference between the groups (P < 0.05), when comparisons were made only

TABLE A-1

Mean nutrient intakes in three groups: Effects ofgroup, gender and their interaction 1 (Continued)
Variables

Placebo

%kcal

Supplement 1

%kcal

Supplement 2

%kcal

Statistical Significance

Group Gender

GxG

Polyunsaturated fat (g)
NS
NS
NS
6.0 ± 0.7
1 3 ± 2.9
8.5 ± 1 . 5
1 8 ± 3 .2
7.2 ± I . I 3.7 ± 0.5
0-d*
NS
NS
NS
1
.
1
±
7.6
3.0
±
9
1
.2
1
±
1
5.
1 2 ± 4.6
14 ± 3.8 6.5 ± 1 .3
7-d
NS
0.0 1 43 *
NS
6. 1 ± 1 .2
1 6 ± 3.9
4.3 ± 1 .2
1 1 ± 4.3
1 0 ± 1 .9 5.7 ± 0.9
1 4-d
NS
0.0470
NS
.0
1
±
6.2
2.0
±
14
0.6
±
3.9
.5
3
±
0
1
.5
1
±
7.4
2 1 -d
1 6 ± 4.7
NS
NS
NS
5.5 ± 1 .0
1 3 ± 2.5
5.8 ± 2. 1
13 ± 5.4
1 1 ± 2.4 4.9 ± 0.8
35-d
Dietary fiber (g)
NS
NS
NS
1 3 ± 1 .8
1 1 ± 2.5
1 0 ± 2.2
0-d
NS
NS
N
NS
1 3 ± 2.0
1 3 ± 2.5
. 10 ± 1 .5
7-d
NS
NS
NS
2.2
±
5
1
1 1 ± 1 .9
1 0 ± 1 .6
0 1 4-d
NS
NS
NS
1 2 ± 2.3
1 2 ± 2.8
2 1 -d
1 0 ± 2.0
NS
NS
NS
2.3
±
3
1
2.7
±
14
1 2 ± 1 .7
35-d
Sugar (g)
NS
0.0076
NS
89 ± 22
69 ± 1 5
91 ± 1 5
0-d
NS
NS
NS
1 35 ± 28
1 1 2 ± 22
85 ± 1 0
7-d
NS
NS
NS
92 ± 29
77 ± 14
1 4-d
60 ± 1 4
NS
00
1
0.0
NS
97 ± 1 9
1 00 ± 12
2 1 -d
72 ± 1 8
NS
0.046 1
NS
93 ± 22
89 ± 1 7
74 ± 1 4
35-d
Vitamin A ( µ g RE)
NS
NS
NS
848 ± 1 32
744 ± 1 0 1
0-d
795 ± 1 59
NS
NS
NS
73 8 ± 1 39
483 ± 1 1 8
537 ± 8 1
7-d
NS
NS
NS
597 ± 1 1 6
62 1 ± 254
72 1 ± 1 57
1 4-d
NS
NS
NS
940 ± 346
888 ± 244
2 1 -d
908 ± 209
NS
NS
NS
1 068 ± 570
1 1 26 ± 253
847 ± 45 1
35-d
1
Values are mean ± SEM. GxG indicates a group and gender interaction. NS indicates no significant difference (P > 0.05)
* indicates significant difference between the groups (P < 0.05), when comparisons were made only in female subjects.
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TABLE A-1
Mean nutrient intakes in three wou2.s: Effects o[woup_, g_ender and their interaction 1 (Continued2
%kcal
Supplement 1 %kcal Supplement 2 %kcal
Variables
Statistical Significance
Placebo
Gender GxG
GrOUJ?
P-carotene (µg)
0-d
336 ± 1 07
1 64 ± 68
NS
NS
NS
55 ± 34
7-d
212 ± 141
1 6 1 ± 92
92 ± 3 1
NS
NS
NS
1 4-d
65 ± 20
NS
NS
1 23 ± 50
224 ± 173
NS
2 1 -d
1 26 ± 48
1 32 ± 53
47 ± 28
NS
NS
NS
3 5-d
225 ± 1 02
346 ± 2 1 5
22 1 ± 80
NS
NS
NS
Thiamin (mg)
0-d
1 .6 ± 0.2
1 .7 ± 0.3
1 . 1 ± 0.2
NS
NS
NS
7-d
1 .3 ± 0.3
1 .3 ± 0.2
1 .6 ± 0.3
NS
NS
NS
1 4-d
1 .2 ± 0.3
2.3 ± 0.8
1 .2 ± 0.2
NS
NS
NS
1 .2 ± 0. 1
2 1 -d
1 .6 ± 0.3
1 .6 ± 0.4
NS
NS
NS
3 5-d
1 .2 ± 0.3
1 .4 ± 0.3
NS
2.5 ± 0.8
NS
NS
Riboflavin (mg)
0-d
1 .6 ± 0.2
1 .7 ± 0.2
1 .4 ± 0.2
NS
NS
NS
7-d
1 . 1 ± 0.3
1 .4 ± 0.2
1 .8 ± 0.3
NS
NS
NS
1 4-d
1 .5 ± 0. 1
1 .3 ± 0. 1
1 .2 ± 0.4
NS
NS
NS
1 .6 ± 0.3
1 .7 ± 0.3
1 .5 ± 0.2
2 1 -d
NS
NS
NS
3 5-d
1 .7 ± 0.3
1 .4 ± 0.2
1 .6 ± 0.2
NS
NS
NS
Niacin (mg)
0-d
19 ± 3 .0
1 6 ± 2.0
2 1 ± 2.8
0.0 1 37 NS
NS
20 ± 2.2
7-d
27 ± 3 .6
20 ± 3 .0
0.0226
0.0 1 64* NS
17 ± 4.4
1 4-d
1 6 ± 1 .9
25 ± 4.3
NS
0.0044 NS
19 ± 3 .8
2 1 -d
17 ± 2.2
22 ± 4. 1
NS
0.0052 NS
1 9 ± 2.6
3 5-d
19 ± 5.1
22 ± 2.9
NS
NS
NS
1
Values are mean ± SEM. GxG indicates a group and gender interaction. NS indicates no significant difference (P > 0.05)
* indicates significant difference between the groups (P < 0.05), when comparisons were made only in female subjects.

TABLE A-1

Mean nutrient intakes in three groups: Effects ofgroup, gender and their interaction 1 (Continued)
Variables

Placebo

Supplement 1

Supplement 2

Statistical Significance
Group Gender GxG

Vitamin B6 : pyridoxine (mg)
1 .3 ± 0.2
0-d
NS
NS
NS
1 .4 ± 0.2
1 .0 ± 0.2
NS
7-d
1 . 3 ± 0.2
1 .4 ± 0.2
NS
1 . 1 ± 0.2
NS
1 4-d
NS
1 .0 ± 0.2
1 .7 ± 0.3
NS
NS
1 .0 ± 0.2
2 1 -d
NS
1 .3 ± 0. 1
NS
1 . 1 ± 0.2
NS
1 . 1 ± 0. 1
NS
35-d
NS
1 .2 ± 0.3
1 .7 ± 0.4
NS
1 .5 ± 0.3
Vitamin B 1 2 ( µ g)
0-d
NS
2.7 ± 0.6
NS
NS
2.7 ± 0.7
2.9 ± 0.6
7-d
NS
NS
3.4 ± 0.7
2.4
±
0.5
NS
2.7 ± 0.8
1 4-d
3 . 1 ± 1 .0
NS
NS
2.5 ± 1 . 1
1 . 8 ± 0.3
NS
N
2 1 -d
NS
NS
3.6 ± 0.9
2.6 ± 0.7
NS
2.6 ± 0.5
N
3 5-d
NS
2.3 ± 0.6
2.4 ± 0.9
1 .8 ± 0.4
NS
NS
Vitamin C (mg)
0-d
NS
NS
99 ± 1 5
77 ± 1 6
79 ± 1 3
NS
7-d
NS
NS
1 14 ± 1 8
NS
90 ± 1 8
83 ± 1 7
1 4-d
80 ± 3 1
NS
1 03 ± 25
NS
58 ± 27
NS
2 1 -d
84 ± 2 1
NS
1 4 1 ± 56
94 ± 35
NS
NS
3 5-d
77 ± 1 8
1 1 1 ± 38
NS
NS
NS
1 09 ± 28
Vitamin D ( µ g)
0-d
2.7 ± 1 .0
3 . 1 ± 1 .3
2.2 ± 0.9
NS
NS
NS
7-d
1 . 8 ± 0.9
1 . 1 ± 0.6
1 . 8 ± 0.7
NS
NS
NS
1 4-d
1 . 1 ± 0.4
1 .6 ± 0.5
2.5 ± 1 .7
NS
NS
NS
2 1 -d
1 .9 ± 0.4
3.5 ± 1 .4
NS
NS
2.9 ± 0.9
NS
3 5-d
1 .5 ± 0.5
2.4 ± 0.9
2.2 ± 1 .3
NS
NS
NS
1
Values are mean ± SEM. GxG indicates a group and gender interaction. NS indicates no significant difference (P > 0.05)
* indicates significant difference between the groups (P < 0.05), when comparisons were made only in female subjects.

TABLE A-1
Mean nutrient intakes in three groups: Effects ofgroup, gender and their interaction 1 (Continued)

Variables

°'w

l'v

Placebo

Supplement 1

Supplement 2

Statistical Significance
GrouI! Gender GxG

Vitamin E (mg a-TE)
5.4 ± 1.9
0.0179
NS
NS
13 ± 2.9
3.7 ± 1.3
0-d*
NS
NS
6.6 ± 1.5
NS
9.6 ± 3.0
7-d
12 ± 3.3
11
±
4.1
NS
NS
NS
6.1
±
2.0
14-d
7.7 ± 3.3
NS
3.4 ± 1.2
8.4 ± 2.2
NS
NS
21-d
14 ± 4.8
4.3 ± 1.2
8.6 ± 2.5
NS
NS
NS
5.5 ± 3.3
35-d
a-Tocopherol (mg)
3.2 ± 0.8
11 ± 4.6
NS
NS
0-d
NS
2.4 ± 0.6
6.1 ± 1.4
NS
NS
NS
4.1 ± 0.9
7-d
4.3 ± 0.6
3.8 ± 1.2
3.8 ± 0.8
NS
NS
NS
14-d
3.9 ± 0.8
NS
NS
4.4 ± 1.6
4.0 ± 0.8
NS
4.3 ± 1.2
21-d
NS
9.2 ± 5.7
NS
NS
4.0 ± 0.8
35-d
3.4 ± 1.2
Folate (µg)
186 ± 39
NS
NS
NS
214 ± 45
213 ± 45
0-d
204 ± 22
201 ± 28
NS
NS
NS
7-d
186 ± 40
233 ± 44
170 ± 44
NS
214 ± 44
NS
NS
14-d
241 ± 77
NS
NS
NS
184 ± 33
21-d
232 ± 37
228 ± 57
242 ± 40
NS
NS
35-d
NS
183 ± 28
Pantothenic acid (mg)
4.1 ± 0.7
2.4 ± 0.5
NS
NS
0.0408
0-d*
2.0 ± 0.4
2.5 ± 0.4
2.0 ± 0.3
NS
7-d .
NS
NS
2.8 ± 0.2
2.5 ± 0.7
3.5 ± 0.5
NS
NS
2.0 ± 0.4
NS
14-d
3.2 ± 1.0
2.8 ± 0.6
21-d
NS
NS
2.7 ± 0.7
NS
3.3 ± 1.0
4.2 ± 0.7
1.9 ± 0.4
35-d
NS
NS
NS
1
Values are mean ± SEM. GxG indicates a group and gender interaction. NS indicates no significant difference (P > 0.05)
* indicates significant difference between the groups (P < 0.05), when comparisons were made only in female subjects.

TABLE A-1

Mean nutrient intakes in three groups: Effects ofgroup, gender and their interaction 1 (Continued)

Variables

Placebo

Supplement 1

Supplement 2

Statistical Significance
GrouE Gender GxG

Biotin (µg)
0-d
7.6 ± 2.5
7.8 ± 2.7
NS
NS
4.3 ± 1.8
NS
7-d
7.2 ± 2.2
5. 1 ± 1.7
NS
8.9 ± 2.5
NS
NS
14-d
6.5 ± 1.9
4.7 ± 1.8
NS
NS
14 ± 4.4
NS
21-d
12 ± 3.2
NS
NS
9.0 ± 3. 1
NS
12 ± 4.9
35-d
4.4 ± 1.5
5.7 ± 1.6
NS
NS
NS
6.5 ± 2.7
Vitamin K (µg)
0-d
237 ± 104
138 ± 61
NS
NS
NS
137 ± 62
7-d
240 ± 68
NS
NS
122 ± 21
138 ± 64
NS
14-d
178 ± 44
148 ± 42
NS
NS
1 18 ± 50
NS
2 1-d
234 ± 48
NS
NS
NS
227 ± 59
143 ± 43
35-d
17 1 ± 42
16 1 ± 6 1
1 14 ± 54
NS
NS
NS
Sodium (mg)
0-d*
2909 ± 397
2729 ± 212
0.0444
3877 ± 253
NS
NS
7-d
2627 ± 269
2873 ± 481
3437 ± 468
NS
NS
0.048 1
14-d
2646 ± 227
2893 ± 563
3075 ± 314
NS
0.00 17
NS
2 1-d
2579 ± 504
3058 ± 4 10
3415 ± 672
NS
NS
0.0090
35-d
2978 ± 238
3690 ± 545
30 10 ± 369
NS
NS
0.0024
Potassium (mg)
0-d
2044 ± 244
21 10 ± 320
2402 ± 3 18
NS
NS
NS
7-d
2158 ± 295
2388 ± 273
2594 ± 142
NS
NS
NS
14-d
1848 ± 197
2465 ± 2 15
NS
2041 ± 466
NS
0.00 13
2 1-d
2594 ± 592
1989 ± 233
2468 ± 257
NS
NS
0.0037
35-d
2578 ± 358
2209 ± 138
NS
2538 ± 323
NS
NS
1
Values are mean ± SEM. GxG indicates a group and gender interaction. NS indicates no significant difference (P > 0.05)
* indicates significant difference between the groups (P < 0.05), when comparisons were made only in female subjects.

TABLE A-1
Mean nutrient intakes in three groups: Effects ofgroup, gender and their interaction' (Continued)
Variables

m

N

Placebo

Supplement 1

Supplement 2

Statistical Significance
GrouE Gender GxG

Iron (mg)
13 ± 1 .7
NS
NS
1 2 ± 2.6
NS
0-d
10 ± 1.1
0.0052
1 4 ± 1 .3
NS
NS
1 2 ± 2. 1
7-d
1 2 ± 1 .5
1 5 ± 2. 1
0.0292*
NS
NS
1 4-d
1 1 ± 3.0
1 1 ± 1 .3
1 1 ± 1 .2
0.003 8
14 ± 3 . 8
NS
NS
1 6 ± 2.5
2 1 -d
14 ± 1 .1
1 4 ± 1 .9
NS
NS
NS
35-d
1 4 ± 3 .4
Calcium (mg)
888 ± 1 1 9
0.0047
NS
779 ± 1 5 1
NS
0-d
664 ± 68
856 ± 1 03
0.0067
656 ± 202
NS
60 1 ± 1 09
7-d
NS
779 ± 1 1 4
0.0 1 25
70 1 ± 2 1 4
NS
NS
1 4-d
545 ± 8 1
0.0490
750 ± 1 52
788 ± 1 04
NS
2 1 -d
83 1 ± 1 98
NS
873 ± 1 9 1
766 ± 74
NS
35-d
NS
NS
743 ± 86
Magnesium (mg)
0.0207
22 1 ± 28
254 ± 40
0-d
NS
1 89 ± 26
NS
225 ± 27
226 ± 20
1 95 ± 23
NS
7-d
NS
NS
273 ± 42
0.0 1 54
208 ± 5 7
1 86 ± 2 1
NS
NS
1 4-d
1 94 ± 28
25 1 ± 54
0.0005
1 97 ± 25
NS
2 1 -d
NS
257 ± 45
NS
274 ± 33
1 80 ± 25
NS
35-d
NS
Phosphorus (mg)
1 3 1 6 ± 1 89
1 253 ± 1 42
0.00 1 1
0-d
871 ± 1 1 7
NS
NS
977 ± 1 82
0.0022
1 1 40 ± 1 59
7-d
1 1 06 ± 1 33
NS
NS
1 098 ± 1 1 8
932 ± 228
793 ± 78
1 4-d
0.005 1
NS
NS
1 1 86 ± 1 89
0.0007
1 03 0 ± 1 66
2 1 -d
1 285 ± 288
NS
NS
746 ± 1 1 2
1 1 92 ± 1 47
3 5-d
1215 ± 161
NS
NS
NS
1
Values are mean ± SEM. GxG indicates a group and gender interaction. NS indicates no significant difference (P > 0.05)
* indicates significant difference between the groups (P < 0.05), when comparisons were made only in female subjects.

TABLE A-1
Mean nutrient intakes in three groups: Effects ofgroup, gender and their interaction1 (Continued)

Variables

Placebo

Supplement 1

Supplement 2

Statistical Significance
GrouE Gender GxG

Zinc (mg)
NS
NS
NS
7.7 ± 1 . 1
0-d
8.6 ± 1.3
6.0 ± 0.8
NS
NS
NS
7.4 ± 1 .2
6.0 ± 1.2
7-d
7.9 ± 1 .4
0.01 36*
NS
NS
8.3 ± 0.9
1 4-d
6.2 ± 2. 1
6.6 ± 0.8
NS
NS
NS
1 3 ± 5.4
2 1 -d
7.2 ± 1.7
9.5 ± 3.9
NS
NS
NS
8.0 ± 1 .9
35-d
7.9 ± 1 .2
5.4 ± 1 .0
Copper (mg)
NS
NS
NS
0.9 ± 0. 1
0-d
1.4 ± 0.4
0.7 ± 0. 1
NS
NS
NS
0.9 ± 0.04
7-d
0.8 ± 0. 1
1 .3 ± 0.4
NS
0.025 1
NS
1 .2 ± 0.2
1 4-d
1.0 ± 0.3
0.7 ± 0. 1
N
NS
NS
NS
0.9
±
0.
1
2
1
-d
1
.
1
±
0.3
1
.0
±
0.2
O'\
O'\
NS
NS
NS
1 . 1 ± 0.2
1.3 ± 0. 1
35-d
0.8 ± 0.2
Selenium (µg)
NS
NS
NS
42 ± 1 4
92 ± 25
0-d
30 ± 7.9
NS
NS
NS
33 ± 1 1
7-d
58 ± 15
51 ± 1 1
NS
0.0265
NS
79 ± 20
1 4-d*
35 ± 7.4
23 ± 7.3
NS
NS
NS
53 ± 1 1
2 1 -d
56 ± 1 7
23 ± 6.0
NS
NS
NS
5 1 ± 23
80 ± 24
35-d
1 1 9 ± 49
Chromium (µg)
NS
NS
33 ± 1 3
NS
0-d
47 ± 9.8
42 ± 1 6
0.0452
NS
33 ± 1 1
NS
70 ± 15
7-d
54 ± 7.6
NS
NS
NS
92 ± 3 1
1 4-d
36 ± 14
33 ± 1 0
NS
NS
NS
81 ± 19
50 ± 8.3
2 1 -d
77 ± 1 9
NS
NS
NS
35-d
3 3 ± 9.5
37 ± 1 5
37 ± 1 6
1
Values are mean ± SEM. GxG indicates a group and gender interaction. NS indicates no significant difference (P > 0.05)
* indicates significant difference between the groups (P < 0.05), when comparisons were made only in female subjects.

TABLE A-2
Mean caffeine intakes in three groups: Effects ofgroup, gender and their interaction1

Variables

Placebo

Supplement 1

Supplement 2

167 ± 55
174 ± 46
226 ± 67
297 ± 93
231 ± 71

196 ± 64
262 ± 58
236 ± 66
259 ± 73
223 ± 68

Caffeine (mg)
. 234 ± 46
0-d
7-d
256 ± 38
14-d
269 ± 67
21-d
309 ± 69
35-d
268 ± 97
N

�

1

Values are expressed as mean ± SEM. GxG indicates a group and gender interaction.
NS indicates no significant difference (P > 0.05)

\
\

Statistical Significance
Group
Gender
GxG
NS
NS
NS
NS
NS

0.0173
NS
NS
NS
NS

NS
NS
NS
NS
NS

APPENDIX D

MEAN MACRO-NUTRIENT INTAKES PER 1000 KCAL AND KG OF BODY WEIGHT
TABLE A-3

Mean macro-nutrient intakes per 1000 kcal and kg ofbody weight ofparticipants in three groups 1

Variables

Placebo

Supplement 1

Supplement 2

Statistical Significance
GxG
Gender
Grou

g/kg bw
g/kcal
Protein
g/kg bw
g/kcal
g/kg bw
g/kcal
NS
NS
NS
38 ± 4.0 1 .02 ± 0. 1 4
0-d
37 ± 3.7 0.96 ± 0.07
35 ± 2.3 0.92 ± 0.08
NS
NS
NS
0.98
±
0.
1
0
3
4
±
3.8
1
.04
±
0.
1
3
43 ± 4.3 1 . 1 7 ± 0. 1 6
7-d
3 9 ± 4.8
NS 0.0097(/bw) NS
34 ± 2.9 1 .04 ± 0. 1 1
3 5 ± 2.3 0.86 ± 0. 1 1
1 4-d
40 ± 2.5 0.95 ± 0. 1 3
N
NS 0.03 1 9(/bw) NS
3 7 ± 5.0 1 .03 ± 0. 1 7
34 ± I . I 0.9 1 ± 0.20
38 ± 3 .4 1 .08 ± 0. 1 0
2 1 -d
NS
NS
NS
37 ± 4.8 1 .06 ± 0. 1 3
3 5-d
3 8 ± 4.5 1 .02 ± 0.09
36 ± 4.5 0.97 ± 0.08
g/kg bw .
g/kcal
Carbohydrate g/kcal
g/kcal
g/kg bw
g/kg bw
NS
NS
NS
1 3 9 ± 5.6 3 . 8 1 ± 0.54
0-d
1 3 8 ± 6.7 3 .6 1 ± 0.28
146 ± 6.2 3 . 9 1 ± 0.46
NS
NS .
NS
1 45 ± 7. 1 4.55 ± 0.59
7-d
1 39 ± 8.0 3 .77 ± 0.48
1 33 ± 8.2 3.65 ± 0.35
NS
NS
NS
1 3 8 ± 1 2 4.35 ± 0.60
1 40 ± 1 0 3 .42 ± 0.38
1 5 1 ± 8.7 3.54 ± 0.38
1 4-d
NS
NS
NS
1 3 1 ± 1 1 3 . 83 ± 0.63
1 46 ± 8.2 4.26 ± 0.44
1 3 1 ± 6.3 3 .52 ± 0.83
2 1 -d
NS
NS
NS
1 34 ± 7.0 4. 1 8 ± 0.67
35-d
143 ± 1 1 4.06 ± 0.46
1 37 ± 1 4 3 .85 ± 0.55
g/kg bw
g/kg bw
g/kcal
g/kcal
g/kg bw
Fat
g/kcal
NS
NS
NS
32 ± 2.0 0.89 ± 0. 1 6
35 ± 2.8 0.90 ± 0.08
0-d
28 ± 1 .8 0.77 ± 0. 1 2
NS
NS
NS
34 ± 2.3 1 .09 ± 0. 1 8
34 ± 2.6 0.88 ± 0. 1 0
7-d
33 ± 2.4 0.93 ± 0. 1 7
NS 0.01 03(/bw) NS
36 ± 3 . 8 1 . 1 4 ± 0.2 1
2 7 ± 4.2 0.7 1 ± 0. 1 9
1 4-d
32 ± 4. 1 0.80 ± 0. 14
NS
NS
NS
2 9 ± 3. 1 * 0.90 ± 0. 1 9
39 ± 3.0 1 .07 ± 0. 1 4
2 1 -d
3 8 ± 2.4 1 .05 ± 0.26
NS
NS
NS
32 ± 4.2 0.89 ± 0. 14
36 ± 2.9 1 .08 ± 0. 1 8
35-d
3 1 ± 3 .2 0.84 ± 0.09
1
Values are expressed as mean ± SEM. GxG indicates a group and gender interaction. NS indicates no significant difference
(P > 0.05) * indicates significant difference between the groups (P < 0.05), when compared with only female subjects.
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